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 Natural products, generally defined as metabolites of biotic origin, have a long history as medicines 
and have remained a fruitful source of new drug leads for multiple diseases in the modern age. Arguably 
the largest asset of natural products, and a pitfall of synthetic compound libraries, is the remarkable diversity 
of structure and chemical group functionality that discloses them as Nature’s handiwork and is critical for 
the bioactivities that many of them possess. Despite this precedent, characterization of new chemical 
entities is met with a significant challenge: rediscovery of known compounds. For compound discovery to 
continue translating to useful, practical chemical matter, it is essential that strides be made to streamline 
and augment current methodology to prioritize novelty. 
 Modern genomics provides a potential resolution to these issues: as the financial and technical 
hurdles for whole-genome sequencing are reduced, annotating the biosynthetic capabilities of sequenced 
organisms becomes more accessible and reliable. It follows that gene clusters can be analyzed before 
undertaking efforts to isolate and characterize compounds, minimizing costs and resources. However, this 
approach is dependent upon a robust understanding of gene function as it translates to natural product 
structure, and assignment of biosynthetic enzyme/cluster function is drastically outpaced by the availability 
of genome sequences, leading to an excess of genomic data that cannot be optimally exploited. We describe 
the current state of these challenges as it relates to the discovery of new natural products in Chapter 1, and 
developments in “reverse genetics” techniques which seek to address these shortcomings. 
 Our group has developed a platform to automate analysis of biosynthetic gene clusters and structure 
prediction, described in Chapter 2, which we applied to an understudied family of natural products. RODEO 
(Rapid ORF Description and Evaluation Online) was designed as a practical tool for high-throughput 
analysis of natural product gene clusters, and initially focused on lasso peptides, where our application of 
hidden Markov models, heuristic and sequence motif analysis, and machine learning revealed new 
scaffolds. This genome-mining approach enabled by RODEO prioritized strains with unique biosynthetic 
clusters and predicted lasso peptides, resulting in the isolation of six new compounds with unique structural 
features including one with a new ribosomal peptide post-translational modification and another with an 
unprecedented “handcuff” topology. 
 In Chapter 3, a family of bioinformatically-identified prenyltransferases is investigated that has 
members in several bacterial pathogens. Starting from genomic data, these terpenoid synthase enzymes are 
biochemically characterized and found to be functionally divergent from previously identified examples. 
Sequence analysis suggests residues which are believed to influence activity, and mutagenesis was used to 
provide a starting point for correlating residues to catalysis. 
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 The enzyme family responsible for formation of azol(in)e heterocycles in ribosomal peptide natural 
products is revealed in Chapter 4 to have a new biosynthetic role. Characterization of the bottromycin 
heterocyclases suggest an instance of Nature using a common amide-backbone activation mechanism for 
different reactions - in this case a macroamidine heterocyclization. Substrate tolerance and recognition are 
explored for the unique substrate, which contains bipartite peptide regions for modification and binding by 
the enzymes. More broadly, the genomic distribution of atypical heterocyclases are investigated, indicating 
a high probability of discovering more examples of new biosynthetic chemistry and consequently, new 
natural product scaffolds.  
In Chapter 5, we extend this approach to a different area of YcaO biosynthetic enzymes which are 
implicated to not perform heterocyclizations at all, but instead appear to utilize this mechanism to induce 
thioamidation, an uncommon and divergent post-translational modification. Genetic evidence is found 
which supports the “TfuA-associated YcaOs” as a subfamily capable of thioamidation of ribosomal natural 
products. Whole genome sequencing of “orphan” natural products containing thioamides but no associated 
gene clusters revealed consistent presence of both TfuA-YcaO genes. The co-occurrence of the TfuA-YcaO 
pair were then used to guide screening for new natural products containing thioamides and aid in the 
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CHAPTER 1: INTRODUCTION 
 
1.1 Perspectives on the value of natural products 
 Natural products (NPs), or metabolites from natural sources, have played an immeasurable role in 
the development of therapeutics, agricultural chemicals and molecular probes for the study of biological 
systems. Arguably the most striking indicator of NPs’ impact on modern society is found in medicinal 
treatments - a recent analysis indicated that the plurality of medicines are either NP or NP-derived, and for 
infectious disease, such as bacterial infections, the dominance of NPs becomes remarkably apparent 
(Figure 1.1).1,2 Consequently, the impetus to discover new drugs became a driving force in NP isolation, 
identification and characterization. Indeed, the most productive period of development, or “golden-age” of 
antibiotics, coincided strongly with industrial investment into NP screening efforts, resulting in the 
discovery of many antimicrobial compounds that are currently in use. Compounds developed during this 
time have been identified as inhibitors of a variety of microbial life processes, and form the foundation for 
addressing a major hurdle in human health and ushered in the modern age of medicine. 
Despite the remarkable positive impact NPs have had on modern society, growing challenges for 
chemistry, such as the rise of drug-resistant bacteria, underscore the need to continue development of 
compound libraries with sufficient diversity.3 The suite of modern antibacterials have a variety of modes of 
action, inhibiting different cellular targets both intracellularly and extracellularly, with differing levels of 
efficacy against certain types of pathogens (i.e. Gram-negative/positive, Mycobacterium etc.). However, as 
the inevitable issue of drug resistance becomes more commonplace, options for treatment, even under 
increased antibiotic stewardship, will continue to decline. In general, antibiotic resistance to clinically-used 
compounds is not a new phenomenon – microbes from isolated ecological systems away from human 
civilization have been found to carry resistance genes for commonly-used treatments.4,5 Intriguingly, these 
findings are in fact a consequence of the natural origin of many potent antimicrobials and illustrates the 
genetic resistance “reservoirs” that have evolved long prior to practical use of antibiotics in modern times. 
These findings indicate that the increased incidence of multidrug-resistant pathogens requires an expanded 
repertoire of antibiotics that covers a greater range of molecular targets and chemical space, effectively 






Figure 1.1: Natural products in modern medicine. Natural products and related scaffolds make up the 
plurality of antiinfective drugs and the majority of antibacterials. Adapted from Newman, D.J. and Cragg, 
G.M. (2016).1  
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1.2 Challenges facing natural product discovery 
 Unfortunately, discovery and characterization of new NPs from natural sources has slowed relative 
to previous decades, due largely to a perceived decrease in productivity. Termed the “rediscovery” problem, 
it is recognized that certain abundant classes of NPs have a tendency to re-occur as hits in screening efforts, 
either as a consequence of compound abundance or organism/genetic prevalence.7 As a result, efforts to 
continue growing NP collections fell out of favor, which coincided with the rise of combinatorial chemistry 





Figure 1.2: (cont.) 
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Figure 1.2: Natural product discovery rates. Based on genomic prevalence in typical soil samples where 
the majority of these compounds were discovered, probabilities of discovery based on a de novo screen 
were calculated. One square represents 1000 screens strained and a red square represents a positive hit for 
the indicated scaffold. Tetracycline, chloramphenicol, vancomycin, erythromycin and daptomycin are all 
on the WHO List of Essential Medicines and isolated from soil bacterium (Streptomyces aureofaciens, 
Streptomyces venezuelae, Amycolatopsis orientalis, Saccharopolyspora erythraea, and Streptomyces 
roseosporus, respectively). Adapted from Baltz, R.H. (2006).7 
 
The NP rediscovery issues can in part be attributed to the conventional methods of NP chemistry: 
phenotypic assay fractionation and a forward-genetics approach (Figure 1.2). In NP screening efforts where 
a desired biological phenotype is coupled to an assay, extract fractions can be tested for inhibitory activity 
against pathogens, cancer cell lines etc. or binding to a target receptor, effectively selecting for the activity 
of the compound during the isolation process.7 If such testing is carried out in parallel to separations, i.e. 
phenotype-guided fractionation, the assay readout also serves as a detection method. Phenotypic screens in 
this manner lend themselves to a forward chemical genetics characterization, where the NP’s structural and 
biological properties are characterized first, followed by correlation to its biosynthetic gene cluster (BGC) 
and other relevant genetic elements (e.g. regulatory elements, compound targets etc.).8  
While this approach has resulted in discovery of the majority of NPs found during the early-mid 
20th century and carries the obvious advantage of selecting for desired properties, it is susceptible to 
rediscovery of known compounds. Phenotype-based isolation requires positive assay readout for successful 
NP isolation, and faces two major challenges which result in unproductive discovery efforts: instances 
where (i) highly-abundant compounds of the desired bioactivity skew the screen results, and (ii) genetic 
abundance make the likelihood of rediscovery disproportionately high. In the first case, a known bioactive 
compound is present in high concentrations from the environmental/biological sample relative to new 
chemical entities, or similarly, novel NPs with desired activity are present at concentrations below the 
detection limit. In the second case, BGCs for previously-discovered NPs are simply more prevalent in 
environmental samples, and hence isolates from either organism subcultures or ecological samples will 
proportionately culminate in similar scaffolds. 
The rediscovery problem is particularly evident in efforts to discover new antibiotics from soil-
dwelling microbes. Indeed, terrestrial bacteria have historically yielded excellent returns for drug discovery 
and development campaigns for infectious disease.10 The World Health Organization (WHO) List of 
Essential Medicines antibacterials lists contain a majority of NP or NP-derived compounds, and a plurality 
of these compounds were discovered from soil bacteria.11 Despite success with NP compounds for 
antibacterial purposes, the latter half of the 20th century saw a shift in efforts by pharmaceutical companies 
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towards the development of synthetic libraries, in part motivated by the growing support for combinatorial 
chemistry. These libraries have been fruitful in several areas of drug discovery, including ligand design for 
G-coupled protein receptors, but largely fail to show efficacy in the context of antibacterial assays.2 
Fundamental differences in the overall structures of synthetic libraries when compared to NP libraries were 
hypothesized to be a major factor in the poor activity against pathogens – generally efficacious antibacterial 
compounds tended to have more complex structure with higher overall functional group diversity, polarity 
and stereocenters than the types of compounds generated from a de novo synthesis involving common 
fragments and coupling reactions used to construct pharmaceutical screening libraries. The often-cited 
“Lipinski’s Rule of 5” ballpark metrics for forecasting “druglike”, orally available qualities of compound 
based on structural characteristics were reported with the initial publication to be unreliable specifically in 
the case for antibacterials, and later empirical chemoinformatic analysis of successful antimicrobial 
molecules confirmed this to be true.12,13 Overall, it appears that discovering new antibacterials would require 
not just investment into NPs, but a prioritization of compounds that occupied new chemical space. 
As a result, there has been a renewed interest in NPs, but also to make synthetic libraries more 
“natural product-like”. Function-oriented synthesis aim to create highly-complex molecules, frequently 
based off NP scaffolds, through high step economy focused on recreating only the portions of the molecule 
useful for activity.14 Diversity-oriented synthesis complements this approach by improving on typical 
synthetic library creation methods with an emphasis on greater functional group diversity, stereocenter 
density and scaffold diversity.15,16 To bridge the gap between NP and synthetic libraries, semisynthesis has 
also emerged as a viable option to introduce a higher level of structural diversity in synthetic libraries, while 
avoiding the difficulties associated with discovering and isolating new NPs. One successful application 
uses commercially available NP starting materials for unbiased synthetic reactions aimed at inducing major 
scaffold changes.17 This methodology relies on intrinsic structural complexity present in the starting NPs, 
which in turn provides multiple handles for reactivity, communicates sterochemical information to later 
reactions, and opens up atypical reaction pathways (i.e. decomposition/hydrolysis reactions) as an efficient 
means to build complex libraries.18,19 
The pressing need for new antibiotic scaffolds has become an internationally-recognized issue with 
the evolution of multidrug resistant and extremely drug resistant pathogens. Contemporary World Health 
Organization guidelines have segregated clinically-approved antibiotics into recommended categories of 
deployment which withhold compounds of “last resort” from use to avoid unnecessary selective pressure 
on pathogens to evolve resistance. Accordingly, antibiotics developed relatively recently, such as linezolid 
(synthetic), daptomycin (NP) and 5th generation cephalosporins (NP/NP-derived) are relegated to the 




1.3 Old dog, new tricks: revitalizing natural product chemistry with genomics 
Taken together, the outstanding question for addressing the need for new drugs in the context of 
NP discovery efforts is “are the number and diversity of NPs produced by Nature sufficient to continue as 
the leader in the source of new compounds?” In other words, is the decreasing rate of NPs as new drugs an 
issue of the lowest-hanging fruit being picked, or have we begun to reach the limits of chemical space 
explored by evolution? Studies utilizing whole-genome and metagenomics sequencing suggest the former, 
rather than the latter is likely the case, at least within the types of organisms typically recognized as 
proficient producers of secondary metabolites (i.e. actinobacteria in general, and usually but not exclusively 
within the Streptomyces genus).  
Roughly concurrent with the completion of the Human Genome Project in 2003, whole genome 
assemblies of simpler prokaryotes had revealed a greater genetic complexity in these organisms than had 
been previously appreciated with more typical forward genetic approaches. Specifically, the assembly of 
the Streptomyces coelicolor genome indicated that in addition to the three secondary metabolites that had 
been previously characterized, an additional 26 “cryptic” BGCs were encoded, indicating this organism 
contained a greater biosynthetic capacity than had been observed.21 More broadly, larger efforts have been 
made to assess the biosynthetic capabilities of sequenced organisms and set boundary estimates on NP 
chemical space that remains unexplored.  
Recent reports have attempted to quantify the number of secondary metabolite BGCs via 
bioinformatic metagenomics. Comparisons between candidate BGCs for several NP families across number 
of homologous genes, gene similarity and protein similarity in an extensive set of sequenced actinobacteria 
was used to classify BGCs for types of metabolites into gene cluster families.22 These metrics for the 
prevalence of gene cluster families in were then analyzed to infer on the diversity of biosynthetic capability 
present in this phyla. Results were encouraging, confirming previous studies10 that: (i) soil bacteria contain 
a high diversity of BGCs and by extension potential metabolites and (ii) the number of BGCs outpace the 
number of explored clusters, with many organisms even in this relatively well-studied taxa possessing 
untapped potential. A parallel study analyzing prokaryotes using a BGC annotation algorithm found similar 
results indicating a wealth of undiscovered metabolites present in sequenced organisms, including but not 
limited to actinobacteria, and places a estimate on explored NP chemical space for certain classes at a 
modest 10%, with several NP classes being greatly underexplored.23 While efforts to quantify cryptic BGCs 
can vary based on metrics for identification and classification (often due to the non-trivial nature of making 
reliable annotations of bona fide BGCs, which is often complicated by modularity and complexity of cluster 




While meta-genome mining optimistically prospects that the majority of BGCs remain untapped, 
significant challenges need to be addressed before the large number of cryptic NPs can be exploited, which 
mainly lie with refining the ability of predictive methods to translate genomic data to accurate inferences 
on metabolite structure, and ideally, function. Practical considerations include efficient management of the 
vast amount of data present and the high number of algorithms that need to be applied to fully annotate a 
BGC from a nucleotide sequence (genomic data must be translated, open reading frame (ORFs) must be 
identified and verified, BGC boundaries would ideally be identified based on known NP clusters, but not 
so inflexible so as to preclude hybrid/novel classes, ORF homology must be determined to infer on function) 
which dictate that the computational methods must be highly efficient, otherwise the potential for 
throughput and benefit of genomic analysis is lost.24,25 Furthermore, each of these steps requires significant 
empirical characterization, particularly for BGC/gene annotation to ensure proper function is assigned and 
all of the biosynthetic steps are accounted for. For emerging NP classes, bioinformatic characterization can 
remain open with little precedent. 
 
1.4 Ribosomally synthesized, post-translationally modified peptides (RiPPs) 
  Natural products can be roughly classified based on the type of precursor building blocks and types 
of biosynthetic enzymes involved. Among the major classes are polyketides, ribosomal and non-ribosomal 
peptides, terpenes, alkaloids, phenols, carbohydrates and fatty acids. Ribosomally synthesized, post-
translationally modified peptides (RiPPs) are a subclass of ribosomal peptides which have received 
considerable attention in recent years.26 RiPPs are biosynthetically distinct from their non-ribosomal 
counterparts, though many in many instances peptidic NPs were assumed to be non-ribosomal, but in fact 
were later identified as RiPPs with extensive post-translational modifications (PTMs). 
  RiPPs display several intriguing features that differentiate them as a NP class. Unlike non-
ribosomal peptides, RiPPs originate as linear precursor peptides which are genomically-encoded and made 
via gene transcription/translation from the proteinogenic amino acid pool. A critical feature that allows for 
this diversity lies in the common biosynthetic logic present across the large number of RiPP subfamilies. 
Precursor peptides are composed of two distinct regions: a leader peptide region (typically at the N-
terminus) which is responsible for substrate recognition and binding to PTM enzymes and a core peptide 
region (typically at the C-terminus) which is modified and proteolytically cleaved to become the final 






Figure 1.3: (cont.) 
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Figure 1.3: Ribosomally synthesized and post-translationally modified peptides (RiPPs). (A) General 
biosynthetic scheme for RiPPs. (B) Some representative RiPPs of various subfamilies with post-
translational modifications (PTMs) highlighted in blue. Families shown here include cyanobactins, 
thiopeptides, azole-containing peptides/thiazole/oxazole-modified microcins (TOMMs), streptides and 
lasso peptides.  
 
Despite the limitation to canonical amino acids, RiPPs achieve remarkable structural diversity 
(Figure 1.3b) through two routes: (i) enzymatic tailoring via PTMs, which are modular and promiscuous 
and (ii) rapid structural diversification by encoding multiple copies of mutated precursor peptides. Both of 
these evolutionary outcomes rely on the discrete roles that the leader and core regions play in biosynthesis: 
conserved sequences for binding relax specificity when processing different core sequences. Importantly, 
this allows for less reliance of co-evolution of entire PTM enzymes provided the binding region of the 
leader peptide is maintained.28 Bioinformatic analysis of some RiPP families indeed shows that Nature has 
taken advantage of this paradigm within related sequences by varying core peptide sequences while strongly 
conserving regions of the leader peptide.29 
Within the context of genome-mining applications, RiPPs present unique advantages and 
challenges for bioinformatics-guided discovery. RiPP BGCs are highly modular, as tailoring enzymes are 
encoded as discrete units, rather than modules of a larger mega-synthase complex, which makes recognition 
of cluster boundaries and distinction of the “minimal BGC unit” difficult. With local genomic encoding of 
a precursor peptide within the BGC, there is great potential to glean information about the structure of the 
natural product, provided the correct peptide sequence(s) is recognized.30 However, this is met with 
complications surrounding identification – within intergenic regions, a far greater number of potential 
peptide sequences exist than actual bona fide RiPP precursors, making genome mining tedious and 
problematic. In spite of these complications, the rapidly growing RiPP class stands to benefit highly from 
genome-analysis pipelines focused on novel NPs.  
 
1.5 Genome-mining approaches to augment natural product chemistry 
  Efforts described herein to facilitate NP discovery and biosynthetic study center on applications 
of genome-mining sequenced organisms for markers that indicate the presence of structurally distinct 
molecules. Broadly, these results can be divided into two approaches: (i) analysis of BGC and precursor 
peptide sequences to prioritize novel NP structure and correlate structures to related molecules via 
metagenomics/phylogenetic analysis, and (ii) an enzyme-based genome mining approach which first 
predicts new catalytic function, and by extension new functional group diversity in compound discovery. 
These two complementary techniques seek to identify new structures and quickly “de-replicate” previously-
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characterized scaffolds on the basis of BGC/precursor novelty or biosynthetic enzyme divergence, 
respectively. 
 Multiple computational tools are in place to identify and annotate BGCs for NP biosynthetic 
capabilities, and many of these platforms have found a place in the modern natural product chemist’s toolkit 
as another means of searching for compounds in the “post-genomic era”. Among the most popular is the 
“antibiotics and secondary metabolite analysis shell” (antiSMASH), which since its debut in 2011, has 
undergone continual updates and expansions, including sister programs for non-bacterial organisms 
(antiSMASH fungal version and plantiSMASH for plants).31-35 The antiSMASH pipeline’s key benefit is 
its comprehensive nature, supporting multiple classes of NPs and accepting inputs of various formats, from 
small contigs to entire genomes. A recent effort to catalog and archive results of experimentally-verified 
BGCs and organisms with closed genomes resulted in the development of the Minimum Information about 
a Biosynthetic Gene cluster (MiBIG) and antiSMASH-db databases, respectively, which serve as standards 
for future annotation.32,36 Prediction informatics for secondary metabolites (PRISM) has recently emerged 
as a leading bioinformatics tool for iterative polyketide synthase/non-ribosomal peptide synthetase analysis, 
and offers excellent usability and a strong structure prediction algorithm for these NPs.37  
 Comparatively few robust methods existed with robust algorithms for RiPP analysis, which may 
be a consequence of the inherently large differences in biosynthetic formats between ribosomal peptides 
and other, more traditional NPs. Unlike iterative synthases, for which substrate prediction can be made 
based on sequence motifs present in the modules, genes for RiPP precursor peptides are encoded locally, 
though generally must be identified manually as they are frequently missed by current standard automated 
genome-annotation software such as Prodigal38 and Glimmer.39 Bipartite separation of the recognition and 
substrate regions of the precursor peptide endow variability in the substrates, complicating inference on 
structure. Moreover, the modular nature of RiPP BGCs means correlation through BGC conservation is 
more dynamic, as BGC architecture for co-occurring genes is less static. For development of a general 
platform for RiPP-focused NP discovery, these issues unique to this NP class must be addressed to ensure 
robust predictions.24 
 When employing bioinformatics methods to infer on new catalytic function for metabolite 
biosynthesis, significant progress has been made through platforms which correlate computational data with 
multiple lines of empirical tests. Protein families made through computational annotation are often based 
on analysis against hidden Markov models (HMMs) or other sequence-based comparative tools, and 
consequently will overlook divergent members of the family or be forced to group un-annotated sequences 
together until further characterization is performed (e.g. domains of unknown function DUFs). However, a 
holistic approach incorporating sequence trends, structural information (either through crystal structures or 
homology modeling) and biochemical data on substrate preference can provide a robust strategy for 
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determining protein function. Efforts to adapt structural biology approaches to a high-throughput platform 
seek to generate unprecedented quantities of structural data aided by automation technology. Coupling this 
strategy with unbiased screens for catalytic function, the Enzyme Function Initiative (EFI)’s approach of 
augmenting bioinformatics data by casting a wide net across protein families stands to greatly enhance the 
rate of protein function assignment.40,41 
 When considering how to adapt these methodologies to bias NP chemistry for greater 
chemodiversity, the objectives are slightly different: instead of broad-scale analysis of largely 
uncharacterized protein families aimed at screening for activity, translating domains of unknown function 
(DUFs) to defined biosynthetic roles in NP biosynthesis is arguably best served by expanding on established 
enzymes families that contain diverse subfamilies. Such an approach is a “bioinformatics derivatization” 
of sorts – by identifying protein families with divergent biosynthetic function, diverse structures with little 
precedent can be predicted from BGCs. 
 The work described herein applies both of these strategies in tandem to augment natural product 
chemistry workflows. We developed a new algorithm to automate large-scale genome mining (see Chapter 
2), which addresses many of the unique challenges present for this class of NPs. RODEO (Rapid ORF 
Description and Evaluation Online) combines proven hidden Markov model (HMM)-based BGC 
annotation techniques with a first-in class combination heuristics/machine-learning algorithm to assist in 
the prediction of lasso peptides. Consequently, RODEO’s predictive capabilities surpassed data sets 
generated in other recent large-scale lasso peptide bioinformatics studies, in both number of predicted 
scaffolds and level of detail in structure and feature analysis. Importantly, the bioinformatics results were 
able to assist in the discovery of several new lasso peptides, greatly reducing the screening time and 
technical difficulty with its sequence-based predictions. 
 For expanding biosynthetic machinery characterization, we investigated a subfamily of 
prenyltransferases present in pathogenic bacteria (see Chapter 3). These enzymes were found to be 
involved in a “head-to-head” condensation reaction and were used to inform on related prenyltransferases 
occupying similar sequence space. Structural and sequence comparisons identified residues which may be 
involved in catalysis of these reactions, and can possibly identify residues which can change reactivity 
profiles in future work. 
 Returning to RiPPs, we investigate the YcaO superfamily, which is known to be involved in azoline 
biosynthesis in ribosomal natural products. Despite significant characterization, this extensive superfamily 
contains outliers in sequence space which show limited homology and unprecedented genome contexts for 
these enzymes. Among these outliers is the BGC for bottromycin, which contains two YcaOs, but lack the 
typical partner protein typically required for effective catalytic activity. Our work indicates that these 
YcaOs constitute a subfamily which is capable of distinct heterocyclization reactions (see Chapter 4), 
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which form the major steps in bottromycin biosynthesis. Our characterization shows that these enzymes 
bind substrate in an unusual fashion and show atypical substrate specificity for these enzymes. More 
broadly, this provides the first conclusive evidence of new catalytic function by a YcaO, setting the stage 
for future investigations in other unexplored areas of this superfamily. As an extension of this work, we 
began characterization of “TfuA-associated” YcaOs, a different subfamily which genetically localized with 
a TfuA-like protein of unknown function in ~10% of all bioinformatically identifiable YcaOs. Whole 
genome sequencing and broad gene cluster analysis revealed a putative role in RiPP thioamide formation, 
an unexplored PTM for these NPs (see Chapter 5). Using the TfuA-associated YcaO as a bioinformatic 
handle, we discovered a subset of thiopeptide NPs which we predicted to contain thioamides and discovered 
candidate RiPPs that we expect to bear this modification, along with a new thiopeptide NP structure.  
 The field of natural products is undergoing of a revitalization by modern genomics - with the advent 
of accessible and rapid whole-genome sequencing chemists and biologists are able to contextualize the 
scope of biosynthetic potential. Even in routine, workhorse microbes it became increasingly clear that 
Nature’s synthetic capabilities were greater than had been previously appreciated. Refinement of the 
collection of techniques that constitute “genome-mining” will continue to expand the chemical space for a 
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CHAPTER 2: AUGMENTING NATURAL PRODUCT DISCOVERY WITH GENOME MINING 
This work has been previously published.*
 
2.1 Introduction 
Natural products have transformed the practice of medicine, where a major percentage of clinically 
relevant molecules are NPs, mimics, or derivatives1. Despite this, the discovery of novel NPs remains an 
endeavor largely based on trial and error; the bioassay-guided isolation method historically was fruitful, but 
abundant, long-known compounds dominate such screens, resulting in the costly and time-consuming 
“rediscovery problem”2. Reconciling the challenges of traditional NP discovery with the opportunities of 
modern genomics, computational methods represent a promising bridge between genes and molecules3,4. 
In this way, genomic information allows for NP structural prediction, facilitates prioritization based on 
predicted novelty, and guides structure elucidation5,6. 
Biosynthetic gene cluster (BGC) analysis tools that predict structure based on functional domain 
content and architecture have been developed3,6-9. These tools work especially well for modular assembly-
line complexes, such as polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS), and 
has enabled their broad-scale profiling10,11. This type of analysis is not as straightforward for other NP 
classes, such as the ribosomally synthesized and post-translationally modified peptides (RiPPs)12. As gene-
encoded peptides, RiPP precursors are enzymatically tailored to produce diverse compounds (Figure 2.1a). 
RiPPs also present unique characteristics for genomic identification: (i) their BGCs are relatively small, (ii) 
RiPP precursors are typically encoded near the modification enzymes, (iii) their sequence can be used to 
predict novelty and aid structure elucidation5, and (iv) RiPP precursors have separate sites for enzyme-
binding and modification (referred to as the leader and core regions, respectively). The unmodified leader 
region is proteolytically removed during maturation. This provides a facile route to evolving new NPs since 
                                                     
* This chapter is adapted in part from Jonathan I. Tietz, Christopher J. Schwalen, Parth S. Patel, Tucker Maxson, 
Patricia M. Blair, Hua-Chia Tai, Uzma I. Zakai, Douglas A. Mitchell “A new genome-mining tool redefines the lasso 
peptide biosynthetic landscape.” Nat. Chem. Biol. 2017, (13), 470–478. doi:10.1038/nchembio.2319. J.I.T. and C.J.S. 
contributed equally to this work. Experiments were designed by J.I.T., C.J.S. and D.A.M and were performed by J.I.T., 
C.J.S., T.M., P.M.B., H-C.T. and U.I.Z. J.I.T., P.S.P. and C.J.S. wrote code. The manuscript was written by J.I.T., 
C.J.S., and D.A.M. We thank Lingyang Zhu (Univ. Illinois Urbana-Champaign) and Ben Ramirez (Univ. Illinois 
Chicago) for NMR assistance. We acknowledge Courtney Cox, Kisurb Choe (Univ. Illinois Urbana-Champaign), and 
Nicholas Tietz for valuable computational and programming input. This work was supported in part by a NIH 
Director’s New Innovator Award Program (DP2 OD008463 to D.A.M.), the David and Lucile Packard Fellowship for 
Science and Engineering (to D.A.M.), the Robert C. and Carolyn J. Springborn Endowment (to J.I.T.), and ACS 
Division of Medicinal Chemistry Predoctoral Fellowships (to P.M.B. and J.I.T.). The Bruker UltrafleXtreme MALDI 
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code 5JPL). The genome of S. albulus was deposited in GenBank with the accession number LWBU00000000. The 
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RiPP enzymes can be highly selective for a particular leader sequence but promiscuously process many 
core sequences13. 
Methods for mining RiPPs include single-input whole-genome analysis (e.g. antiSMASH and 
BAGEL3)9,14 and RiPPquest, a mass spectrometry-based method for connecting BGCs to molecules. 
However, a customizable platform to predict RiPP BGCs across all taxa in a single query has remained an 
unmet challenge. To develop such a platform, we have initially focused on lasso peptides, a RiPP subfamily. 
Lasso peptides present additional challenges, for instance, there can be as few as two essential biosynthetic 
enzymes, both closely related to primary metabolism. The BGCs are thus very small and easily overlooked. 
Furthermore, nearly all lasso peptide precursors are not recognized as coding sequences and their 
hypervariability makes their identification nontrivial.  
Lasso peptides biosynthesis requires two enzymes: a lasso cyclase (C-protein) homologous to 
asparagine synthase and a leader peptidase (B-protein) homologous to transglutaminase. Lasso peptides 
contain a macrocyclic linkage between an Asp or Glu side chain to the N-terminus of the core peptide. The 
C-terminal tail is threaded through the macrocycle, giving a lariat topology for which the lasso peptides are 
named (Figure 2.1b). Threading is maintained either by disulfide bonds between the macrocycle and tail 
or by bulky tail residues15. These features impart exceptional stability towards proteases and heat, as well 
as a diversity of bioactivities. Lasso peptide BGCs frequently feature transporters and a RiPP recognition 
element (RRE, E-protein) which binds the leader peptide and directs enzymatic modification13. Interest in 
these scaffolds is evident from the numerous studies geared toward generating unnatural lasso peptides16-
18. 
Herein we report the development of RODEO (Rapid ORF Description and Evaluation Online), an 
algorithm developed to analyze RiPP BGCs via a combination of profile hidden Markov model (pHMM)-
based local genomic analysis and precursor peptide/structure prediction using a combination of heuristic 
scoring, motif analysis, and machine learning. We have demonstrated the utility of RODEO by surveying 
and annotating the observable lasso peptide genomic space, revealing >1,400 BGCs, which expands the 
family by an order of magnitude. Our data revealed unforeseen trends in both precursor sequences and BGC 
architecture that yielded the most complete picture of lasso peptides to date. In addition to connecting all 
previously isolated lasso peptides to their respective BGCs, our analysis revealed a large number of 
conserved lasso peptide families. Furthermore, trends in core peptide sequence and BGC architecture, 
including co-occurrence of previously-unrecognized tailoring enzymes are described. Lastly, we leveraged 
this new data set to isolate and characterize several new lasso peptides, which revealed a modification 
heretofore unseen in any RiPP, as well as a novel lasso topology. Hence, RODEO aids in the generation of 
high-quality, extensive data sets that here revealed the extent of chemical/genetic diversity in a RiPP class 




Figure 2.1: Ribosomal natural product (RiPP) biosynthesis and overview of RODEO. (A) General 
overview of RiPP biosynthesis. (B) Overview of lasso peptide biosynthesis by leader peptidase, lasso  
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Figure 2.1: (cont.) cyclase, and RRE. (C) RODEO workflow and output. (D) Comparison of scoring 
accuracy on a randomly selected training set using heuristic scoring only or scoring with combined motif 
analysis (MEME) and machine learning (SVM). Sensitivity is represented by recall; specificity is 
represented by precision. (E) Comparative scoring distribution on the final peptide dataset using either 
heuristics only or scoring with MEME and SVM integrated. Scoring distributions were practically 
indistinguishable between training and full data sets (Figure 2.2). Currently, RODEO is optimized to score 




Figure 2.2: Scoring distributions for peptides. This figure expands upon what is shown in main text 
Fig. 2.1e. (A) Peptide scoring distribution using only heuristics-based linear combination scoring; (B) 
Scoring in panel A with the addition of MEME/FIMO-identified sequence motif presence; (C) Scoring in 





2.2 Identification of lasso peptide biosynthetic gene clusters 
To address the challenges associated with lasso peptides, RODEO can rapidly analyze a large 
number of BGCs by predicting the function for genes flanking query proteins. This is accomplished by 
retrieving sequences from GenBank followed by analysis with HMMER3. The results are compared against 
the Pfam database with the data being returned to the user in spreadsheet and HTML format19-21 (Figure 
2.1c). For analysis of BGCs encoding proteins not covered by Pfam, RODEO allows usage of additional 
pHMMs (either curated databases or user-generated). Although RODEO was designed for lasso peptides, 
it provides a logically expandable framework to target other RiPP and non-RiPP BGCs.  
Taking advantage of RODEO’s ability to rapidly analyze genes neighboring a query, we compiled 
a list of all observable lasso peptide BGCs in GenBank. We reasoned that a comprehensive evaluation of 
this data set would provide unprecedented insight into a widespread, but understudied, NP family. Lasso 
peptide BGCs were defined by the local presence of genes encoding proteins matching the Pfams for the 
lasso cyclase, leader peptidase, and RRE (Figure 2.1b). This procedure identified 1,419 prospective lasso 
peptide BGCs. 
 
2.3 Identification of lasso peptide precursor peptides 
The previously mentioned challenges regarding the confident identification of RiPP precursors 
render traditional methods insufficient. For example, in our final set of lasso peptide precursors described 
below, ~85% were not recognized as coding sequences in GenBank. Moreover, nucleotide and protein 
BLAST searches using all known lasso peptides as the query sequence, cumulatively returned <300 hits, of 
which validation without laborious manual inspection of each BGC was unreliable. Low alignment scores 
between even closely-related peptides made distinguishing false positives from true lasso precursors 
impossible in most cases. To confidently predict lasso precursors, RODEO next performed a six-frame 
translation of the intergenic regions within each of the potential 1,419 BGCs. The resulting peptides were 
assessed based on length and essential sequence features and split into predicted leader and core regions. A 
series of heuristics based on known lasso peptide characteristics15,22 were defined to predict precursors from 
a large pool of false positives (Table 2.1). After optimization of heuristic scoring, we obtained good 





















Within 500 nucleotides of any biosynthetic protein (E, B, C) +1 
Within 150 nucleotides of any biosynthetic protein (E, B, C) +1 
Greater than 1000 nucleotides from every biosynthetic protein (E, B, C) -2 
Core region has 2 or 4 Cys residues +1 
Leader region is longer than core region +2 
Core has 7 (Glu) or 8(Glu/Asp) or 9 (Asp) membered ring possible +1 
Core starts with G +2 
Leader region contains GxxxxxT +3 
Peptide and lasso cyclase are on same strand +1 
Leader/core region length ratio < 2 and > 0.5 +1 
Core starts with Cys and has an even number of Cys 0 
Core contains no Gly -4 
Core has at least one aromatic residue +1 
Core has at least 2 aromatic residues +2 
Core has odd number of Cys -2 
Leader region contains Trp -1 
Leader region contains Lys +1 
Leader region has Cys -2 







Peptide contains sequence motif #2 +2 
Peptide contains ANY lasso sequence motif +2 
Peptide contains NO lasso sequence motifs -1 






SVM classifies as valid +10 
 
Table 2.1: Scoring metrics for lasso peptides. Peptide scoring guidelines for heuristics-based linear 
combination scoring with the addition of MEME/FIMO-identified sequence motif and support vector 




We reasoned that machine learning, particularly support vector machine (SVM) classification, 
would be more effective in locating precursor peptides from predicted BGCs more distant to known lasso 
peptides23. Although SVM has been previously used to predict NRPS substrate specificity24, to our 
knowledge, it has not yet been used to predict NP structures themselves. SVM is well-suited for RiPP 
discovery due to availability of SVM libraries that perform well with large data sets with numerous 
variables and the ability of SVM to minimize unimportant features25. After calculation of >100 features 
(Table 2.2), we optimized the SVM classifier using a randomly selected and manually curated training set 
from the unrefined whole data. Of these, a random sub-population was withheld as a test set to avoid over-
fitting. We found that by combining SVM classification with motif (MEME) analysis,26 along with our 
original heuristic scoring, prediction accuracy was greatly enhanced as evaluated by recall and precision 
metrics (Figure 2.1d-e, Figures 2.2-2.3). This tripartite procedure yielded a high-scoring, well-separated 
population of 1,315 lasso precursor peptides from >24,000 candidate peptides. The training set was found 
to display nearly identical scoring distributions upon comparison to the full data set.  
 
Feature Data type Feature Data type 
Calcd. lasso peptide mass (Da) Float Core has adjacent identical aas Boolean 
Minimum distance from C, E, or 
B protein (nt) 
Integer Core length (aa) Integer 
Within 500 nt of C, E, or B Boolean Leader length (aa) Integer 
Within 150 nt of C, E, or B Boolean Precursor length (aa) Integer 
Further than 1000 nt from C, E, 
or B 
Boolean Leader/core ratio Float 
Core has 2 or 4 Cys Boolean Number of Pro in first 9 aa of 
core 
Integer 
Leader is longer than core Boolean Estimated core charge at neutral 
pH 
Integer 
Can form most common size 
ring 
Boolean Estimated leader charge at 
neutral pH 
Integer 
Leader has GxxxxxT motif? Boolean Estimated precursor charge at 
neutral pH 
Integer 
Core starts with G? Boolean Absolute value of core charge at 
neutral pH 
Integer 
Table 2.2: (cont.) 
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Core and BGC in same 
direction? 
Boolean Absolute value of leader charge 
at neutral pH 
Integer 
Ratio leader/core < 2 and > 0.5 Boolean Absolute value of precursor 
charge at neutral pH 
Integer 
Core starts with Cys and has 
even number of Cys 
Boolean Number in leader of each amino 
acid 
Integer 
No Gly in core Boolean Number in leader of each amino 
acid type (aromatic, aliphatic, 
hydroxyl, basic, acidic) 
Integer 
Core has at least 1 aromatic aa Boolean Number in core of each amino 
acid 
Integer 
Core has at least 2 aromatic aa Boolean Number in core of each amino 
acid type (aromatic, aliphatic, 
hydroxyl, basic, acidic) 
Integer 
Core has odd number of Cys Boolean Number in entire precursor of 
each amino acid 
Integer 
Leader has Trp Boolean Number in entire precursor of 
each amino acid type (aromatic, 
aliphatic, hydroxyl, basic, acidic) 
Integer 
Leader has Lys Boolean Presence of each of motifs 1–16 Boolean 
Leader has Cys Boolean Total motifs hit Integer 
Cluster has PF00733 Boolean MEME/FIMO score of each of 
motifs 1–16 
Float 
Cluster has PF05402 Boolean Sum of MEME scores Float 
Cluster has PF13471 Boolean No motifs present Boolean 
Leader has LxxxxxT motif Boolean Alternate start codon used Boolean 
Core starts with aa (for each) Boolean   
 
Table 2.2: SVM features list. Features and their data types are shown. Features were calculated for each 
prospective peptide using RODEO or using Excel on the RODEO output. Feature lists were then used 




The identification of 1,315 high-scoring lasso precursors within 1,419 BGCs further bolstered our 
confidence in the predictive value of RODEO. Most BGCs contain one lasso precursor peptide, although 
two contain as many as six. For the cases where a precursor was not identified, it is possible the peptide 
deviated too far from prediction guidelines, is encoded elsewhere in the genome, or the BGC is defunct. 
 
Figure 2.3: Evaluation of scoring accuracy and generality. Shown are accuracy scores, as represented 
by precision (specificity) and recall (sensitivity) as well as a multiplied optimization score, for various score 
cutoffs used to classify lasso peptides as true positives. Shown accuracy rates are for the randomly selected 
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Figure 2.3: (cont.)  training set. Accuracy progressively improves from a heuristic-only approach (A) when 
motif presence (B) or motif presence and SVM classification (C) are used in scoring. Scoring distributions 
are nearly identical between the training dataset (25% of full set) and the full dataset, as shown 
comparatively in (D). 
 
2.4 Comparison of RODEO to existing bioinformatic tools 
To compare predictive abilities with existing tools, the 1,419 RODEO-identified lasso peptide-
containing genomes were submitted to antiSMASH. Contrary to RODEO, each genome had to be 
individually queried given that antiSMASH is a single-input whole-genome analysis tool3. AntiSMASH 
identified 87% of the lasso peptide BGCs found by RODEO (Table 2.3). This good agreement was 
expected given the dual reliance on pHMM analysis in identifying BGCs. AntiSMASH, however, does not 
predict RiPP precursor peptides but the program does attempt to predict local coding sequences. For 16% 
of cases, the RODEO-identified lasso precursor gene was predicted as a gene by antiSMASH, albeit along 
with many others (Table 2.3). A companion repository, the antiSMASH Database, was recently developed 
to analyze antiSMASH data compiled from many genomes27. This program currently surveys only complete 
genomes listed in GenBank and thus predicted only 351 lasso peptide BGCs with no predictions for 
candidate precursor peptides.  
Recently, PRISM’s functionality has been expanded to analyze prokaryotic genomes for RiPP 
BGCs, including lasso peptides28. RiPP-PRISM, which combines heuristics with pHMM validation, 
returned a similar estimate to the total number of lasso BGCs as RODEO, although the composition varied 
significantly (Table 2.3). Lastly, we compared the predictive capabilities with another popular tool, 
BAGEL314. This program was capable of identifying the majority of a randomly selected subset of lasso 
peptide BGCs; however, BAGEL3 either misclassified the RRE protein as the precursor peptide or missed 











# lasso peptide BGCs 
identified 
1,419 1,237 (87%) 1,4662 
# lasso peptide precursors  
annotated as a gene 









Actinobacteria 507 35.9 544 37.5 
Proteobacteria 494 35.0 843 58.1 
Firmicutes 301 21.3 57 3.9 
Cyanobacteria 57 4.0 2 0.1 
Bacteroidetes 25 1.8 1 0.1 
Euryarchaeota 11 0.8 0 0.0 
Acidobacteria 10 0.7 1 0.1 
Verrucomicrobia 4 0.3 0 0.0 
Candidatus 
Tectomicrobia 
2 0.1 1 0.1 
Fusobacteria 1 0.1 1 0.1 
 
Table 2.3: Comparison of RODEO with antiSMASH 3.0 and PRISM. AntiSMASH 3.0.5 was locally 
installed according to the instructions: http://secondarymetabolites.org/antismash. RODEO-predicted 
lasso peptide queries were formatted into nucleotide FASTA sequences using NCBI Batch Entrez 
(https://www.ncbi.nlm.nih.gov/sites/batchentrez) and analyzed by antiSMASH in groups of <300 
queries per run to avoid crashing. The EMBL, SVG, XLS, BiosynML, metabolicmodel, HTML and TXT 
                                                     
2 PRISM output lacked explicit GI/accession identifiers for the BGCs identified, limiting a direct 
comparison. A phylogenetic distribution comparison (panel B) illustrates there are major differences in the 
predictive capability of these programs. 
3 antiSMASH 3.0 does not make explicit predictions about which gene may be the precursor peptide (and 
there is no scoring function). Instead, the antiSMASH pipeline utilizes Glimmer 329. Delcher, A.L., 
Bratke, K.A., Powers, E.C. & Salzberg, S.L. Identifying bacterial genes and endosymbiont DNA with 
Glimmer. Bioinformatics 23, 673-679 (2007). for gene prediction 
(https://ccb.jhu.edu/software/glimmer/). In 16% of cases, antiSMASH displays predicts a nearby gene 
that actually encodes the correct lasso peptide core sequence. 
4 Lasso peptide precursor peptides predicted by PRISM28. Skinnider, M.A. et al. Genomic charting 
of ribosomally synthesized natural product chemical space facilitates targeted mining. Proceedings of the 
National Academy of Sciences 113, E6343-E6351 (2016). are not provided in the Supporting Information 
data sets, and accordingly could not be directly compared to those predicted by RODEO. 
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Table 2.3: (cont.) outputs were all disabled. The GenBank output files were analyzed using a Python script. 
Due to constraints with running >1,400 queries on the PRISM webserver, and with no local installation 
available, the supplemental dataset was instead queried and compared on the basis of lasso peptide BGC 
counts per phylum. Percentages of BGCs and precursors predicted by antiSMASH are shown as fraction of 
matches that were also found in the RODEO set. 
 
 
Figure 2.4: Phylogenetic map of all identified lasso peptides. A SSN of precursor peptides is shown with 
an E-value cutoff of 10-8. Background shading indicates phylum. Node shading indicates if the NP has been 
isolated or detected in culture (including this study). 
 
2.5 Analysis of lasso peptide core sequences 
A sequence similarity network (SSN) of the 1,315 lasso precursors was constructed to visualize 
diversity, distribution, and discovery status (Figure 2.4)30. It was immediately apparent that the majority of 
lasso peptide structural diversity remains unexplored, particularly in the Firmicutes, Cyanobacteria, 
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Euryarchaeota, and Bacteroidetes. Intriguingly, many large lasso peptide families do not have any isolated 
members. Also, two of the best-known lasso peptides, microcin J25 and lariatin, are in fact unique 
examples. 
As sequence biases have important discovery and engineering implications, we next analyzed the 
residue composition of the 1,315 precursors. We surmised this would reveal a more universal perspective 
on sequence trends compared to rules inferred from the limited number of previously-isolated lasso 
peptides. For instance, it was long believed that lasso peptide biosynthesis required Gly to be the first core 
peptide residue22,31. Recently, lasso peptides with N-terminal Cys, Ala, and Ser have been reported32,33, 
demonstrating that sequence diversity at this position has been markedly underestimated. Upon inspection 
of the full set of lasso peptides, the first core position does indeed prefer small residues, with the majority 
being Gly (62%) or Ala (16%). However, Leu is unexpectedly common (7%) and fittingly, we isolated 
members of the lagmysin and citrulassin families (Figure 2.5) that contain the first examples of N-terminal 





Table 2.4: Residue frequencies within lasso precursor peptides.  
31 
 
Table 2.4: (cont.) Reference: Amino acid scale: Amino acid composition (%) in the UniProtKB/Swiss-
Prot data bank. http://web.expasy.org/protscale/pscale/A.A.Swiss-Prot.html. Aliphatic: (Ala, Gly, Ile, Leu, 
Pro, Val); aromatic: (Phe, Trp, Tyr); acidic: (Asp, Glu); basic: (Arg, His, Lys); hydroxyl: (Ser, Thr); 
sulfuryl: (Cys, Met); amide (Asn, Gln). 
 
The hallmark lasso peptide macrocycle poses many questions that only an extensive data set is 
poised to answer. For instance, the conformation-restricting Pro residues of caulosegnin aids in maintaining 
stability34, but do similar trends broadly hold true? We found that Pro is only slightly overrepresented in 
the macrocycle region of the core, accounting for 6.1% (expected 4.7%, Table 2.4)35. In contrast, Gly is 
significantly overrepresented in the macrocycle (22.8% versus 7.1% expected), suggesting that flexibility 
is biosynthetically crucial. Aromatics are overrepresented in the tail region, likely due to their role in 
maintaining a threaded topology (Figure 2.5a)15. The unexpected prevalence of C-terminal Ser strongly 
correlates with the co-occurrence of a Ser kinase gene in several lasso peptide families, including the 
paeninodins34 and yet-unexplored mesonodins and aneurinodins (Tables 2.5-2.6), suggesting an O-
phosphorylation site. These sequence biases point to roles for particular residues to interact with enzymes, 
maintain threading, and elicit bioactivity. Knowledge of these trends will facilitate future biosynthetic, 





















Table 2.5: (cont.) 
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Table 2.5: Major lasso peptide families. Structural families with >7 members are indicated. Families with 
italicized names have no isolated members. Novel families were named based on either conserved sequence 




Pfam Count Title Name 
none 1748 none none 
PF00733 1437 Asn_synthase Asparagine synthase (lasso cyclase) 
PF13471 1164 Transglut_core3 Transglutaminase-like superfamily (leader peptidase) 
PF05402 959 PqqD Coenzyme PQQ synthesis protein D (PqqD, RRE) 
PF00005 841 ABC_tran ABC transporter 
PF07475 456 Hpr_kinase_C HPr Serine kinase C-terminal domain 
PF14907 387 NTP_transf_5 Uncharacterised nucleotidyltransferase 
PF00664 243 ABC_membrane ABC transporter transmembrane region 
PF00593 240 TonB_dep_Rec TonB dependent receptor 
PF00535 221 Glycos_transf_2 Glycosyl transferase family 2 
PF00326 199 Peptidase_S9 Prolyl oligopeptidase family 
PF08281 192 Sigma70_r4_2 Sigma-70, region 4 
PF00392 163 GntR Bacterial regulatory proteins, gntR family 
PF02397 132 Bac_transf Bacterial sugar transferase 
PF04773 130 FecR FecR protein 
PF00072 127 Response_reg Response regulator receiver domain 
PF12730 119 ABC2_membrane_4 ABC-2 family transporter protein 
PF13560 117 HTH_31 Helix-turn-helix domain 
PF00419 99 Fimbrial Fimbrial protein 
PF07690 98 MFS_1 Major Facilitator Superfamily 
PF13302 95 Acetyltransf_3 Acetyltransferase (GNAT) domain 
PF12833 86 HTH_18 Helix-turn-helix domain 
PF00440 81 TetR_N Bacterial regulatory proteins, tetR family 
PF00106 74 adh_short short chain dehydrogenase 
PF01381 74 HTH_3 Helix-turn-helix 
PF00722 69 Glyco_hydro_16 Glycosyl hydrolases family 16 
PF00196 66 GerE Bacterial regulatory proteins, luxR family 
PF02563 63 Poly_export Polysaccharide biosynthesis/export protein 
PF13407 63 Peripla_BP_4 Periplasmic binding protein domain 
PF00291 61 PALP Pyridoxal-phosphate dependent enzyme 
PF01943 61 Polysacc_synt Polysaccharide biosynthesis protein 
PF02653 61 BPD_transp_2 Branched-chain amino acid transport system / permease 
component 
PF00528 60 BPD_transp_1 Binding-protein-dependent transport system inner membrane 
component 
PF00534 60 Glycos_transf_1 Glycosyl transferases group 1 
PF00132 59 Hexapep Bacterial transferase hexapeptide (six repeats) 
PF00501 59 AMP-binding AMP-binding enzyme 
PF01757 59 Acyl_transf_3 Acyltransferase family 
Table 2.6: (cont.) 
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PF05721 59 PhyH Phytanoyl-CoA dioxygenase (PhyH) 
PF01041 57 DegT_DnrJ_EryC1 DegT/DnrJ/EryC1/StrS aminotransferase family 
PF07730 56 HisKA_3 Histidine kinase 
PF13614 55 AAA_31 AAA domain 
PF11089 53 SyrA Exopolysaccharide production repressor 
PF00583 52 Acetyltransf_1 Acetyltransferase (GNAT) family 
PF03466 51 LysR_substrate LysR substrate binding domain 
PF08240 51 ADH_N Alcohol dehydrogenase GroES-like domain 
 
 
Table 2.6: Pfam co-occurrence analysis for all lasso peptide gene clusters. Pfams with >50 occurrences 
are indicated (which represents a co-occurrence within at least 3.5% of all lasso peptide BGCs). A 
comprehensive list can be found in the Supplementary Data Set. Counts indicate number of proteins for 





Figure 2.5: Lasso peptide sequence analysis. (A) Lasso peptide structural features and common residues 
mined from RODEO analysis. (B) Organization of predicted lasso peptides into families. Roughly half of 
the identified BGCs had identical or closely related clusters in other organisms. (C) Sequence logos for 
lasso peptide families with >20 members show wide variance in sequence composition and degree of 
conservation. Numbers in parentheses refer to number of instances found per family. Residues are color-
coded according to basic (green), acidic (purple), or hydrophobic (orange) character. 
 
2.6 Evolutionary insights into lasso peptide biosynthesis 
SSNs of the lasso peptide biosynthetic enzymes show strong correlation to those with closely-
related precursor peptides (Figure 2.4 and Figures 2.7-2.9). The similarity of these proteins also strongly 
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correlates with phylum, which in conjunction with %GC comparison of the BGC to the whole genome 
(Figure 2.6), suggests that lasso peptide BGCs are primarily transferred vertically. 
 
Figure 2.6: Lasso peptide distribution & %GC. (A) Number of precursor peptides per cluster. (B) 
Taxonomic distribution of lasso peptide producers. Genera with more than 10 identified lasso BGCs are 
indicated. (C) Counts of class I, II, and III lasso peptides (based on number of Cys and disulfides, in 
predicted core regions). (D) GC content analysis. Parametric analysis for horizontal gene transfer was 
performed by comparing GC content of the lasso synthase to the organism genome on 1,089 RODEO-
mined lasso clusters. Linear regression was calculated and the five percent with the highest residual 
deviation were analyzed. Points corresponding to the well-known microcin J25 and lariatin B lasso peptide 





Figure 2.7: Sequence similarity network of lasso peptide cyclases (PF00733). Only PF00733 proteins 
predicted to belong to lasso peptide BGCs are shown. This figure, which expands upon Figure 2.10, was 





Figure 2.8: Sequence similarity network of lasso peptide protease (PF13471). Only PF13471 proteins 






Figure 2.9: Sequence similarity network of lasso peptide RRE (PF05402). Only PF05402 proteins 





Akin to other RiPPs, lasso peptide biosynthesis is orchestrated by the binding of the leader peptide 
by a ~90 residue RRE domain13. This facilitates interaction with modification enzymes and largely accounts 
for the substrate specificity of RiPP biosynthesis. With rare exception (discussed later), the lasso peptide 
RRE is present as a discrete protein (E; previously, B1) or fused to the leader peptidase (B; previously, B2). 
We noted from our survey that E-B fusions occur only in a subset of Proteobacteria (and a few scattered 
additional examples), distinct E and B proteins are present in all phyla and vastly outnumber fused cases 
(Figure 2.10). Therefore, we recommend adoption of an E/B nomenclature, as it is more logical 




Figure 2.10: Phylogenetic and co-occurrence analysis of lasso BGCs. A maximum-likelihood tree was 
generated from a representative 10% of lasso cyclases. Non-lasso Asn synthases are given as outgroups. 
Co-occurrence with seven common Pfams are indicated by symbols defined in the legend. The lasso 
cyclases form three large clades: the kinase/nucleotidyltransferase-containing clade, the fused RRE-leader 
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Figure 2.10: (cont.) protease clade within Proteobacteria, and the Actinobacterial clade. Comprising ~50% 
of the Proteobacterial clade are BGCs also containing the lasso-linearizing isopeptidase. Fused and discrete 
E/B proteins are indicated with open or filled black circles, respectively. 
 
Figure 2.11: Precursor peptide/RRE co-evolution analysis. (A) Plot of GREMLIN-derived co-evolving 
residues for a paired alignment of precursor peptides (site 1-40) and RREs (41-125). Dot size corresponds 
to probability. (B) Alignment of precursor peptides with motif L1 site indicated. (C) Alignment of RREs 
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Figure 2.11: (cont.) with motifs R1, R2, and R3 indicated. (D) Co-occurring motifs between leader regions 
and RREs. (E) Motifs and co-evolving residues mapped onto a homology model of the RRE StmE 
(streptomonomicin biosynthesis), based on structure of LynD. 
 
In addition to inferring evolutionary lineages, analysis of the data set enabled us to evaluate 
interactions between the precursor and biosynthetic proteins. We reasoned that physically interacting 
residues may be discernable by analyzing conserved motifs that correlate between the two binding partners. 
Therefore, paired alignments of lasso precursors and RREs were analyzed for the presence of gapless 
sequence motifs using MEME (Figure 2.11). Whereas most RRE motifs did not correlate to any core motifs 
(and vice versa), this analysis revealed a widely-distributed leader sequence motif (motif L1: 
YxxPxLx3Gx5Tx) that showed excellent correlation to three motifs in the RRE. Motif L1 is present in 800 
(63%) lasso precursors with the first portion of the motif, YxxP, represented in all lasso peptide-containing 
phyla (Figure 2.12). Notably, the strong YxxP correlation was only observed for BGCs harboring distinct 
E- and B-proteins. Upon surveying RREs from fused E-B proteins, only 1 motif remained significantly 





Figure 2.12: Distribution of the YxxP motif in lasso precursor peptides. A sequence-similarity map 
with an E-value threshold cutoff of 10-8 is shown. Nodes represent precursor peptide. Sequences where the 
leader region contains a YxxP motif are indicated in dark grey. This figure is analogous to Figure 2.4. 
 
To augment motif correlations, we further reasoned that interacting residues could be identified via 
co-evolutionary analysis, given that if one binding partner were to mutate at a critical location, the other 
would need a compensatory mutation to maintain binding36. We thus employed GREMLIN37  to identify 
such residues and the results agreed well with previously-reported binding constants for StmE, the RRE for 
streptomonomicin (Figure 2.11)13,33. For instance, StmE-D69A bound StmA with 75-fold lower affinity 
compared to wild-type. Several locations of the leader peptide are clearly co-evolving with the RRE, 
especially towards regions of the RRE involved in peptide binding (α3/β3). Upon mapping the co-evolving 
sites onto a StmE homology model, the residues localized primarily to one face of the protein38. No evidence 
of co-evolution was found between the core region and the RRE, underscoring the functionally bipartite 
nature of RiPP precursors12. These results provide an evolutionary model for leader peptide recognition by 
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RRE-containing proteins, and more broadly, support the hypothesis that variation in RiPP core peptides 
seeds NP diversification. 
 
 
Figure 2.13: Annotated SSNs of lasso cyclase protein. Network was visualized with an edge cutoff E-
value threshold of 10-80 with nodes colored by phylum. Location within the network of known lasso peptides 
(including this study) are indicated. 
 
2.7 Identification of BGCs with unusual architectures 
Our survey revealed a large number of lasso peptide BGCs containing unusual domain 
architectures. Fusions of the leader peptidase and transporter, for instance, are found in 38 BGCs, including 
various Ruminococcus species (Figure 2.14) as well as Streptococcus, and Enterococcus, etc. Other notable 
findings include fusions of a lasso cyclase and RRE, as well as a leader peptidase and lasso cyclase in 
Bifidobacterium reuteri and Acidobacteriaceae bacterium TAA166, respectively. Also noteworthy from 
Acidobacteriaceae is the precursor, which replaces the otherwise invariant Thr at the penultimate position 
of the leader with Ile. This first identification of a natural lasso precursor lacking this Thr reconciles 





Figure 2.14: Unusual lasso peptide BGCs discovered using RODEO. Examples of unusual gene fusions 





2.8 Other genes preferentially co-occur with lasso peptide BGCs 
In addition to essential biosynthetic genes, other proteins families were found to frequently co-
occur with lasso peptide BGCs (Table 2.6). As expected, ABC transporters were common, appearing in 
62% of BGCs (Figure 2.10). Many transferases also frequently co-occur, including kinases (32%), 
nucleotidyltransferases (26%), glycosyltransferases (14%), and acetyltransferases (6.6%), etc. Taken 
together, we propose there exist undiscovered lasso peptides bearing additional tailoring. Whereas the 
transferases mentioned above are found in many phyla, there is a clear subset of proteobacteria devoid of 
these genes. Instead, proteobacteria encode an isopeptidase reported to linearize the lasso macrocycle39.  
 
2.9 Assignment of BGCs to known lasso peptides 
Although the first reported lasso peptide, anantin, was discovered 25 years ago40, the BGC has not 
yet been reported, despite commercial availability and usage as an atrial natriuretic factor antagonist. In 
fact, BGCs for 10 known lasso peptides from 6 families remain elusive due to the unavailability of the 
producer’s genome. We sought to connect all known lasso peptides to BGCs by querying our data set with 
the core sequences of the known lasso peptides. Since ~50% of lasso peptides belong to families (Figure 
2.5), we expected those with unknown BGCs could be traced to RODEO-predicted precursor peptides with 
identical or nearly identical sequences. Indeed, queries using 4–5 contiguous core residues located 
precursors for every lasso peptide of previously unknown origin. (Figure 2.15). All lasso peptides with 
newly assigned BGCs were from Actinobacteria. Consistent with others from this phylum, each encode a 
single lasso precursor immediately upstream of discrete C, E, and B proteins. By assigning BGCs to all 
known lasso peptide families, this study underscores the utility of comparative genomics in providing 





Figure 2.15: Previously known lasso peptides with newly assigned BGCs. (A) Gene cluster diagrams. 
(B) Precursor peptides from identified clusters compared to the primary sequence of the orphaned lasso 
peptides from organisms without sequenced genomes. In multiple cases, several candidate precursor 
peptides and clusters were found, shown aligned on the right against the known core sequence of the 
identified lasso peptide. Minor differences between the identified core peptides and the known compounds 
are indicated in red. The BI-32169 homologue required a BLAST-P search against the JGI-IMG database, 
which returned an intact cluster in Streptomyces sp. AmelKG-E11A. 
 
2.10 Structure-prioritized discovery of lasso peptides 
We next applied RODEO’s predictive capabilities to discover lasso peptides expected to harbor 
intriguing structural features. We examined our data set for lasso peptides predicted in the USDA-ARS 
actinomycete collection (http://nrrl.ncaur.usda.gov/). Instances of widely-distributed families, as well as 
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rare ones, with unique variations in sequence and topology, were selected for further investigation. Thirty-
seven strains were chosen, grown on three media, and screened by MALDI-TOF-MS for the presence of 
peaks consistent with the RODEO predictions (Figure 2.16).  
 
Figure 2.16: RODEO-assisted screening for lasso peptides. MALDI-TOF-MS screen indicating lasso 
production by cultured bacteria (note two from NRRL S-146). 
 
Of these, metabolites from five cultures were isolated for further study and their identity was 
confirmed by high-resolution, tandem MS (Figure 2.16, Appendix B1). For citrulassin, lagmysin, and 
LP2006, which all contained unprecedented structural features, extensive NMR analysis was conducted. 
Chemical shifts of individual residues were assigned by 1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, and 
1H-1H NOESY (Appendix B1). Residue order was assigned by analysis of sequential NH-CαH NOEs in 
conjunction with MS/MS and the sequence of the precursor’s coding gene. The site of the isopeptide linkage 
was confirmed by the presence of strong NOE signals from the N-terminal residue to the Asp/Glu  side 
chain. Lagmysin, LP2006, and citrulassin each showed a wide range of NH chemical shift values (~7.25–
9.50); unthreaded lasso peptides show a narrower distribution of NH chemical shift values41. We also 
observed NOE correlations between the ring and tail, indicating their proximity (Appendix B1). Further, 
TOCSY data for anantin B1, citrulassin, lagmysin, and LP2006 indicated that multiple backbone amides 
were resistant to deuterium exchange, implying solvent occlusion (Appendix B1). All lasso peptides were 
thermally stable, showing no unthreading by HPLC after extended heating, and were either resistant or 
impervious to carboxypeptidase Y digestion (Appendix B1)46,47. These data strongly support a threaded 




Figure 2.17: Lasso peptides discovered via RODEO-based prioritization. (A) Five gene cluster 
diagrams for the six investigated lasso peptides. (B) Precursor sequences and predicted modified sites from 
BGCs in (A). (C) NOE-based NMR ensemble structure and schematic diagram of LP2006 showing the 
looped-handcuff topology. (D) Comparison of LP2006 (class IV) to previous lasso topologies. 
 
The precursor from Nocardiopsis alba was particularly interesting because it was predicted to bear 
a novel topology (Figure 2.17). This peptide contains two Cys, that presumably would form a disulfide; 
however, both Cys were predicted to reside on the tail whereas in all other known cases, disulfides link the 
tail to the macrocycle. This resulting “handcuff” topology of LP2006 was confirmed by solution-state 
NMR. We propose this rare lasso peptide topology be referred to as class IV. 
Moomysin, isolated from Streptomyces cattleya, has no known structural analogues but 
topologically belongs to class II (Figure 2.17). Lagmysin, another class II lasso peptide from Streptomyes 
sp. NRRL S-118, belongs to one of the largest families (Figure 2.17) and contains an unprecedented N-
terminal Leu. Currently, this is the largest residue with demonstrated biosynthetic compatibility. 
Additionally, we characterized by HR-MS/MS anantin B1 and a congener lacking the C-terminal Phe 
(anantin B2) from a previously unknown producer, Streptomyces sp. NRRL S-146 (Figure 2.17 and 
Appendix B1). The anantins comprise a lasso peptide family with 8 currently identifiable members.  
The citrulassins also contain N-terminal Leu and form a family with 55 members (Figure 2.5). 
During screening, the masses of seven of nine citrulassins were 1 Da heavier than predicted. This caught 
our attention, as additional tailoring of lasso peptides is rare34,42,43. One previously unsequenced organism, 
Streptomyces albulus NRRL B-3066, also produced citrulassin, as gleaned from C-terminal tail MS/MS 
fragmentation. This compound purified most readily of all citrulassins; therefore, we sequenced the 
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producer’s genome and deemed the compound citrulassin A. NMR, HR-MS/MS, and quantitative amino 
acid analysis of citrulassin A confirmed that its genetically encoded Arg9 was modified to citrulline (Figure 
2.18 and Appendix B1), accounting for the mass difference. Intriguingly, Arg9 is invariant among the 55 
citrulassins, although codon usage varies. To our knowledge, this is the first known instance of citrulline in 
any RiPP, but also, only the second known instance of peptidylarginine deiminase (PAD) activity in the 
entire bacterial domain44.  In an attempt to locate the responsible PAD, we performed conservation analysis 
of the genes flanking the citrulassin BGCs. Not only were these flanking genes highly variable, no obvious 
candidate for a PAD was found. To determine if the responsible PAD was locally encoded, we generated a 
fosmid library of S. albulus to heterologously express the citrulassin BGC. Two fosmids were expressed in 
Streptomyces lividans, together covering ~20 kb upstream and downstream of the BGC (Figure 2.18). MS 
analysis revealed that expression of either fosmid led to the production of Arg-containing des-citrulassin. 
These data suggest the responsible PAD is distally encoded. 
 
Figure 2.18: Citrulassin, a rare example of bacterial PAD activity. (A) The two-dimensional structure 
of citrulassin A with Cit9 highlighted. (B) Two-dimensional structure of heterologously expressed des-
citrulassin A with Arg9 highlighted. (C) Gene cluster diagrams are shown for two fosmids (3H4 and 1F3) 
from S. albulus NRRL B-3066 expressed in S. lividans. (D) Production of heterologous des-citrulassin A 
as indicated by MALDI-TOF MS.  
57 
 
2.11 Antibacterial activity of lasso peptides 
We tested all of the lasso peptides isolated herein for growth-suppressive activity against a panel 
of bacteria (Table 2.7). Citrulassin A, moomysin, and lagmysin lacked growth suppressive activity towards 
all organisms tested. In contrast, LP2006 was active against Enterococcus faecium, Bacillus subtilis, 
Bacillus anthracis, and Mycobacterium smegmatis while anantin B1/B2 showed weak activity against E. 
coli. Interestingly, the anantin B2 was also moderately active against B. subtilis. 
 
 
Table 2.7: Antimicrobial activity of RODEO-identified lasso peptides. Microbroth dilution assays were 
performed on a series of both gram-positive and gram-negative bacteria.  
 
2.12 Conclusions 
Genome-mining tools have been closing the gap between the large number of predicted BGCs and 
the significantly smaller number of known NPs. Despite the development of methods for identifying and 
predicting structures for NRPs and PKs, similar methods for RiPPs have been hampered by the homology 
of some RiPP biosynthetic proteins to those in primary metabolism and the difficulty in locating precursor 
peptides3. However, the gene-encoded nature of RiPP precursors provides an opportunity: a confident 
precursor prediction near a reasonable BGC is strong evidence for a valid BGC. Thus, a robust platform for 
BGC identification and precursor scoring provides predictive power not possible in other NP classes. 
Although manual identification of RiPP precursors is common, it is performed on a case-by-case basis 
which is tedious and inefficient. Methods that facilitate predictions for large numbers of BGCs will be 
increasingly necessary given that genome sequencing significantly outpaces the rate of functional 
annotation. These issues are amplified for lasso peptides, which are sequence hypervariable. Machine 
learning is an ideal tool to address this challenge: it is scalable for large data sets, and in an unbiased fashion, 
can determine which scoring parameters to prioritize. This results in a powerful, adaptive scoring metric 
58 
 
that only requires a comparatively small (but diverse) training set. Despite these strengths, machine learning 
remains underutilized in NP discovery. 
We herein describe the development and utility of RODEO, an algorithm for BGC identification. 
RODEO provides a graphical and tabular output of BGCs and peptides that can be later analyzed to reveal 
statistical correlations and examine phylogenetic relationships. The customizability of the program in taking 
user-supplied configuration files and pHMMs renders RODEO extensible to any gene neighborhood 
analysis, although currently, the precursor-scoring portion of RODEO is optimized exclusively for lasso 
peptides. With customization to other RiPP classes, or by turning off the precursor scoring function, 
RODEO complements existing tools focused on individual whole genomes, such as BAGEL314 and 
antiSMASH3, as well as general gene context tools such as the Gene Ortholog Neighborhood analysis 
option within JGI-IMG and the Prokaryotic Sequence homology Analysis Tool, PSAT45,46. Beyond RiPPs, 
we have already used RODEO to analyze polyketide BGCs by constructing pHMMs for enzymes 
responsible for plecomacrolide-specific backbone tailoring47.  
RODEO here was used to identify 1,315 lasso precursors within 1,419 BGCs from a basis set of 
only 28 characterized BGCs. This is notable in light of the sequence hypervariability seen in lasso peptides 
relative to other RiPPs. This study revealed that ~50% of lasso peptides exist in structural families. In 
addition to locating BGCs for all genetically unassigned lasso peptides, we isolated six new examples, four 
of which were chosen on the basis of predicted structural novelty, and subsequently characterized their 
structures and antibacterial activities. Of these, LP2006 was found to adopt an unprecedented topology and 
displayed activity against several pathogens. Lasso peptides are reported to display diverse bioactivities, 
such as receptor antagonists and enzyme inhibitors; however, it is common for lasso peptides to be reported 
without an associated activity. This suggests some will display more esoteric activities or influence signal 
transduction. This last possibility is consistent with sviceucin’s inhibition of Enterococcus faecalis quorum 
sensing48. One such lasso peptide described herein that lacks bacterial growth-suppressive activity, 
citrulassin A, belongs to a 55-membered family. Citrulassin A is exemplified by the conversion of an Arg 
to citrulline by a yet-unidentified PAD. MS-based screening suggests that additional citrulassins contain 
citrulline. This simple modification is quite unique: not only was citrulline previously unknown in RiPPs, 
but only one example of PAD activity—a virulence factor—is known in the entire bacterial domain44,49,50. 
The RODEO-enabled genome-mining methods described here has allowed for broad-scale 
investigations of a NP family only possible with a large, high-confidence dataset. Our analysis indicates 
that lasso peptide BGCs are widely distributed among bacteria, with Streptomyces harboring the plurality. 
We identified rare cases of lasso peptide BGCs in unprecedented phyla, although most appear to be 
inherited vertically. Despite their widespread nature, fewer than 50 lasso peptides have been isolated. This 
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work provides a roadmap for the future discovery of additional lasso peptides, novel RiPP classes, and 
allows for a rapid means to curate and interpret emerging BGCs. 
 
2.13 Experimental 
General methods. Unless otherwise specified, chemicals were purchased from Sigma, Fisher Scientific, 
or GoldBio. DNA sequencing was performed by the Roy J. Carver Biotechnology Center (Univ. of Illinois 
at Urbana-Champaign). Restriction enzymes were purchased from New England Biolabs (NEB), Platinum 
Taq HiFi was purchased from Thermo Scientific, and dNTPs were purchased from NEB. Oligonucleotide 
primers were synthesized by Integrated DNA Technologies (IDT). 
 
Lasso peptide cluster dataset assembly. GI numbers for essential biosynthetic genes (lasso cyclase, lasso 
protease, and RRE) of all known lasso peptides were collected. The set of lasso cyclases was then used as 
a BLAST-P query against the nr database in GenBank, returning the top 1,000 hits for each with default 
settings. Hits were ranked by maximum similarity to any query sequence, and the top local genomic region 
(6 genes in either direction of cyclase) of top hits were sequentially analyzed with RODEO until no new 
lasso peptide-like BGCs were returned. Because our initial query set contained only Actinobacteria and 
Proteobacteria, we repeated the above using as queries representative lasso peptide cyclases, obtained 
during the first search, from the Bacteroidetes, Cyanobacteria, Firmicutes, Fusobacteria, and 
Veruccomicrobia, and Archaea. The RODEO data sets were then merged for analysis, giving a set of 4,672 
potential BGCs with 25,506 potential precursor peptides. Refinement and scoring (below) of this data 
yielded a final dataset of 1,419 lasso peptide BGCs and 1,315 lasso peptide precursors. 
 
Precursor peptide scoring optimization. From the initial set of prospective lasso peptide BGCs, the 
RODEO output of a randomly-chosen sample (~25%; whole training set) were inspected, and gene clusters 
were classified qualitatively as lasso, non-lasso, or indeterminate. Peptides in each cluster were also 
classified as valid likely precursors, non-precursors, or indeterminate. This formed an unbiased training set 
for scoring optimization. In addition to the scoring features output by RODEO directly, an additional set of 
features were calculated in Excel for each peptide (Supplementary Tables 1 and 2). The linear 
combination score of each peptide was calculated as the dot product S of weight vector A and feature vector 
X, 







where for each of i features n, Ai is the feature point weight and Xi is the absence, 0, or presence, 1, of the 
feature.  
 
For analysis and optimization, 80% of the manually classified set was randomly selected (“training set”), 
with the other 20% retained as a validation set to avoid over-fitting. Feature weighting optimization was 
done by plotting comparative score histograms of classified precursor peptides and stochastically adjusting 
individual weights to minimize overlap. For final analysis, additional points were given to any peptide 
classified as valid by the SVM classifier (see below) or showing MEME/FIMO-identified sequence motifs 
(see below), resulting in two minimally overlapping populations (Supplementary Figure 2). 
 
Sequence motif-based unsupervised learning of precursor peptides. Precursor peptide sequences from 
the training set (see above) were analyzed for the top 16 sequence motifs with zero or one occurrences per 
sequence using MEME (parameters: -nmotif 16 -mod zoops)51. All output peptides from RODEO (n = 
25,506) were scanned for these motifs using FIMO, and both the presence of motifs and the resulting scores 
were passed to final linear-combination scoring and used as features for SVM. Motifs were only considered 
for linear-combination scoring if their score from FIMO was greater than 1, which we found to increase 
accuracy. The sequence motifs used by FIMO are included with the Supplementary Data. 
 
Support vector machine (SVM) supervised learning classifier. Machine learning model training and 
classification was performed using the scikit-learn library for Python. The manually classified training set 
(see above) was used as model data. Five-fold cross-validation (i.e. randomly witholding one-fifth of the 
training data as a testing data set) was used to optimize the prediction method and avoid over-fitting. Kernel 
modes (linear, polynomial, rbf) and parameters (C, gamma, polynomial degree, class weight) were 
systematically varied to optimize prediction accuracy, assessed as the product of precision [precision = true 
positives/(true positives + false positives)] and recall [recall = true positives/(true positives + false 
negatives)]. Optimal parameters used an rbf kernel with C = 25, gamma = 2.75E-06, and ‘auto’ class weight. 
This gave 97.9% precision and 92.8% recall, which we estimated would likely result in ~30 false positives 
and ~100 false negatives when applied to the entire data set. Thus, we subjected the entire 25,506-member 
RODEO-derived peptide set to classification. Code availability: The Python scripts used for SVM 
optimization and classification, as well as features, are available with the source code, documentation, and 
link to the RODEO web tool (http://www.ripprodeo.org/) and Supplementary Table 2. 
 
Precursor peptide set determination. We utilized a combination of SVM classification, motif analysis, 
linear-combination scoring, and SSN analysis to determine valid lasso precursor peptides. To minimize the 
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false positive and negative rate, we compared SVM classifications to linear-combination scores and 
inspected the highest-scoring SVM negatives and lowest-scoring SVM positives, resulting in 
reclassification of several peptides. We also manually inspected peptides that clustered abnormally on an 
SSN (alignment score cutoff = 1E-6) of the precursor peptides (e.g. singleton SVM negatives clustering 
with SVM). SVM positives and negatives with high or low scores, respectively, that clustered with valid or 
invalid precursor peptides were assumed to be most likely correct. Leader/core alignment verification: 
RODEO predicts the leader/core cut site on the basis of a conserved Thr found in the penultimate leader 
position and a putative cyclization site (Asp/Glu) in the core. We manually refined the RODEO-generated 
leader/core split sites based on conserved leader residues (YxxP and Gx5T motifs); although correct in 94% 
of cases, 75 required manual adjustment due to the presence of multiple possible Thr and Asp/Glu residues 
in the precursor. 
 
Gene cluster classification. Gene clusters were classified on the basis of cluster architecture (identifiable 
E, B, or C proteins) as well as the presence of valid precursor peptides. Any cluster with a valid lasso 
precursor was classified as a lasso peptide BGC. Those containing only one identifiable E, B, or C protein 
and no precursor peptide were discarded. The remaining clusters were classified by analysis of an SSN of 
the lasso cyclases. Those that contained two or more identifiable lasso biosynthetic genes and showed high 
similarity to valid BGCs, as judged by network connectivity, were retained. In this way, the initial data set 
of 4,672 potential gene clusters was refined to a set of 1,419 predicted lasso peptide BGCs, 1,165 of which 
(82%) contained a RODEO-identified lasso peptide precursor. 
 
RRE/precursor peptide co-evolution analysis. A paired alignment of precursor peptide sequences and 
RREs (PF05402 in lasso BGCs) (n = 846) was generated; RRE sequences were aligned using MUSCLE on 
default settings in MEGA752. The aligned precursor peptides and RREs were concatenated. (1) 
Residue/residue co-evolution analysis. The paired alignment was analyzed using the GREMLIN web server 
(http://gremlin.bakerlab.org/)53 on default settings, filtered at 75% gap removal and 25% coverage 
thresholds. No multiple sequence alignment (MSA) generation was performed. The precursor peptide and 
RRE (GenBank: WP_040271204.1) from the streptomonomicin BGC were used as a reference. (2) 
Sequence motif analysis with MEME/FIMO. Sets of paired precursor peptides/RREs were analyzed using 
MEME 4.11.1, which detects ungapped sequence motifs51. Precursor sequences were trimmed to include 
only the leader region and analyzed to find the 8 most significant motifs with zero or one occurrences per 
sequence (parameters: -nmotif 8 -mod zoops). All precursors and RREs were then analyzed for the presence 
of each discovered motif using FIMO on default settings51. Motif correlation was calculated as the number 
of co-occurrences of each of two motifs divided by the number of total occurrences of each. Sequence 
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motifs were mapped onto the StmE homology model generated as previously described.13 (3) Homology 
modeling. HHpred (http://toolkit.tuebingen.mpg.de)54 was used to generate sequence alignments for the 
RRE from the gene cluster of streptomonomicin (GenBank: WP_040271204.1). LynD (PDB ID: 4V1T) 
was used to generate a model using the HHpred modeling toolkit (aligned residues 8-84). Inter-protein 
GREMLIN-output probability scores of residue-residue co-evolution were used to map regions of predicted 
evolutionary significance 
 
Analysis of GC content. The %GC of nucleotide sequences for a representative set of lasso cyclases (n = 
1,085) were calculated and compared to NCBI Taxonomy records (organism %GC content). Lasso cyclase 
%GC was plotted against average organism genome %GC. Linear regression was calculated to draw a best-
fit line and calculate absolute residual regression for each point. The top 5% of outliers (n = 54) were 
highlighted. 
 
Phylogenetic tree generation. For visual clarity, we chose to represent only a representative subset of lasso 
cyclases (n = 185 of 1,419). From the phyla with the most lasso BGCs (Actinobacteria, Proteobacteria, 
Firmicutes), approximately ~10% of sequences were randomly selected. From all others, which had many 
fewer lasso BGCs, approximately half were selected in order ensure qualitative representation of all phyla. 
As diverse outgroups, non-lasso asparagine synthases (PF00733) were chosen from E. coli (GenBank: 
KJW30448.1; tree root), B. subtilis (GenBank: AID00505.1), and Streptomyces rimosus (GenBank: 
KEF03673.1). Protein sequences were first aligned in MEGA752 using MUSCLE on default settings. A tree 
was generated from the alignment using the Maximum Likelihood method based on the JTT matrix-based 
model in MEGA7 on otherwise default settings52 and visualized with iTOL (http://itol.embl.de/)55 and 
Adobe Illustrator. For suggestions on how to incorporate RODEO-generated data into tree-visualization 
programs like iTOL, see: http://www.ripprodeo.org/advanced.html 
 
Sequence similarity network (SSN) generation. SSNs were generated using EFI-EST 
(http://efi.igb.illinois.edu/efi-est/)30. Initial networks were generated using alignment score cutoffs of 1E-1 
(precursor peptides), 1E-5 (RREs), 1E-7 (leader proteases), or 1E-25 (lasso cyclases) as clustering 
thresholds. Networks were visualized using the Organic layout within Cytoscape v. 3.2.056 and Adobe 
Illustrator. Nodes were annotated using RODEO output (via Microsoft Excel) and the NCBI Taxonomy 





Lasso data set Circos visualization. Alignment scores for precursor peptides were obtained during SSN 
generation. Individual precursor peptides were annotated from a RODEO-generated and curated 
spreadsheet for the presence of co-occurring Pfams, structural novelty, phylum, and structural family. Lasso 
peptide, BGCs, and and their genomic contexts were visualized using Circos (Supplementary Figure 14)58. 
For suggestions on how to import RODEO data for Circos visualization, see: 
http://www.ripprodeo.org/advanced.html  
 
Sequence logo generation. Sequence logos were generated using WebLogo 2.8.2 
(http://weblogo.berkeley.edu/)59. Core sequences of some families (i.e. sphingonodin, caulonodin, 
sphingopyxin and paeninodin) were first aligned using MUSCLE v.3.8.3160 prior to sequence logo 
generation. 
 
Microbiological methods. All actinomyces strains were grown in either ATCC medium 172 [ATCC172] 
(per L: glucose, 10 g; soluble starch, 20 g; yeast extract, 5 g; N-Z-Amine type A, 5 g; CaCO3, 1 g; pH 7.3), 
ISP Medium no. 4 [ISP4] (per L: soluble starch, 10 g; K2HPO4, 1 g; MgSO4·7H2O, 1 g; NaCl, 1 g; 
(NH4)2SO4, 2 g; CaCO3, 2 g; FeSO4, 1 mg; MnCl2, 1 mg; ZnSO4, 1 mg), or AltMS (per L: mannitol, 10 g; 
soy flour, 10 g; malt extract, 10 g). All solid media included 1.5% (w/v) agar. Neisseria meningitidis was 
grown on gonococcal broth [GCB] (per L: proteose peptone #3, 15 g; K2HPO4, 4 g; KH2PO4, 1 g; NaCl, 1 
g) with sterile filtered bicarbonate (100x: NaHCO3, 0.42 g to 10 mL H2O) and sterile filtered Kellogg’s 
Supplements I (100x to 500 mL: D-glucose, 200 g; L-glutamine, 5 g; thiamine pyrophosphate, 0.01 g) and 
II (1000x to 50 mL: Fe(NO3)3·9H2O, 0.025 g). 
 
Escherichia coli strains for DNA manipulation were DH5α, grown in LB medium (10 g tryptone, 10 g 
NaCl, 5 g yeast extract to 1 L of deionized water; Fisher Scientific) with 50 µg/mL kanamycin. A Gibson 
assembly master mix (NEB) was used to clone the anantin gene cluster from Streptomyces sp. S-146 into a 
pET28a backbone. Qiagen QIAprep Spin Miniprep Kit was used to purify plasmids. Primer walk 
sequencing was used to generate overlapping sequencing reads connecting the biosynthetic machinery for 
anantin. 
 
Screening of Actinomycetes for lasso peptide production. Prioritized strains were grown on each ATCC 
Media 172, ISP Media 4, and AltMS on 6-well plates with 5 mL of agar media per well. Cultures were 
incubated at 30 °C for 7 d prior to whole-cell mass spectrometry. A portion of cell mass (pinhead-sized) 
including aerial hyphae was picked from the plate and placed in 2 µL of sat. 50% aq. MeCN solution of α-
cyano-4-hydroxycinnamic acid (CHCA) with 0.1% trifluoroacetic acid (v/v) on a ground steel MALDI 
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target. Additional aliquots of matrix (2 µL) were spotted and allowed to dry on the cell mass three times to 
extract metabolites onto the plate. Samples were analyzed using a Bruker UltrafleXtreme MALDI-TOF MS 
using manufacturer methods for reflector positive mode. 
 
Isolation of high molecular weight DNA. Streptomyces albulus str. NRRL B-3066 was grown in liquid 
ATCC172 media supplemented with 0.8% glycine at 30 °C with agitation until a dense culture had 
developed (~5 d). A 30 mL portion of the culture was pelleted (4,000 × g, 10 min), and the supernatant was 
removed by aspiration. The cells were resuspended in 2 mL of TE25S buffer (25 mM Tris, 25 mM EDTA 
disodium salt, 30% sucrose, pH 8) and large clumps of cells were broken up by physical disruption with a 
glass rod. Lysozyme was added to a final concentration of 10 mg/mL and the suspension was incubated at 
37 °C with agitation. After 1 h, 6 mL of modified lysis buffer (569 mM 4-aminosalicylic acid sodium salt, 
69 mM sodium dodecyl sulfate, 100 mM Tris, pH 8) and 20 µL of proteinase K (NEB, 30 U/mg at 20 
mg/mL) were added. The suspension was then incubated at 75 °C for 30 min, with the suspension being 
mixed once by gentle inversion several times after 15 min. An equal volume of phenol:chloroform:isoamyl 
alcohol (25:24:1, v/v) was then added and mixed by gentle inversion several times. The mixture was 
centrifuged at 10,000 × g at 4 °C for 10 min, and the aqueous phase was transferred to a new container 
using a wide bore pipet (or pipet tips with the ends cut off to provide a wider opening). To the aqueous 
phase, an equal volume of chloroform:isoamyl alcohol (24:1, v/v) was added and mixed by gentle inversion 
several times. The mixture was again centrifuged at 10,000 × g at 4 °C for 10 min, and the aqueous phase 
was transferred to a new container using a wide bore pipet. Another round of chloroform:isoamyl alcohol 
extraction was performed if solid material was still present in the aqueous phase. The aqueous phase was 
then transferred to a 50 mL conical tube, to which 0.1 volume equivalents of 5 M NaCl was added. The 
tube was then filled to the top with isopropyl alcohol and the mixture was gently inverted several times to 
mix. A small glass hook fashioned from a melted Pasteur pipet was used to collect the precipitated DNA. 
The DNA was washed twice with 75% aq. EtOH followed by a single wash with 100% EtOH. The DNA 
was then allowed to air dry on the glass hook overnight. 
 
Fosmid library generation. High molecular weight DNA was resuspended in 600 µL TE buffer (10 mM 
Tris, 1 mM EDTA, pH 8), 330 µL 10x CutSmart buffer (NEB), and 2310 µL DNase-free water. Gentle 
pipetting with a wide bore pipet and heating at 65 °C were used to help dissolve the DNA. After the majority 
of the DNA was dissolved, 30 µL of RNase A was added and the solution was mixed by gentle inversion. 
The DNA solution was split into 14 fractions and Sau3AI (NEB) was added to each in a 2-fold serial 
dilution, starting with 2.5 µL of Sau3AI into 400 µL of DNA solution. Solutions were mixed by gentle 
pipetting with a wide bore pipet. Digest reactions were incubated at 37 °C for 1 h and were then inactivated 
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by incubation at 75 °C for 30 min. Fractions were analyzed by field-inversion gel electrophoresis, and 
fractions containing approximately 40 kb pieces of DNA were utilized in cosmid construction. These 
fractions were dephosphorylated by the addition of 20 µL of shrimp alkaline phosphatase and incubation at 
37 °C for 1 h. DNA fragments were isolated by phenol:chloroform:isoamyl alcohol extraction and air dried 
for 3 h. 
The previously reported vector pJK050 was used for fosmid construction61. pJK050 was doubly 
digested with NheI-HF and BamHI-HF (NEB) and dephosphorylated with shrimp alkaline phosphatase. 
Cut vector was purified with a GeneJET PCR Purification Kit (Thermo Scientific). Approximately 1 µg of 
cut vector, 2 µL of 10x T4 ligase buffer (NEB), and water (to give 20 µL total volume) was used to 
resuspend the digested high molecular weight DNA. A portion (5 µL) was removed as a control and 1 µL 
of high concentration T4 ligase (NEB, 2,000,000 U/mL) was added to the remainder. The ligation reaction 
was incubated at 4 °C overnight and used without further modification. 
A culture of E. coli WM4489 was started in LB and grown at 37 °C overnight. The culture was 
then used to inoculate a new 10 mL culture of LB supplemented with 10 mM maltose. This culture was 
grown at 37 °C with shaking until it reached an optical density of 0.8 to 1.0. The culture was pelleted at 
4,000 × g for 10 min, and the supernatant was removed by aspiration. The pellet was resuspended in 2 mL 
of sterile 10 mM MgCl2 and chilled on ice until needed. Ligated DNA was then packaged into phage and 
transfected into E. coli WM4489 with MaxPlax Lambda Packaging Extracts (Epicentre) following the 
manufacturer’s instructions. The transfection reaction (2 mL) was pelleted at 17,000 × g for 5 min and 1.4 
mL of the supernatant was discarded. The remaining supernatant was used to resuspend the pellet and the 
suspension was plated onto 5 LB agar plates (100 µL/plate) containing 12.5 µg/mL chloramphenicol. The 
plates were incubated at 37 °C overnight, resulting in thousands of colonies per plate. Colonies were scraped 
from the plates utilizing 1 mL of LB per plate, pooled together, and mixed with 3 mL of sterile 50% glycerol 
in water to give a library stock solution. The solution was plated on fresh LB agar plates containing 12.5 
µg/mL chloramphenicol at an appropriate dilution to provide individual colonies. Colonies were screened 
by PCR for the presence of approximately 650 base sequences before and after the citrulassin A gene 
cluster. Positive hits were verified by an additional round of PCR screening and were then grown in LB 
containing 12.5 µg/mL chloramphenicol and 20 mM rhamnose at 37 °C with agitation overnight. Two hits 
were found to contain the citrulassin A gene cluster and were named p1F3 and p3H4. Cosmid DNA was 
isolated with a GeneJET Plasmid Miniprep Kit (Thermo Scientific). The start and end of the genomic insert 
in each cosmid was determined via sequencing with primers designed to anneal up- and downstream of the 




Heterologous expression of citrulassin A gene cluster. Cosmid DNA was recombined in vitro with pAE4 
using Gateway BP Clonase II (Thermo Scientific) following the manufacturer’s instructions to insert the 
functions necessary for transfer and integration into Streptomyces lividans. The resulting fosmids were 
transformed into the conjugation strain E. coli WM6026 by electroporation, with 20 µg/mL of sterile 
diaminopimelic acid (DAP) added during the recovery step (E. coli WM6026 is a DAP auxotroph). 
Transformants were plated on LB agar containing 12.5 µg/mL chloramphenicol, 50 µg/mL apramycin, and 
20 µg/mL DAP. Cultures of E. coli WM6026 containing the fosmids were started in LB supplemented with 
12.5 µg/mL chloramphenicol, 50 µg/mL apramycin, and 20 µg/mL DAP and grown overnight at 37 °C 
with agitation. The overnight cultures were then used to inoculate fresh 5 mL cultures with the same 
supplements, which were grown to an optical density of 0.4 to 0.6. The cultures were pelleted by 
centrifugation at 4,000 × g for 10 min, and the supernatants were discarded. The pellets were washed twice 
with sterile 2xYT media (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl), resuspended in 1 mL of 2xYT 
containing 20 µg/mL DAP, and chilled on ice until use. A frozen suspension of S. lividans 66 spores was 
heat shocked at 56 °C for 15 min straight from the freezer. After 15 min, 500 µL of 2xYT was added and 
mixed by pipetting. Conjugation reactions were set up with 200 µL of the spore suspension and either 4 µL 
(50:1), 40 µL (5:1), or 200 µL (1:1) of a fosmid containing E. coli WM6026 solution. The suspensions were 
briefly centrifuged to settle the cells together at the bottom of the tubes and were incubated at room 
temperature for 10 min. The cells were then resuspended by pipet and the entire solutions were plated on 
individual mannitol-soy plates (20 g/L mannitol, 20 g/L soy flour, 16 g/L agar) supplemented with 10 mM 
MgCl2. The plates were incubated at 30 °C for 16 h, and then the plates were flooded with 2 mL of a 1 
mg/mL aqueous apramycin solution. The plates were dried while open in a biosafety cabinet and then 
incubated at 30 °C until colonies appeared. The strains were named S. lividans 1F3 and S. lividans 3H4, 
corresponding to the respective cosmids used to construct them. 
Colonies of S. lividans 1F3 and S. lividans 3H4 were used to inoculate ATCC172 liquid media 
containing 12.5 µg/mL chloramphenicol and 50 µg/mL apramycin. The cultures were grown at 30 °C with 
agitation until a dense culture was obtained. These cultures were plated on 5 ATCC172 agar plates each 
(antibiotic free) to generate a lawn and these plates were grown at 30 °C for 10 d. The plates were frozen, 
thawed, and squeezed to collect the liquid from the agar. The liquid was filtered through Whatman paper 
by vacuum filtration and then applied to a 0.5 g Hypersep C18 solid phase extraction column (Thermo 
Scientific) that had been equilibrated with 20 mL of MeCN, 20 mL of 50% aq. MeCN, and 30 mL of H2O. 
The column was washed with 20 mL of water and eluted with 5 mL each of 10%, 20%, 40%, 60%, and 
100% aq. MeCN. Fractions were analyzed by MALDI MS with CHCA as a matrix. Des-citrulassin A was 




The primers used for heterologous expression are given in Supplementary Table 11. 
 
Isolation of anantin B1 and B2. Streptomyces sp. S-146 was grown on ATCC 172 with 1.5% agar on 15 
cm sterilized petri dishes (n = 48) and incubated at 30 °C for 7 d. Cells were harvested by scraping cell 
mass from the plates with razors and collectively extracted with 600 mL MeOH with shaking at room 
temperature overnight. The methanolic extract was vacuum-filtered and dried under reduced pressure onto 
5 g of Celite 545 adsorbent.  
Spent agar was frozen at ˗20 °C overnight and then allowed to thaw. The agar was squeezed and 
filtered through cheesecloth to harvest the aqueous portion, which was vacuum-filtered with Whatman filter 
paper and loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) pre-equilibrated with H2O. 
The loaded column was washed with 200 mL of H2O, and bound material was eluted with successive 50 
mL portions of 5%, 10%, 25%, 50% and 75% aq. MeCN, followed by 100 mL of MeCN. Fractions were 
analyzed via MALDI-TOF MS. Fractions containing anantin B1 and B2 were pooled with the methanolic 
extract and dried under reduced pressure onto 5 g of Celite 545 adsorbent. 
Anantin adsorbed onto Celite was purified by medium pressure liquid chromatography (MPLC) 
using a Teledyne Isco Combiflash EZprep equipped with a RediSep Rf C18 cartridge (130 g media, 60 Å 
pore size, 40–63 µm particle size, 230–400 mesh) using a mobile phase of 10 mM aq. NH4HCO3/MeCN at 
85 mL min-1 over a gradient from 20–60% MeCN (10 column volumes), then 60–95% MeCN (5 column 
volumes). Fractions were analyzed via MALDI-TOF and dried under reduced pressure.  
Anantin B1 and B2 were dissolved in 7 mL of water each and filtered with a 0.22 µm syringe filter 
(BD Technologies) prior to injection. HPLC was performed using a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 5 µM particle size) with a 
mobile phase of 10 mM aq. NH4HCO3/MeCN (gradient from 10 to 95% MeCN) at 19 mL min-1. Fractions 
containing either anantin B1 or B2 were dried under reduced pressure, resuspended in H2O, flash-frozen, 
and lyophilized overnight to dryness.  
Preparative HPLC was performed with a Perkin Elmer Flexar HPLC equipped with a Betasil C18 
(Thermo Scientific) reverse phase column (250 × 10 mm, 5 µm particle size). Anantin B1 and B2 were 
dissolved separately in 1.5 mL of water, subjected to centrifugation at 17,000 × g to remove precipitate, 
and injected with a mobile phase of water/MeCN + 0.1% formic acid (v/v) with a gradient from 10–95% 
over 30 min. Elution was monitored at 220 nm and appropriate fractions were dried under reduced pressure, 
dissolved in water (2 mL), flash-frozen, and lyophilized overnight to dryness. Anantin B1 and B2 were 
collected as colorless powders (1.8 mg and 2.1 mg, respectively). Yields for anantin B1 and B2 were 75 
µg/15 cm dish and 88 µg/15 cm dish respectively. 
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Analytical HPLC to assess purity was performed using a Betasil C18 column (100 Å pore size, 250 
× 4.6 mm, 5 µM particle size) (Thermo Scientific) with a mobile phase of H2O/MeCN + 0.1% (v/v) formic 
acid (FA) gradient from 10% to 95% aq. MeCN over 30 minutes at 1 mL min-1. For anantin B2, a mobile 
phase of 10 mM aq. NH4HCO3/MeCN gradient from 5 to 25% MeCN over 30 minutes, then ramp to 95% 
MeCN over 5 minutes and held at 95% MeCN for 10 minutes at 1 mL min-1. Both anantin B1 and anantin 
B2 were detected eluting at 220 nm.  
 
Isolation of LP2006. Nocardiopsis alba NRRL B-24146 was grown on ATCC 172 and 1.5% agar in 
sterilized aluminum cake pans (12-¼ inches by 8-¼ inches; n = 12; ~300 mL media ea.) and incubated at 
30 °C for 21 d. Cells were harvested by scraping cell mass from the plates with a razor blade and collectively 
extracted with 100 mL MeOH with shaking at rt overnight. Following filtration, the remaining cell mass 
was re-extracted with 100 mL of n-BuOH shaking at rt overnight. The MeOH and n-BuOH extract was 
vacuum-filtered and dried under reduced pressure onto 10 g of Celite 545 adsorbent. 
LP2006 adsorbed on Celite was purified by MPLC using a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Rf C18 cartridge (86 g media, 60 Å pore size, 40–63 µm particle size, 230–400 
mesh) using a mobile phase of 10 mM aq. NH4HCO3/MeCN at 60 mL min-1 over a gradient from 10–95% 
MeCN (12 column volumes), and held at 95% MeCN (5 column volumes). Fractions were analyzed via 
MALDI-TOF MS. Fractions containing LP2006 were combined and the solvent was evaporated. 
HPLC was performed using a Teledyne Isco Combiflash EZprep equipped with a RediSep Prep 
C18Aq column (100 Å pore size, 150 × 20 mm, 5 µM particle size) with a mobile phase of 10 mM aq. 
NH4HCO3/MeCN (gradient from 25 to 95% MeCN) at 19 mL min-1. Fractions found by MALDI-TOF to 
contain LP2006 were combined and evaporated to dryness. 
Preparative chromatography on a Perkin Elmer Flexar HPLC equipped with a Betasil C18 (Thermo 
Scientific) reverse phase column (250 × 10 mm, 5 µm particle size) was performed with a mobile phase of 
10 mM aq. NH4HCO3/MeCN (gradient from 20–40% MeCN for 20 min, then 40–95% MeCN for 5 min) 
at 4 mL min-1. This yielded 1.9 mg of LP2006, which was dissolved in water, flash-frozen, and lyophilized 
to dryness with a final yield of 158 µg/pan.  
The purity of LP2006 was checked by HPLC with a Perkin Elmer Flexar HPLC equipped with a 
Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å pore size). 
A mobile phase of 10 mM aq. NH4HCO3/MeCN gradient from 5–25% MeCN over 15 minutes, then ramped 
to 95% MeCN over 5 min and held at 95% MeCN for 10 min at a flow rate of 1 mL min-1. Elution of 




Isolation of moomysin. Streptomyces cattleya NRRL 8057 was grown on AltMS medium with 1.5% agar 
on sterilized aluminum cakepans (12-¼ inches by 8-¼ inches; n = 12; ~300 mL media ea.) and incubated 
at 30 °C for 14 d. Cells were harvested by scraping cell mass from the plates with razors and cell material 
was extracted with 200 mL of 50% aq. MeCN overnight with shaking at room temperature. The cell mass 
was filtered with Whatman filter paper and the filter cake was re-extracted 3 additional times. Extracts were 
combined and dried under reduced pressure onto ~5 g Celite 545 adsorbent. Agar extracts did not contain 
detectable quantities of moomysin by MALDI-TOF MS, and were not purified or analyzed further. 
 Adsorbed moomysin was purified by MPLC using a Teledyne Isco Combiflash EZprep equipped 
with a RediSep Rf C18 cartridge (130 g media, 60 Å pore size, 40–63 µm particle size, 230–400 mesh) 
using a mobile phase of 10 mM NH4HCO3/MeCN at 85 mL min-1 over a gradient from 10–20% MeCN (5 
column volumes), 20–50% MeCN (5 column volumes), then 50–100% MeCN (2.5 column volumes) then 
holding at 100% MeCN (5 column volumes). Fractions were analyzed via MALDI-TOF MS, and fractions 
containing moomysin were pooled and dried under reduced pressure and stored at -20 °C. 
 Samples for HPLC were resuspended in 7 mL of water, subjected to centrifugation at 17,000 × g 
to remove precipitate and filtered with a 0.22 µm syringe filter (BD Technologies) prior to injection. 
Moomysin was injected onto a Teledyne Isco Combiflash EZprep equipped with a RediSep Prep C18Aq 
column (100 Å pore size, 150 × 20 mm, 5 µM particle size) at 19 mL min-1 with a mobile phase of 10 mM 
NH4HCO3/MeCN gradient starting at 10% MeCN (10 column volumes), 10 to 45% MeCN (7 column 
volumes) then 45 to 100% MeCN (5 column volumes) and held at 100% MeCN for 5 column volumes. 
Elution of moomysin was monitored at 214 nm, and the corresponding fractions were dried under reduced 
pressure and stored at -20 °C. 
 Preparative chromatography was performed with a Perkin Elmer Flexar HPLC equipped with a 
Betasil C18 (Thermo Scientific) reverse phase column (250 × 10 mm, 5 µm particle size). Moomysin was 
dissolved in 1.5 mL of H2O, subjected to centrifugation at 17,000 × g to remove precipitate and injected 
with a mobile phase of water/MeCN + 0.1% formic acid (v/v) gradient from 10–95% over 30 min with a 
flow rate of 4 mL min-1. Elution was monitored at 220 nm and fractions containing moomysin were dried 
under reduced pressure, resuspended in 2 mL water, flash-frozen, and lyophilized overnight to dryness. 
Moomysin was collected as a colorless powder (0.8 mg) after lyophilization, with an overall yield of 133 
µg/pan.  
The purity of moomysin was verified by HPLC with a Perkin Elmer Flexar HPLC equipped with a 
Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å pore size). 
A mobile phase of 10 mM aq. NH4HCO3/MeCN gradient from 5–15% MeCN over 25 minutes, then ramped 
to 95% MeCN for 5 minutes and held at 95% for 10 minutes at a flow rate of 1 mL min-1. Elution of 




Isolation of citrulassin A. Streptomyces albulus NRRL B-3066 was grown on ATCC172 medium with 
1.5% agar on sterilized, aluminum half sheet cake pans (n = 4; 750 mL per pan) and incubated at 30 °C for 
10 d. The agar was frozen, thawed, and squeezed (filtering through cheesecloth) to collect the bulk aqueous 
extract. The solid agar was then extracted with 600 mL of 50% methanol in water for 2 h. The methanol 
was removed under vacuum and the remaining aqueous extraction was combined with the liquid from the 
agar squeeze. The combined aqueous extract was vacuum filtered through Whatman filter paper to remove 
residual solid material. The extract was loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) 
pre-equilibrated with 100 mL MeCN, 100 mL 50% aq. MeCN, and 200 mL water prior to loading. The 
column was washed with an additional 200 mL of water. Product was eluted with successive 50 mL portions 
of 10%, 20%, 30%, 40%, and 50% aq. MeCN, followed by 100 mL of MeCN. Fractions were analyzed via 
MALDI-TOF MS (Supplementary Methods: screening Actinomycetes for lasso peptide production). 
Fractions containing citrulassin A were pooled and dried under reduced pressure onto ~15 g Celite 545 
adsorbent. 
Adsorbed citrulassin A was purified by MPLC using a Teledyne Isco Combiflash EZprep equipped 
with a RediSep Rf C18 cartridge (130 g media, 60 Å pore size, 40–63 µm particle size, 230-400 mesh) 
using a mobile phase of 10 mM aq. NH4HCO3/MeCN at 85 mL min-1 over a gradient from 10–100% MeCN 
(25 column volumes). Fractions were analyzed via MALDI-TOF MS, pooled, and dried under reduced 
pressure. Partially purified material was stored at -20 °C between purification steps. 
The partially purified material was resuspended in 5 mL water and was injected onto a Teledyne 
Isco Combiflash EZprep equipped with a RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 5 
µM particle size). The product was purified with a mobile phase of 10 mM aq. NH4HCO3/MeCN at a flow 
rate of 19 mL min-1 utilizing a method of: 5% MeCN (isocratic, 5 min), 5–40% MeCN (gradient, 20 min), 
40–100% MeCN (gradient, 5 min), 100% MeCN (isocratic, 5 min). Elution of citrulassin A was monitored 
at 214 nm. Fractions containing the product were dried under reduced pressure and stored at -20 °C. 
Final preparative chromatography was performed with a Perkin Elmer Flexar HPLC equipped with 
a Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å pore 
size). The partially purified product was dissolved in 6 mL of water and injected over 6 consecutive runs. 
A mobile phase of 10 mM aq. NH4HCO3/MeCN was utilized at a flow rate of 1 mL min-1 with a method 
of: 20% MeCN (isocratic, 5 min), 20%–30% MeCN (gradient, 35 min), 30%–95% MeCN (gradient, 5 min), 
100% MeCN (isocratic, 3 min). Elution was monitored at 220 nm and fractions containing citrulassin A 
were dried under reduced pressure, resuspended in 5 mL water, flash frozen, and lyophilized overnight to 
yield a white, cotton-like solid (8 mg, ~2 mg/half sheet cake pan). 
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The purity of isolated citrulassin A was checked by HPLC with a Perkin Elmer Flexar HPLC 
equipped with a Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 
100 Å pore size). A mobile phase of 10 mM aq. NH4HCO3/MeCN was utilized at a flow rate of 1 mL min-
1. Citrulassin A was injected as 10 µL of a 1 mM solution with a method of: 15% MeCN (isocratic, 5 min), 
15–27% MeCN (gradient, 20 min). Elution was monitored at 220 nm. 
 
Isolation of lagmysin. Streptomyces sp. S-118 was grown on ISP Medium 4 (Supplementary Methods: 
microbiological methods) with 1.5% agar on 15 cm sterilized petri dishes (n = 24) and incubated at 30 °C 
for 10 d. Cells were harvested by scraping cell mass from the plates with razors and collectively extracted 
with 600 mL MeOH with shaking at room temperature overnight. The cell mass was filtered with Whatman 
filter paper and re-extracted with 600 mL BuOH with shaking at room temperature overnight before 
filtering again. Cell extracts were combined and dried under reduced pressure onto ~5 g Celite 545 
adsorbent. 
 Spent agar was frozen at -20 °C overnight and then allowed to thaw. The agar was squeezed and 
filtered through cheesecloth to harvest the aqueous portion, then vacuum filtered with Whatman filter paper 
and loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) pre-equilibrated with 100 mL 
MeCN, 100 mL 50% aq. MeCN, and 200 mL water prior to loading. The column was then washed with an 
additional 200 mL of water, then eluted with successive 50 mL portions of 5%, 10%, 25%, 50%, 75% aq. 
MeCN, followed by 100 mL MeCN. Fractions were analyzed via MALDI-TOF MS. Fractions containing 
lagmysin were pooled and dried under reduced pressure onto ~5 g Celite 545 adsorbent and combined with 
the adsorbed cell extract. 
 Adsorbed lagmysin was chromatographed by MPLC using a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Rf C18 cartridge (130 g media, 60 Å pore size, 40–63 µm particle size, 230–400 
mesh) using a mobile phase of 10 mM NH4HCO3/MeCN at 85 mL min-1 over a gradient from 20–60% 
MeCN (10 column volumes), then 60–95% MeCN (5 column volumes) then holding at 95% MeCN (5 
column volumes). Fractions were analyzed via MALDI-TOF MS, pooled and dried under reduced pressure 
and stored at -20 °C. 
 To prepare samples for preparatory HPLC, dried lagmysin was resuspended in 7 mL of water, 
subjected to centrifugation at 17,000 × g to remove precipitate, and filtered with a 0.22 µm syringe filter 
(BD Technologies) prior to injection. Lagmysin was injected onto a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 5 µM particle size) utilizing 
a flow rate of 19 mL min-1 with a mobile phase of 10 mM NH4HCO3/MeCN gradient from 10 to 50% 
MeCN (15 column volumes) then 50 to 100% MeCN (5 column volumes) and held for an additional 5 
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column volumes. Elution of lagmysin was monitored at 214 nm, and fractions containing the desired 
material were dried under reduced pressure and stored at -20 °C. 
 Final preparative chromatography was performed with a Perkin Elmer Flexar HPLC equipped with 
a Betasil C18 (Thermo Scientific) reverse phase column (250 × 10 mm, 5 µm particle size). Lagmysin was 
dissolved in 1.5 mL of water, subjected to centrifugation at 17,000 × g to remove precipitate and injected 
with a mobile phase of water/MeCN + 0.1% formic acid (v/v) gradient from 20–95% over 30 min with a 
flow rate of 4 mL min-1. Elution was monitored at 220 nm and fractions containing lagmysin were dried 
under reduced pressure, resuspended in 2 mL water, flash frozen and lyophilized overnight to dryness. 
Lagmysin was collected as a colorless powder (6.5 mg) after lyophilization, with an overall yield of 270 
µg/15 cm plate.  
Analytical HPLC to assess purity of lagmysin was performed with a Perkin Elmer Flexar HPLC 
equipped with a Betasil C18 column (100 Å pore size, 250 × 4.6 mm, 5 µM particle size) (Thermo 
Scientific) with a mobile phase of H2O/MeCN + 0.1% (v/v) formic acid (FA) gradient from 10% to 95% 
aq. MeCN over 30 minutes and held at 95% MeCN for 10 minutes at 1 mL min-1. Elution was monitored 
at 220 nm. 
 
Broth microdilution antimicrobial assay. A broth microdilution assay was used to determine the 
minimum inhibitory concentration (MIC) against a panel of bacteria. E. coli MC4100, Pseudomonas 
aeruginosa PA01, Klebsiella pneumoniae ATCC 27736, Acinetobacter baumannii ATCC 19606, 
Enterococcus faecium U503 (VRE), Staphylococcus aureus USA300 (MRSA), Bacillus subtilis 168, 
Bacillus anthracis Sterne, Listeria monocytogenes serotype 4b str. F2365, and Mycobacterium smegmatis 
NRRL B-14616 were grown in Mueller-Hinton broth (BD). Neisseria meningitidis 8013 was grown in 
gonococcal broth (GBC) with Kellogg’s supplements. Bacteria were grown overnight in 5 mL of medium 
at 37 °C to stationary phase. Cultures were diluted 50-fold into 5 mL of fresh media, allowed to grow back 
to mid-exponential phase (OD600 = 0.500), and diluted to OD600 = 0.01. Lasso peptide stocks (10 mM in 
DMSO; or 1 mM in 0.2 µm filtered H2O for citrulassin A) were serially diluted (2-fold) in broth in a 96-
well microplate. An equal volume of bacterial culture in broth was added to each well (final vol. 
100 μL/well) to give a final range of 100 µM to 49 nM compound. Plates were sealed with Parafilm M and 
incubated at 37 °C with shaking. The MIC is the concentration that resulted in no visible growth after 18 h, 
or 24 h for M. smegmatis. All measurements were made with at least 2 replicates. 
 
Sequencing of Streptomyces albulus str. NRRL B-3066 genome. The genome of S. albulus was 





Quantitative amino acid analysis of citrulassin A. Purified citrulassin A was submitted to the Texas 
A&M Protein Chemistry Laboratory (http://tamupcl.com/) for quantitative amino acid analysis in triplicate 
using a total of 75 µg. 
 
Chiral amino acid analysis. Microwave assisted vapor phase acid hydrolysis of peptides was performed 
in a CEM Discover 3000 Microwave System (CEM). Peptides were hydrolyzed in a sealed chamber with 
6 N deuterium chloride (DCl) at 150 °C for 30 min under anaerobic conditions. Hydrolysates were 
derivatized with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA) (Thermo-Fisher 
Scientific) to enhance separation of L-/D-amino acids. Hydrolysates were reconstituted in 25 μL of 0.5 M 
NaHCO3, combined with 20 μL of 1 mg/mL FDAA in MeCN, and incubated at 60 °C for 3 h. Derivatized 
amino acids from each peptide sample were analyzed using a LC-MS/MS-MRM system consisting of an 
Advance Ultra-High Pressure Liquid Chromatography (UHPLC) (Bruker) system coupled to an EVOQ 
Elite Triple-Quadrupole MS (Bruker) with a Kinetex 2.6 μm Phenyl-Hexyl 100 Å LC column (100 × 2.1 
mm) (Phenomenex). Gradient elution was performed with binary solvents (Solvent A: 25 mM ammonium 
formate, Solvent B: MeOH) at 300 μL/min. The gradient was 5% B for 2 min, 5–15% B for 5 min, 15–60% 
B for 5 min, 60% B for 3 min, 60–100% B for 3 min, 100% B for 3 min, 100–5% B for 1 min, 5% B for 2 
min. Data Review (Bruker) was used to analyze the MRM data. 
 
High resolution mass spectrometry. Lasso peptides were dissolved in 80% aq. MeCN with 1% AcOH 
and subjected to centrifugation (17,000 × g, 5 min). Samples were infused onto a ThermoFisher Orbitrap 
Fusion ESI-MS using an Advion TriVersa NanoMate. The MS was calibrated weekly using calibration 
mixture, following manufacturer instructions, and tuned daily with Pierce LTQ Velos ESI Positive Ion 
Calibration Solution (ThermoFisher). Spectra were collected in profile mode with a resolution of 100,000. 
Ions were selected for fragmentation in the Ultra-High-Field Orbitrap Mass Analyzer using an isolation 
width of 5 m/z, a normalized collision energy of 35, an activation q value of 0.4, and an activation time of 
30 ms. Data analysis was performed using Thermo Xcalibur software. 
 
NMR spectroscopy. HPLC-purified and lyophilized samples (ca. 1–5 mg) were dissolved in 600 µL of 
CD3OD (99.96 atom % D; Sigma-Aldrich) or CD3OH (99.5 atom % D; Cambridge Isotope Labs). Spectra 
were obtained with either a Bruker AVANCE 900 MHz narrow bore spectrometer equipped with an inverse 
5 mm TCI cryogenic probe with z-axis pulsed field gradient (pfg) capability or on an Agilent VNMRS 750 
MHz narrow bore magnet spectrometer equipped with a 5 mm triple resonance (1H-13C-15N) triaxial 
gradient probe and pulse-shaping capabilities. Samples were held at 298 K during acquisition. Standard 
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Bruker or Varian pulse sequences were used for each of the following experiments: 1H, 1H with solvent 
suppression using excitation sculpting (Bruker: zgesgp), 1H-1H TOCSY (80 ms mixing time; Bruker: 
dipsi2esgpph), 1H-13C HSQC (multiplicity-edited; Bruker: hsqcedetgpsisp2), and 1H-1H NOESY (400 ms 
mixing time; Bruker: noesyesgpph; Varian: dpfgse_noesy). 2D spectra in CD3OH employed solvent 
suppression as per the listed pulse sequences. Spectra were recorded with Bruker TopSpin 1.3 or VNMRJ 
3.2A software, and data was processed using MestReNova 8.1.1. Chemical shifts (δ, ppm) were referenced 
internally to the solvent peak. 
 
Three-dimensional solution structure calculation. Solution structures were calculated by simulated 
annealing using distance and angle restraints within XPLOR-NIH v 2.3662. Standard XPLOR-NIH 
potentials for bond angles, improper angles, van der Waals, and favored/allowed Ramachandran regions 
were used. The lasso-forming isopeptide linkage was specified using a manual patch of the “protein-
1.0.top” XPLOR-NIH file (Supplementary Note 4); the disulfide linkage was created using a pre-installed 
patch (DISL). Distance restraints were derived from peak area integrations in the NOESY data. The 
program nmrPipe was used for processing of NOESY data and conversion from Bruker to UCSF format 
(Sparky), and Sparky was used for peak picking, volume integration, and creation of the distance restraint 
table for use in XPLOR.  Two hundred structures were calculated, of which the 20 of lowest energy were 
retained.  
 
Thermal unthreading assay. Lasso peptide stock solutions were diluted to 40 µM in a final volume of 50 
µL, heated at 95 °C for 4 h, and cooled to rt. Samples were then analyzed by liquid chromatography 
electrospray ionization tandem mass spectrometry (LC/ESI-Q/TOF MS) using a Synapt ESI quadrupole 
TOF Mass Spectrometry System (Waters) equipped with an Acquity Ultra Performance Liquid 
Chromatography (UPLC) system (Waters). Lasso peptides were analyzed from 2 to 98% aq. MeCN (with 
0.1% formic acid) over 24 min at a flow rate of 130 µL min-1. Total ion chromatograms were used to 
monitor retention times via Waters MassLynx MS Software. 
 
Enzymatic digestion assay. Lasso peptide stock solutions were diluted to 20 µM in 50 mM MES (pH 6.7) 
and 1 mM CaCl2 with 1 U carboxypeptidase y. Lasso digestions were carried out overnight at 22 ˚C before 
being desalted and dissolved in 75% MeCN (with 1% acetic acid) for analysis by high resolution mass 
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CHAPTER 3: DIVERGENT PRENYLTRANFERASES IN PATHOGENIC BACTERIA 
This work has been previously published.5 
 
3.1 Introduction 
Terpenes or isoprenoids are small molecules that contain one or more C5 (isoprene) building 
blocks1. There are ~70,000 such species known2, produced by a wide range of terpene synthases. 
Isoprenoids are of general interest since they are involved in the formation of important drugs 3; bacterial 
cell wall biosynthesis4; fragrances5; quinones and hemes for electron transport6 as well as the post-
translational modification of proteins that are important in cellular signaling 7.   
Although the number of terpenes is large, there are a much smaller number of protein classes 
involved in their biosynthesis1. Our interest here is in the so-called “head-to-head”8 class of terpene 
synthases which are found in prokaryotes and eukaryotes, including humans. These enzymes condense two 
isoprenoid diphosphates, such as farnesyl diphosphate (FPP, 1, Scheme 1), at C1 to form e.g. presqualene 
diphosphate (PSPP, 2), hence the "head-to-head" designation, with PSPP then being converted to either 
dehydrosqualene (DHS, 3), hydroxysqualene (4) or squalene (SQ, 5). In contrast, “head-to-tail” 
condensations are involved in isoprenoid chain elongation with e.g. 1 reacting with isopentenyl diphosphate 
(IPP, 6) to form the C20 product geranylgeranyl diphosphate (GGPP, 7), which can then be converted by 
phytoene synthases to pre-phytoene diphosphate and phytoene, the building blocks of plant carotenoid 
biosynthesis. The structures of the head-to-head synthases, how they function, and how they might be 
inhibited are all important questions because several of these enzymes are drug targets9 as well as, 
potentially, herbicide targets. 
Perhaps one of the simplest reactions (i.e. one step; no reductant) carried out by a head-to-head 
synthase is carried out by the enzyme HpnD (Hpn refers to genes involved in hopanoid biosynthesis) and 
involves the condensation of two FPP molecules to form PSPP (2), as in e.g. Zymomonas mobilis10,11, Figure 
1A. PSPP is then converted by HpnC to 12-hydroxysqualene (4) which, in turn, is converted by HpnE to 
squalene, used in hopanoid biosynthesis. In S. aureus, the enzyme CrtM converts two FPP molecules to 
                                                     
5 This chapter is adapted in part from Christopher J. Schwalen, Weidong Liu, Xinxin Feng, Bing O-Dowd, Tzu-Ping 
Ko, Rey-Ting Guo, Eric Oldfield, and Douglas A. Mitchell “Head-to-head prenyl synthases in some pathogenic 
bacteria” ChemBioChem 2017, (18), 985-991. This work was supported in part by an NIH Director's New Innovator 
Award (DP2 OD008463 to D.A.M.), the David and Lucile Packard Fellowship for Science and Engineering (to 
D.A.M.); the National Natural Science Foundation of China (grants 31200053, 31300615, 31400678, and 31470240); 
the Chinese Academy of Sciences (grant KSZD-EW-Z-015-2); the United States Public Health Service (NIH grants 
CA158191 and GM065307 to E.O.); a Harriet A. Harlin Professorship, and the University of Illinois 
Foundation/Oldfield Research Fund. C.J.S. is a member of the NIH Chemistry–Biology Interface Training Program 
(NRSA 1-T32 GM070421). We thank the National Synchrotron Radiation Research Center of Taiwan for beam time 




PSPP and then to dehydrosqualene, the first committed step in biosynthesis of the carotenoid virulence 
factor, staphyloxanthin (Figure 3.1).12 In eukaryotes such as fungi and protozoa, the enzyme squalene 
synthase (SQS) again first converts FPP to PSPP, but this is then converted to squalene in a second step, 
one that requires NADH/NADPH (Figure 3.1c). In the green alga, Botryococcus braunii Race B13, a 
squalene synthase-like protein (SSL-1) also converts FPP to PSPP (Figure 3.1), which can then be 
converted to squalene or to botryococcene (by SSL-3), making these prenyltransferases a potential source 
of biofuel. Finally, in plants, GGPP (7) is converted by phytoene synthase (PHY) to phytoene (the C40 
analog of dehydrosqualene), Figure 1E, the precursor of carotenoid pigments such as -carotene. 
 
Scheme 1. Structures of compounds discussed in the text. 
 
In this work, we identified homologs of the “head-to-head” terpene synthases in human pathogenic 
bacteria to investigate their structure and function. Earlier work14 showed that S. aureus CrtM (SaCrtM; 
dehydrosqualene synthase) had a structure that was remarkably similar to that of human squalene synthase 
(HsSQS) and could be inhibited by known SQS inhibitors. This led to a novel approach to targeting S. 
aureus virulence in vivo14 and so, we reasoned, learning more about the occurrence, structure, and function 
of related head-to-head terpene synthases in other pathogens might—in the future—result in novel 
therapeutic leads. 
 















Figure 3.1: Some reactions catalyzed by “head-to-head” prenyl transferases. (A) PSPP formation from 
FPP by HpnD in hopanoid biosynthesis. (B) dehydrosqualene formation from FPP by S. aureus CrtM in 
staphyloxanthin biosynthesis. (C) squalene formation from FPP and NADH/NADPH by SQS in sterol (e.g. 
cholesterol, ergosterol, sitosterol) biosynthesis. (D)  PSPP formation from FPP by Botryococcus braunii 
Race B SSL-1 in botryococcene biosynthesis. (E) phytoene formation from GGPP by PHYS in plant 
carotenoid biosynthesis; PPPP = prephytoene diphosphate. 
 
3.2 Bioinformatics analysis  
We first carried out a BLAST (Basic Local Alignment Search Tool15) search of all bacterial 
genomes using SaCrtM as a query. There were several hits including genes from Neisseria meningitidis 
(the causative agent of meningitis), Neisseria gonorrhoeae (the causative agent of gonorrhea), and 
Enterococcus hirae (a causative agent of endocarditis and septicemia in humans). In an  attempt to link 
primary sequence to predicted function, we then utilized the Enzyme Function Initiative (EFI)’s Sequence 
Similarity Network (SSN) tool16 to map similarities and recognize clustering (Figure 3.2). 
 
Figure 3.2: Network analysis of CrtM-like proteins. The Enzyme Function Initiative Enzyme Similarity 









Figure 3.2: (cont.) synthases) using an e-value cutoff of e-50 and an 85% amino acid sequence identity. 
SaCrtM = Staphylococcus aureus CrtM; EhCrtM = Enterococcus hirae CrtM; NmHpnD = Neisseria 
meningitidis HpnD; NmHpnC = Neisseria gonorrhoeae HpnC;  ZmHpnD = Zymomonas mobilis HpnD; 
ZmHpnC = Zymomonas mobilis HpnC; HsSQS = Homo sapiens SQS. 
 
From the SSN, which clusters proteins of related sequences, the S. aureus CrtM proteins (Figure 
3.2, mid left; orange) form a tight cluster with a predicted E. hirae CrtM (EhCrtM; mid-left, blue) close-
by, suggesting that the E. hirae protein might also produce dehydrosqualene. The adjacent cluster contains 
the Neisseria proteins (from N. meningitidis, N. gonorhoeae and N. sicca; green), annotated as HpnD due 
to proximity to the cluster containing Z. mobilis (top center cluster; blue). Previously characterized HpnD 
enzymes utilize a partner terpene synthase, HpnC, which converts the PSPP product of HpnD to 12-OH 
squalene and such HpnD/HpnC systems are also found in Neisseria spp. (but not in E. hirae), and are 
present in an operon together with HpnE, the flavoprotein reductase that in other organisms is known to 
convert HSQ to SQ. HpnCs and SQS are more distant from CrtM/HpnD (Figure 3.2). 
     We next sought to determine the structures and products of EhCrtM and Neisseria spp. HpnD 
and HpnC-like proteins which—based on the bioinformatics analysis—were expected to produce 
dehydrosqualene, PSPP or 12-OH squalene.  
 
 
Figure 3.3: Enterococcus hirae CrtM. (A) structure of EhCrtM (PDB entry 5IYS showing two FSPP 
ligands bound. (B) Superposition of EhCrtM with S. aureus CrtM (PDB:3W7F, ref 13) showing a 1.3 Å Cα 
rmsd/266 residues. Yellow protein is EhCrtM; magenta FSPP is from EhCrtM; green Mg ions are from 
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Figure 3.3: (cont.) EhCrtM; cyan protein is SaCrtM; blue FSPP is from SaCrtM; grey Mg ions are from 
SaCrtM. 
 
3.3 Prenyltransferase biochemical characterization 
We first cloned, expressed, purified and crystallized EhCrtM and solved its structure 
crystallographically. Full details are given in the Experimental and data acquisition and refinement details 
are given (Table 3.1). The protein produced dehydrosqualene from FPP, as anticipated based on the EFI 
analysis, and the two substrate analog S-thiolo-FPPs (FSPP) were found to bind to the active site, consistent 
with previous work on SaCrtM14. A view of the complete EhCrtM structure with two FSPPs bound is shown 
in Figure 3.3a, and a superposition of the EhCrtM (yellow) and SaCrtM (cyan) structures (with FSPP 
ligands) is shown in Figure 3B in which there is a 1.3 Å Cα rmsd over 266 residues. The SaCrtM and 
EhCrtM structures are therefore very similar, as are  the FSPP (substrate analog) binding modes. We next 
cloned, expressed and purified the putative HpnDs from N. menigitidis, N. gonorrhoeae and N. sicca (Nm, 
Ng and Ns, respectively). All three proteins expressed well and were >95% pure as judged by SDS-PAGE 
electrophoresis (Figure 3.4). However, given the sequence differences to SaCrtM, EhCrtM and ZmHpnD 
seen in the BLAST alignment and discussed more below, the actual substrates and products of the putative 
Neisseria spp. HpnDs were uncertain, so a range of potential isoprenoid diphosphate substrates were tested. 
There was no reaction with IPP, dimethylallyl diphosphate (DMAPP), geranyl diphosphate (GPP) or GGPP, 
but FPP was a good substrate (Figure 3.4). There was no increase in activity with FPP together with either 
IPP, DMAPP, GPP or GGPP. The product of the putative HpnD with FPP as substrate was then found by 
TLC autoradiography to be PSPP, based on Rf values with authentic PSPP, as well as by its conversion to 
squalene with SQS/NADH addition (after complete conversion to PSPP), as shown in Figure 3.4c, with no 
longer-chain products observed. Figure 3.4d shows the LC-MS chromatograms of NmHpnD+FPP and 
HsSQS+FPP (no NADPH) reaction products, and the major products of both reactions are consistent with 
PSPP formation, based on their m/e values. To evaluate competency, the rates of the reactions of the 
NmHpnD, NgHpnD and NsHpnD were evaluated via a kinetic phosphate release assay, which produced 
similar results for the three Neisseria HpnDs, Figure 3.4e (for NmCrtM) and Figure 3.4f (Km, Vmax and 





PDB code 5IYS 
Data collection  
space group P21 
unit-cell  
a [Å] 37.2 
b [Å] 41.1 
c [Å]  93.5 
α /β /γ (°) 90.00/96.35/90.00 
resolution [Å] 25-2.68 (2.78-2.68) 
unique reflections 21560 (2126) 
redundancy 5.2 (5.0) 
completeness [%] 99.7 (99.8) 
average I/σ(I) 24.43 (5.98) 
R merge
[a] [%] 6.3 (26.9) 
Refinement  
no. of reflections 20009 (1465) 
Rwork
[a] (95 % of data) 0.166 (0.198) 
Rfree
[a] (5 % of data) 0.219 (0.254) 
r.m.s.d. bonds [Å] 0.010 
r.m.s.d. angles [º] 1.445 
dihedral angles  
most favored [%] 98.9 
allowed [%] 1.1 
disallowed  [%] 0.0 
no. of non-H atoms / average B 







Table 3.1: Data collection and refinement statistics for EhCrtM in complex with FSPP. Values in 





Figure 3.4: Neisseria HpnD protein expression and activity. (A) SDS-PAGE analysis of NmHpnD (two 
replicates), NgHpnD and NsHpnD. (B) Activity of NmHpnD with various prenyl diphosphates as 
determined in an MESG/PNP/PPase assay for phosphate. (C) TLC autoradiography of NmHpnD products 
with [u-14C-FPP]. Lane 1, FPP control; lane 2, MBP-NmHpnD plus FPP (PSPP product); lane 3, same as 
lane 2 but TEV cleaved protein to remove the MBP tag; lane 4, as lane 2 but SQS/NADPH added after 
PSPP reaction completion, which converts PSPP to SQ ; lane 5, SQS+NADPH (SQ product); lane 6, 
SaCrtM+FPP, DHS product. (D) LC-MS traces showing reaction products of NmHpnD+FPP (in blue) and 
HsSQS+FPP (in red). Inset shows the mass spectrum of PSPP ([M-1]-=585.5 Da) from the NmHpnD 
reaction. (E) Michaelis-Menten plot for MBP-NmHpnD with different FPP concentrations. (F) Kinetic 
parameters for Neisseria spp. 
 
We attempted to crystallize NmHpnD, but we were not successful. Furthermore, we were unable 
to obtain catalytically active HpnCs, as judged by the lack of new products in reaction mixtures containing 
HpnD plus HpnC. We thus used the structure prediction program Phyre217 to predict possible HpnD 
structures. HpnD structures were predicted with "100% confidence" over 94-98% of their sequences when 
utilizing either an SaCrtM template, an Alicyclobacillus acidocaldarius squalene synthase HpnC (Protein 
Data Bank, PDB entry 4HD1), or Bacillus subtilis YisP (PDB: 3WE918). While structure predictions are 
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less reliable than are actual crystal structures, the similarities in the folds of SaCrtM, EhCrtM, AaHpnC and 
BsYisP all support the use of computational modeling to suggest which residues are likely to be in the 
NmHpnD active site region. And, when combined with the results of amino acid sequence alignment 
comparisons, both sets of results could suggest which residues might be involved in determining why 
NmHpnD produces only PSPP, and does not carry out the second half reaction found in CrtM, formation 
of dehydrosqualene.  
We show in Figure 5A an alignment of the SaCrtM structure (cyan) containing PSPP (purple sticks) 
(PDB:3NPR19) with the NmHpnD model (yellow), and in Figure 5B the corresponding sequence alignment. 
As can be seen in Figure 3.5b, the only obvious difference in the active site region (residues within 4Å of 
PSPP, highlighted in yellow), shown in the red box, is that  S19 in SaCrtM is R15 in NmHpnD model 
(Figure 3.5b). The presence of this charged residue could contribute to stabilizing PSPP (in HpnD), or, it 
might prevent the second-half reaction, conversion of PSPP to dehydrosqualene, for example by preventing 
formation of a [Mg2+]3 complex used to facilitate ionization/diphosphate release.   
To investigate the possible role of R15 in NmHpnD we replaced it with serine, R15S, in addition 
to substituting S19 in SaCrtM with arginine, S19R. The possibilities are that since the HpnD reaction is a 
“single-step ” reaction, 2FPP  PSPP, the R15S mutation in HpnD might have little effect on the reaction 
rate since it appears that R15 may coordinate to the PSPP  product, Figure 3.5c. However, in CrtM, there 
are two reactions: 2FPP  PSPP, and PSPP  dehydrosqualene. If PSPP is stabilized by an S19R variant 
in CrtM with R19 binding to the PSPP diphosphate, as well as potentially having a repulsive Coulombic 
interaction with the [Mg2+]3, there could be a decrease in dehydrosqualene production. As can be seen in 
Figures 5D and 5E, in each of the wild type Neisseria spp., lanes 2-4, the major product is PSPP and the 
same is found with the R15S NmHpnD variant (Figure 3.5d-e, lane 5). However, there is significantly less 
dehydrosqualene formed using SaCrtM S19R (Figure 3.5d-e lane 7 in red), compared to the wild type 




Figure 3.5: Role of NmHpnD R15/SaCrtM S19 in product formation. (A) alignment of the SaCrtM 
structure containing PSPP (PDB:3NPR) on a Phyre2 model of NmHpnD. (B) Structure-based sequence 
alignment of SaCrtM and NmHpnD based on A. The aligned active site residues (with 4 Å of PsPP) from 
both proteins are highlighted in yellow. Residue pair with different residues of interest (R15 in NmHpnD 
and S19 in SaCrtM) is boxed in red. (C) A zoomed-in view of A showing the close proximity of the R15/S19 
residues. (D) and (E) Effects of mutations on product formation by HpnD and CrtM. Lane 1, FPP control; 
lane 2, MBP-NsHpnD, PSPP product; lane 3, MBP-NgHpnD, PSPP product; lane 4,  MBP-NmHpnD, PSPP 
product; lane 5, MBP-NmHpnD R15S mutant, PSPP product; lane 6, SaCrtM, dehydosqualene product 
(gold); lane 7, SaCrtM S19R mutant showing large decrease in DHS formation (red) versus wt (lane 6). 
 
3.4 Conclusions 
Using bioinformatics, we uncovered multiple “head-to-head” prenyl transferases in the bacterial 
pathogens that cause meningitis, gonorrhea, and some cases of endocarditis and septicemia. The products 
of these enzymes are presqualene diphosphate (from HpnD, in the Neisseria spp.) and dehydrosqualene (in 
Enterococcus hirae). We solved the structure of the E. hirae CrtM finding it to be very similar to the S. 
aureus enzyme. Computational modeling (and sequence similarity) suggested a role for R15 in stabilizing 
PSPP formation in HpnD, and in a CrtM S19R variant, an SR substitution decreased formation of 
dehydrosqualene. Further work will be required in order to deduce the biological role of the "Hpn" cluster 
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enzymes (HpnC, HpnD and HpnE) in Neisseria because neither squalene nor hopanoids have been reported 
in these species with virulence, adhesion/entry as well as biofilm formation (as with YisP) being intriguing 
possibilities. In addition, unlike S. aureus, E. hirae is not pigmented, so the role of its CrtM likewise remains 
to be determined. What is clear, however, is that HpnD is the first example of a presqualene diphosphate 




SDS-PAGE analysis of recombinant proteins. Proteins were expressed as N-terminal MBP fusions in 
BL21(DE3-RIPL) Escherichia coli. Protein purity was assessed by SDS-PAGE and Coomassie staining 
using 12% gels. Briefly, proteins were overexpressed by inoculating 1 L of LB with 50 µg/mL kanamycin 
and 34 µg/mL chloramphenicol and monitoring growth until OD600=0.6, then placing cultures on ice for 15 
minutes. Cultures were then induced with 0.6 mM IPTG for 8 hours at 30 °C. Typical yields were 28-32 
mg/L as determined by A280 and Bradford assay. Comparison of kinetic competence showed that with MBP 
tags, the proteins were stable at -80 °C for ~1 year. 
 
Time-course cleavage of MBP with TEV (tobacco etch virus) protease. A solution of MBP-HpnD was 
treated with 1/100 (w/w) of TEV protease at 23 °C and 37 °C and samples were checked for proteolytic 
progress at 1, 2, and 3 h by SDS-PAGE. Complete removal of the MBP fusion partner was seen at the last 
time point. Experiments using TEV-cleaved MBP-fusion proteins were treated in the same way, to affect 
full cleavage. 
 
Substrate selectivity of Neisseria HpnD. Substrate selectivity was determined by using a continuous 
colorimetric inorganic phosphatase/purine nucleoside phosphorylase (PNP) coupled assay for diphosphate 
release. In reaction mixtures containing either 50 µM isopentenyl diphosphate (IPP, C5), dimethylallyl 
diphosphate (DMAPP,  C5), geranyl diphosphate (GPP, C10), farnesyl diphosphate (FPP, C15) or 
geranylgeranyl diphosphate (GGPP, C20), 200 µM of methylthioguanosine (MESG), 0.5 U of purine 
nucleoside phosphorylase and 0.5 U of inorganic diphosphatase were added. Reactions were initiated with 
the addition of 2 µM MBP-NmHpnD. Reaction buffers contained 50 mM Tris (7.4), 125 mM  NaCl and 20 
mM MgCl2 and reactions were allowed to proceed at room temperature for up to 5 minutes, monitoring the 
absorbance at 360 nm. Initial velocities were calculated using an extinction coefficient ε = 11000 M-1 cm-1. 
In a second set of experiments, FPP was co-incubated with either IPP, DMAPP, GPP or GGPP, all at 50 




Autoradiography of products. NmHpnD reactions were monitored by autoradiography/thin-layer 
chromatography using 14C-labeled substrates. Reactions were terminated by the addition of potato acid 
phosphatase (PAP), diluted with 1 volume of satd. NaCl, then extracted with 2 volumes of chloroform. 
Extracts were dried, then resuspended in the minimal volume of hexanes (~50 µL), spotted on reverse-
phase C18 thin-layer chromatography plates and developed with a mobile phase of 8:2 acetone/methanol, 
dried and exposed overnight on a storage phosphor screen. A BioRad Quantity One instrument was then 
used to image and analyze the exposed screens.  
 
Kinetic analysis of NmHpnD. To reaction mixtures containing either 2.5, 5, 10, 20, 40 or 80 µM FPP, 0.5 
U of purine nucleoside phosphorylase, 0.5 U of inorganic diphosphatase and 200 µM of MESG, 2 µM of 
MBP-NmHpnD was added and absorbance at 360 nm monitored for up to 5 minutes. Initial velocities were 
calculated as a function of substrate concentration and Km and kcat calculated using Origin software 
(OriginLab Corporation, MA).  
 
Sequence similarity analysis. The Enzyme Function Initiative Enzyme Similarity Tool was used to 
generate a sequence similarity network for InterPro family IPR002060 squalene/phytoene synthase using 
an e-value cutoff of e-50 and 85% sequence identity convergence to a node.  
 
EhCrtM purification, crystallization and structure determination. The gene encoding EhCrtM 
(dehydrosqualene synthase from Enterococcus hirae ATCC 9790, GenBank accession number: 
AFM70029.1) was chemically synthesized by Beijing Genomics Institute (Beijing, China) and ligated into 
a pET28a vector. Plasmids were transformed into E. coli BL21(DE3) and cultivated at the 5 L scale. Protein 
was induced with 0.2 mM isopropyl- -D-thiogalactopyranoside (IPTG) in LB medium at 16 °C for 24 
hours. Purification was carried out at 4 °C, as follows. Cells were harvested by centrifugation at 5,000 x g 
for 10 minutes, re-suspended in lysis buffer containing 25 mM Tris-Cl, pH 8.0, 500 mM NaCl and 20 mM 
imidazole, then homogenized using a French Press. Cell debris was removed by centrifugation at 17,000 x 
g for 1 hour. Supernatants were applied to an FPLC system (GE Healthcare) containing a Ni-NTA column 
and the target protein was eluted at ~150 mM imidazole when using a 20-500 mM imidazole gradient. The 
protein was dialyzed against buffer containing 25 mM Tris, 500 mM NaCl, pH 8.0, and subjected to TEV 
protease digestion overnight to remove the 6x His tag. The mixture was then passed through another Ni-
NTA column and the untagged protein eluted with 25 mM Tris, pH 8.0 and 500 mM NaCl. The protein was 
further purified by using a Superdex-200 gel-filtration column with a buffer containing 20 mM Tris, pH 8.0 
and 500 mM NaCl. The purified protein was finally concentrated to 10 mg/mL in buffer containing 25 mM 
Tris, pH 8.5, 500 mM NaCl, 5 mM MgCl2 and 10 mM DTT for crystallization trials. 
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     Using the sitting-drop vapor diffusion crystallization method, 1 μL 8 mg/mL EhCrtM was mixed 
with 1 μL of reservoir solution in 24-well Cryschem Plates and equilibrated against 500 μL of the reservoir 
solution at 25 oC. Crystals were first seen in the No. 75 condition (0.2 M lithium sulfate, 0.1 M bis-Tris pH 
6.5, 25 % w/v polyethylene glycol 3350) of the Crystal Screen Index kit (Hampton Research). The crystals 
reached dimensions suitable for X-ray diffraction within 2-3 days in an optimized reservoir solution 
containing 0.1 M bis-Tris pH 6.5, 24%-28% PEG 3350, and 0.1 M Li2SO4. EhCrtM-S-thiolo-diphosphate 
(FSPP) crystals were obtained by soaking EhCrtM crystals in the mother liquor containing 20 mM FSPP 
for 2 hours prior to data collection. Crystals were mounted in a cryo-loop and flash-cooled by liquid nitrogen 
for data collection. Data sets were collected at beam line BL13C1 of the National Synchrotron Radiation 
Research Center (NSRRC, Hsinchu, Taiwan) and processed by using the HKL2000 program20. Structures 
were solved by molecular replacement using the Phaser program in the of CCP4 suite of programs21,22 using 
the structure of SaCrtM (PDB: 4E9U) as the search template. Structure refinements were carried out using 
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CHAPTER 4: EXPANDING NATURAL PRODUCT POST-TRANSLATIONAL 
MODIFICATIONS: (I) NEW YCAO HETEROCYCLASES 
This work is previously published6and in preparation for publication7 
 
4.1 Introduction 
 With the advent of high throughput genome sequencing technology, the number of available protein 
sequences has grown at a staggering rate. To organize all of this data, public databases collate protein 
sequences into superfamilies based on amino acid sequence similarity and conserved domains. 
Computationally, these groupings are determined by hidden Markov models (HMMs),1,2 which in layman’s 
terms can be thought of as pattern recognition algorithms that predict whether one protein sequence matches 
an established group. Once a protein is matched with a superfamily, it is presumed to be functionally similar 
with other members of that superfamily. Alternatively, function can often be understood by analyzing a 
protein’s constituent domain(s).3,4 This function inference process is essential for automating the annotation 
of whole genomes, and fittingly, has been employed to predict the functions for millions of proteins without 
them having been experimentally validated. 
Unsurprisingly, these homology-based approaches to protein function annotation are not without 
errors or inaccuracies.5,6 Although useful in certain situations, simply matching a superfamily does not 
necessary imply one specific function because many protein superfamilies consist of multiple different iso-
functional families, which may only share a partial mechanistic step or certain sequence motifs.7-10 
Moreover, there are many proteins, ~20% of all classified protein domains, that consist entirely of domains 
of unknown function (DUFs) and possess no characterized homologs.11,12 
Thus, much can be learned by investigating proteins that are too divergent to be confidently 
assigned a function by homology or contain DUFs with no assigned function. This is especially true for 
such proteins found in natural product (NP) biosynthetic pathways. The enzymes encoded by these 
pathways catalyze the chemical reactions that build complex small molecules and exploration of their 
reactions often reveals unexpected or entirely new reaction mechanisms.13-16 The topic of this review, the 
                                                     
6 This chapter is adapted in part from Brandon J. Burkhart, Christopher J. Schwalen, Greg Mann, James H. Naismith, 
Douglas A. Mitchell “YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function” 
Chem. Rev. 2017, (8), 5389–5456. This work was supported in part by the U.S. National Institutes of Health 
(GM097142 to D.A.M.) and fellowships from the Chemistry-Biology Interface Training Grant Program (2T32 
GM070421 to B.J.B. and C.J.S.). Additional financial support came from the David and Lucile Packard Fellowship 
for Science and Engineering (to D.A.M.) and the University of Illinois at Urbana–Champaign Department of 
Chemistry (Robert C. and Carolyn J. Springborn Endowment to B.J.B.) and a National Science Foundation Graduate 
Research Fellowship (DGE-1144245 to B.J.B.). J.H.N. acknowledges the European Research Council (339367) and 
UK Biotechnology and Biological Sciences Research Council (K015508/1) and is a Royal Society Wolfson Merit 
Award Holder and 1000 talent scholar at Sichuan University. 




YcaO superfamily, exemplifies many of the challenges, triumphs, and future benefits in studying these 
uncharacterized biosynthetic proteins.  
Originally defined as DUF181, YcaO proteins were studied through genetic and biochemical 
methods for over two decades until sufficient evidence could be gathered to suggest a common function for 
this superfamily in ATP utilization.17,18 However, the end goal of binding and hydrolyzing ATP is unknown 
for much of the superfamily. The term “YcaO” itself alludes to the enigmatic nature of this superfamily as 
it originates from a gene-naming rubric established in Escherichia coli (E. coli). If a gene was of unknown 
function, it was given a provisional, four-letter name beginning with “y” and ending with three letters that 
indicated its genomic location.19 Hence, the ycaO gene of E. coli is located between the 21- and 30-min 
region of the genome, after ycaN but before ycaP. Many of these “y” proteins remain uncharacterized to 
this day, even for the most studied model organism, which underscores the difficulty in defining roles for 
genes when no clear phenotype is evident upon deletion, overexpression, or other functional genomics 
methods.20-22  
  Despite the mystery that still surrounds many YcaO proteins, the currently available data suggest 
four functions within the YcaO superfamily: (1) azoline formation, (2) macroamidine formation, (3) 
thioamide formation, and (4) potentiation of RimO-dependent methylthiolation. Very little rationale has 
been provided for YcaO involvement in methylthiolation beyond the associated effect from gene deletion 
studies.23-25  However, the other functions are better understood and come from work on YcaO proteins 
encoded within the biosynthetic gene clusters (BGCs) of ribosomally synthesized and posttranslationally 
modified peptide (RiPPs).26  
RiPPs comprise a structurally and functionally diverse class of NPs and are categorized into 
subclasses based on common features installed by conserved biosynthetic enzymes.26 With rare exception, 
RiPP biosynthesis begins with posttranslational modification of an inactive precursor peptide, composed of 
N-terminal leader and C-terminal core region (Figure 4.1). Within the leader region are specific motifs that 
are recognized and bound by key biosynthetic proteins. To govern this substrate-binding event, several 
RiPP modifying enzymes rely on a structurally conserved domain, known as the RiPP precursor peptide 
recognition element (RRE),27 whereas other RiPP biosynthetic protein bind their cognate leaders peptides 
in structurally unique ways.28,29 Once engaged with the substrate, the biosynthetic enzymes (e.g. YcaO) 
then install residue-specific modifications to the core region. After these modifications are complete, the 
leader region is removed while other tailoring enzymes, if present, further modify peptide. After enzymatic 
processing is completed, the mature compound is usually exported by ATP-binding cassette (ABC) 
transporters.26 In some cases, mature RiPPs have been so heavily modified that they no longer resemble 
ribosomal peptides and had been postulated to derive from non-ribosomal pathways.30-32 Moreover, because 




Figure 4.1: RiPP and azoline-containing peptide biosynthesis. (A) Generic RiPP pathway. (B) Overview 
of common steps in maturation of RiPP NPs. (C) Example of a posttranslational modification within a RiPP 
biosynthetic pathway. Here, a peptidic azoline is generated by the ATP-dependent cyclodehydration of a 
Cys, Ser, or Thr residue. This is the best characterized function for a YcaO protein.  
 
Within the field of RiPP biosynthesis, the first conclusive role of a YcaO protein was elucidated by 
studying the biosynthesis of the antibiotic microcin B17 (MccB17). In 1986, the MccB17 ycaO gene was 
linked to an unknown posttranslational modification,33 which was later identified as peptide backbone azole 
heterocycles.34-36 A decade later in 1996, azole biosynthesis was reconstituted in vitro and demonstrated to 
depend on ATP and a trimeric enzyme complex of the YcaO protein, a dehydrogenase, and a member of 
the E1-ubiquitin activating (E1-like) superfamily.37 At the time, it was clear that the FMN-dependent 
dehydrogenase (encoded by a gene adjacent to the YcaO) would oxidize azolines to the corresponding 
azoles, but it was unclear what roles ATP, the YcaO, and E1-like protein played in azoline heterocycle 
synthesis. In 2012, it was determined again through in vitro reconstitution that the YcaO and E1-like protein 
functioned together as a cyclodehydratase wherein the YcaO protein performs the ATP-dependent 
cyclodehydration reaction by catalyzing the attack of a β-nucleophilic side chain (Cys, Ser, or Thr) into the 
preceding amide bond to form a presumed hemiorthoamide intermediate (Figure 4.1C).17 This species then 
undergoes an ATP-driven O-phosphorylation, followed by N-deprotonation and elimination of phosphate 
to yield the azoline heterocycle . In the absence of the E1-like protein, the catalytic activity of the YcaO 
was minimal; the E1-like protein potentiates cyclodehydratase activity by nearly three orders and binds the 
97 
 
precursor peptide through what is now known to be its N-terminal RRE domain.17,18,27 This finding resolved 
the historical confusion over the roles of the two components of the cyclodehydratase. In the past, the E1-
like and YcaO proteins have been wrongly referred to as the cyclodehydratase and docking protein, 
respectively. Although these were the originally postulated functions, data now establishes the YcaO as the 
cyclodehydratase while the E1-like protein brings the substrate into proximity of the catalytic center of the 
YcaO. Since most YcaO cyclodehydratases are all but inactive without their cognate E1-like protein, the 
cyclodehydratase is most properly defined as the combination of both proteins. More detail into the 
cyclodehydratase reaction mechanism and substrate processing is covered in. 
As YcaO/DUF181 members became functionally linked with azoline heterocycles in RiPPs, 
intriguing counterexamples surfaced which suggested a YcaO-mediated role in other peptide backbone 
modifications, namely amidine and thioamide posttranslational modifications. For example, the BGC for 
the antibiotic NP bottromycin encodes two YcaO proteins yet only one azoline heterocycle is present.38-40 
However, bottromycin contains a second amide backbone modification in the form of a macroamidine. 
Surprisingly, the two YcaOs within this gene cluster also do not have an E1-like partner protein suggesting 
that fully functional, standalone YcaOs are a possible division within the YcaO superfamily. Another case 
for additional YcaO functional capacity comes from biosynthesis of the thioviridamide, whose BGC 
encodes a YcaO protein, but the mature product is devoid of azol(in)e heterocycles. Instead, it has several 
thioamides (sulfur in place of the oxygen in the peptide backbone) and an uncharacterized protein (TfuA) 
seems to co-occur immediately adjacent to the YcaO gene in many divergent YcaO-containing gene 
clusters, indicating that this may be another distinguishable division. While the role of the YcaO proteins 
during bottromycin and thioviridamide have yet to be experimentally established, these posttranslational 
modifications could share a mechanism, proceeding through a common phosphorylated amide intermediate, 




Figure 4.2: Overview of YcaO superfamily. Asterisk denotes putative functions. 
  
With the varied activities associated with the YcaO superfamily, categories have been introduced 
to help distinguish different types of YcaO (Figure 4.2). The most well-studied are azoline-forming YcaOs 
that cyclodehydrate Cys, Ser, and Thr through collaboration with a member of the E1-like superfamily. 
Related to this type are standalone YcaOs, like those in bottromycin biosynthesis, that appear to install 
azoline heterocycles without any partner protein. Also found in the bottromycin BGC is an amidine-forming 
YcaO. Another emerging type are YcaOs that co-occur with a TfuA gene. The only investigated example 
to date is found in the thioviridiamide gene cluster and may be a thioamide-forming YcaO, also referred to 
as “TfuA-associated” (see Chapter 5). Lastly, because some YcaOs lack the experimental data to be 
confidently assigned a function, the remaining YcaOs are generally referred to as enigmatic YcaOs. These 
would include members like the YcaO associated with RimO-dependent thiomethylation and other YcaOs 
with no predicted function. This review covers the current knowledge for each of these groups, with 
emphasis on the extensively explored azoline-forming YcaOs, and outlines future research directions and 
applications. 
 
4.2 Azoline-forming YcaOs 
By far the most explored group of the YcaO superfamily are the azoline-forming YcaOs. These are 
associated with thiazoline and (methyl)oxazoline biosynthesis and have been found exclusively within RiPP 
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biosynthetic pathways. Among RiPPs, backbone azole and azoline heterocycles are found within several 
formally defined subclasses, including the linear azol(in)e-containing peptides (LAPs), azol(in)e-
containing cyanobactins, thiopeptides, and bottromycin.26,41 In each RiPP subclass, the YcaO protein is 
responsible for azoline formation, but additional structural modifications further differentiate them. For 
instance, LAPs are linear peptides with backbone azol(in)e heterocycles. However, azol(in)e-containing 
cyanobactins are formed by N- to C-macrocylization of a LAP intermediate,42,43 and it is this 
macrocylization that defines the cyanobactins as some lack azol(in)e heterocycles and correspondingly do 
not have a ycaO.26 Similarly, during thiopeptide biosynthesis, a LAP intermediate is formed which later 
undergoes a class-defining [4+2] cycloaddition to give rise to a six-membered, nitrogen-containing 
heterocycle (often pyridine).44,45 Lastly, the bottromycins bear not only a Cys-derived thiazole, but also a 
macroamidine. To underscore the biosynthetic commonality of these four RiPP subclasses, we will 
generally refer to them as azol(in)e-containing RiPPs.41  Throughout this review, an azoline-forming YcaO 
is defined as any member of the YcaO superfamily that is involved in heterocycle formation with a RiPP 
substrate through the cyclodehydration of Cys, Ser, or Thr. Additionally, we will use RiPP 
cyclodehydratase to refer to the protein complex of an azoline-forming YcaO and any associated partner 
proteins that catalyze heterocycle formation in RiPP pathways.  
The first YcaO to be studied was from a LAP named microcin B17 (MccB17),37,46,47 and owing to 
their relative chemical simplicity, LAPs have historically provided the most significant insights into the 
function of YcaO proteins. Moreover, because other more structurally complex azol(in)e-containing RiPPs 
proceed through a LAP-like intermediate, this classic work laid a foundation for the more recent 
comprehension of  RiPP cyclodehydratase function senso lato. However, it would require the revolution in 
genome sequencing before the broad distribution of the cyclodehydratase and the diversity of molecular 
scaffolds that were biosynthesized by azoline-forming YcaOs was fully realized. In the mid-2000s, the next 
group to be biochemically characterized after MccB17 was the cyanobactins.48-50 The number of BGCs was 
then greatly expanded as a result of studying the genetic distribution of the cytolytic bacterial virulence 
factor, streptolysin S (SLS).51 As sequencing technology continued to advance, the long-known and potent 
antibacterial thiopeptides were also demonstrated to be RiPPs that employed azoline-forming YcaO 
proteins.52-56 A 2015 survey found a total of ~1,500 azoline-forming YcaO gene clusters distributed among 
numerous bacterial phyla and even some archaea.57  
The ability of RiPP biosynthetic pathways to incorporate thiazole(in)e and oxazol(in)e heterocycles 
through a YcaO protein greatly expands their structural variability and bioactive potential. From a structural 
perspective, azol(in)e heterocycles rigidify and enforce specific orientations in peptidic NPs so they 
presumably can interact with their intended targets more efficiently. Consequently, these heterocycles are 
also found in the products of non-ribosomal peptide synthetases (NRPS) or hybrid polyketide synthase 
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(PKS)/NRPS pathways.58,59 Bleomycin, a PKS/NRPS approved anticancer agent, has a crucial 
bisheterocycle that drives DNA intercalation.60 Another azole-containing PKS/NRPS is epothilone, which 
is a macrolactone with anticancer activity. It’s synthetic macrolactam analog, ixabepilone, has also been 
approved for human use (Figure 4.3).61 In addition to their appearance in NPs, thiazoles are a popular 
heterocycle for medicinal chemists and thus they can be found in a number of approved drugs with activities 
spanning many therapeutic categories.62-64 For example, meloxicam, a nonsteroidal anti-inflammatory drug, 
and ritonavir, an HIV protease inhibitor, both possess thiazoles Figure 4.Figure 4.(Figure 4.3). However, 
no azoline-containing RiPP has been approved for use in humans because they tend to have inadequate 
pharmacological properties. Their peptidic nature lowers stability in vivo, and the more highly modified 
azol(in)e-containing RiPPs, which are not susceptible to proteases are often limited by poor solubility, 
absorption, and bioavailability. Nonetheless, several are used in animals for various purposes with two 
examples being growth promotion in livestock (nosiheptide) and treatment of skin infections for both 
companion animals and livestock (thiostrepton).65-67 Additionally, azol(in)e-containing RiPPs often 
represent enticing, but challenging, drug leads for treatment of human disease. For instance a semi-synthetic 
derivative of GE2270A named LFF571 has enhanced solubility (12 mg/mL compared to <0.001 mg/mL) 
and is showing promise in clinical trials for treating Clostridium difficile infections (Figure 4.4).68-70 
 
 







Figure 4.4: Derivatization of the thiopeptide GE2270A enhances water solubility. 
Based on the bioactivities of azol(in)e-containing RiPPs, there has been much interest in identifying 
gene clusters that have potential to encode structurally and functionally unique compounds. This has 
generated interest in identifying YcaO-containing BGCs, but as new YcaO sequences are added to public 
databases regularly, there is a need to bioinformatically distinguish which may catalyze azoline formation. 
Fortunately, azoline-forming YcaOs are in many cases readily differentiated from other YcaOs based on 
whether the a partner (E1-like) protein is locally encoded or if one is fused to the YcaO to yield a single 
polypeptide.17,18,57 Identifying standalone azoline-forming YcaOs is more difficult and currently relies on 
homology to proteins encoded by the bottromycin and trifolitoxin BGCs. 
From the known or putative azoline-forming YcaOs, a powerful insight into the diversity of their 
products has been revealed by plotting all proteins on a sequence similarity network (a method of clustering 
homologous sequences in two dimensional space).57 Multiple distinct clusters of related YcaO proteins are 
form as a result and can be viewed as a family given their genetic relatedness. An analogy can be drawn to 
human genealogy: identical twins look more alike than non-identical twins, parents and children also tend 
to more closely resemble each other in appearance as opposed to distant cousins or non-family members. 
Thus, if two YcaO proteins have high sequence similarity, they will be part of the same cluster and family, 
and correspondingly their BGCs and the structure of their mature NPs will generally be similar as well. 
However, more divergent YcaOs will be part of other discrete clusters and are likely to make a structurally 
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different product. By comparing and analyzing the distribution of sequence clusters, an overview of the 
different potential molecular scaffolds encoded by azol(in)e-containing RiPPs is revealed, and distinct 
families are identified. Interestingly, many groups emerged from this analysis that fall within established 
subclasses (e.g. LAPs, cyanobactins, thiopeptides) but others had no characterized members, which implies 
new opportunities for the discovery of new biologically active azol(in)e-containing RiPPs.57 Another very 
recent bioinformatic survey went further and predicted the products of putative LAP, cyanobactin, and 
thiopeptide BGCs based on the encoded genes/peptides.71 The result of this analysis again underscored the 
great diversity of potential azol(in)e-containing RiPPs.  
In contrast to the BGCs discussed above, a significant number of YcaO family members are present 
in genomic contexts that deviate from the established patterns of characterized YcaOs. Specifically, many 
YcaOs in the sequence databases do not occur near  or fused to an E1-like72,73 or ThiF-like partner proteins,57  
Given that these partner proteins are essential for azoline-formation, it would suggest these most of these 
other types of YcaOs are not involved in azoline formation, unless they are able to act as a standalone YcaO. 
As discussed, not all protein superfamilies are iso-functional so it cannot be assumed that all YcaO proteins 
participate in thiazoline/oxazoline formation. Thus, to differentiate the different types of YcaOs, we have 
introduced a nomenclature based on the inferred function and whether there is an identifiable protein that 
co-occurs with the YcaO. These features are crucial because the function of the active site and whether a 
protein complex is required for activity will have a profound effect on the conserved motifs present in each 
type of YcaO. Moreover, establishing these categories is useful when predicting function for large numbers 
of bioinformatically-identified YcaOs for which only a genome is known because when a function is 
inferred for one type of YcaO, the similarity of a new YcaO sequence to the different types can help assign 
its function.73 
Examples of YcaOs that act without an E1-like or ThiF-like partner have been markedly less well-
characterized than their more established azoline-forming YcaO counterparts. However, local genomic 
neighborhoods and connections to intriguing NP structures suggest that these less-studied types of YcaOs 
could harbor distinct functions or biosynthetic capabilities. For example, in addition to the plasmid-born 
BGC for MccB17, E. coli also encode a YcaO protein (Ec-YcaO) that does not appear to be related to NP 
biosynthesis based on the identity of its flanking genes, although it does utilize-ATP.18 Current evidence 
suggests a role in enhancing RimO-dependent -thiomethylation of ribosomal protein S12 and is postulated 
to function as a scaffolding protein.23 However, no mechanism has been proposed for how ATP might be 
used so Ec-YcaO remains an enigmatic YcaO. As another example, the bottromycin BGC encodes two 
YcaO proteins with no obvious candidates for partner proteins. Seeming to correspond with the two YcaOs, 
the structure of bottromycin includes two amide backbone modifications: a thiazoline and amidine. There 
is no clear cyclodehydratase partner protein so the azoline-forming YcaO has been classified as 
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“standalone.” The nature of the second, putative amidine-forming YcaO is not clear. For a final example of 
new biosynthetic modifications, the thioviridamide BGC contains a YcaO but is associated with thioamide 
formation. Lastly, this section also covers the molecule trifolitoxin, which does not have a fully elucidated 
structure, but the partial structure includes a thiazoline. Based on its BGC and the lack of any partner 
proteins, this appears to be another instance of a standalone azoline-forming YcaO.18  
 The YcaO from E. coli (Ec-YcaO) poses a cryptic function and is thus categories as an enigmatic 
YcaO. Unlike those involved in typical azoline formation, this YcaO exists outside of a discernable RiPP 
BGC and lacks a partner protein.18 Although the exact function of this YcaO is not known, it has been 
implicated in a post-translational modification (PTM) of ribosomal protein S12. The S12 ribosomal protein, 
a component of the 30S subunit, contains an Asp88 residue that is universally conserved across all domains 
of life and known to be crucial for organism viability. In select organisms, such as Rhodopseudomonas 
palustris74 and Thermus thermophilus,75 the Asp88 residue was found to be β-thiomethylated in vivo, 
whereas in eukaryotes this modification is not present.76,77 Studies have shown that RimO, a member of the 
radical SAM superfamily, is responsible for β-thiomethylation of S12-Asp88.78 RimO is homologous to 
MiaB, an enzyme involved in the β-thiomethylation of tRNA.79  
Affinity enrichment experiments using recombinant E. coli S12 protein demonstrate the expected 
association with RimO, but the Ec-YcaO and several other proteins, were found to co-purify as well. 
Deletion strains lacking RimO and YcaO were then analyzed for the relative amounts of S12 β-
thiomethylated Asp88 by quantitative mass spectrometry. The strain lacking RimO contained no detectable 
level of Asp88 β-thiomethylation while the strain lacking the YcaO showed an 18% reduction.80 It is 
hypothesized that this YcaO functions in a multi-protein complex with S12 and RimO, although the details 
of the mechanism have not yet been elucidated and will require more effort to firmly establish the role of 
YcaOs in S12 modification. 
Despite being associated β-thiomethylation, the actual function of Ec-YcaO is unknown. It does 
hydrolyze ATP in vitro with KM comparable to other characterized YcaOs and has had its structure solved 
by X-ray crystallography (Figure 4.5).18 This structure was the first conclusive evidence for the site of ATP 
binding in YcaO proteins and revealed that the region around this binding site was conserved among all 
members of the YcaO superfamily. For example, even though Ec-YcaO has only 20% identity to the 
azoline-forming YcaO from Bacillus sp. Al Hakam (BalhD), the sequence conservation is centered around 
the ATP binding site, and mutation of the corresponding residues in BalhD abolish ATP binding and 
cyclodehydration activity. Furthermore, comparison of the Ec-YcaO structure and the cyanobactin 
cyclodehydratases TruD81 and LynD82 further verify the conservation of structure and ATP-binding site 
predicted based on sequence homology. These results suggest that insights from one YcaO protein, 




Figure 4.5: Ribbon structure of dimeric Ec-YcaO. Colored regions represent the YcaO domain (blue), 
tetratricopeptide-like domain (gray), ATP (orange spheres), or different monomers (dark vs. light coloring).  
 
4.3 Bottromycin heterocyclase YcaOs 
The bottromycin family of NPs was first reported in 1957 from Streptomyces bottropensis.83 The 
proposed structure of bottromycin underwent several revisions. Initially proposed to be a linear peptide,84-
86 the major bioactive component bottromycin A2 was later determined to contain several non-proteinogenic 
amino acids and a macroamidine.87 On the basis of 15N-NMR, the macrocycle vertex was determined to be 
located in between two t-butyl-containing amino acids, consistent with condensation between the N-
terminus and a backbone amide carbonyl.88 Minor congeners bottromycin B2 and C2 displayed different 
methylation patterns.89 The structure of bottromycin A2 was finally confirmed by total synthesis, which also 
resolved any stereochemical ambiguity.90 Several notable structural features include the 12-membered 
macroamidine, Asp O-methylation/epimerization, and a single thiazole that are shared by all currently 
known members (Figure 4.6). The variation in structure of the analogs comes from differing patterns of 
Pro, Val, and Phe β-methylation.  
The antimicrobial properties of bottromycin have been described since the initial isolation reports, 
but characterization of its activity has, like its structure, been incremental over decades. Bottromycin A2, 
whose biological activity is best characterized, was found to have extremely potent antimicrobial activities 
against Mycoplasma gallisepticum,91 methicillin-resistant Staphylococcus aureus (MRSA), and 
vancomycin-resistant Enterococcus (VRE)90 with MIC of 12 nM, 1.2 µM, and 0.6 µM, respectively. Studies 
to elucidate the mechanism have indicated a role in protein synthesis inhibition, as demonstrated by 
synthetic polynucleotide in vitro translation systems, which localized bottromycin A2 binding to the A-site 
of the 50S subunit.92,93 Moreover, experiments on polysomes showed both a lack of inhibitory activity 
towards the translocation and peptidyl transferase steps, but released aminoacyl-tRNA.94,95 Hence, 
bottromycin is believed to interfere with the binding of charged aminoacyl-tRNA to the ribosome, and as 
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such, would act in a manner distinct from other ribosome translation inhibitors such as erythromycin (which 
does not bind to the A-site), tetracycline, and micrococcin (which interact with the A-site, but neither release 
aminoacyl-tRNA).94 
Efforts to explore the structure-activity relationship have demonstrated the importance of the Asp-
derived methyl ester in biological activity. Amide derivatives of bottromycin B/C outperformed ester 
analogs in assays against S. aureus in vivo, while esters tended to be more active than amides in vitro, 
suggesting a possible difference in pharmacokinetic properties.86 Indeed, upon addition of bottromycin A2 
in mouse plasma, rapid degradation of the side chain ester to acid was observed (compared to a chemically 
hydrolyzed standard), and hypothesized to contribute to the poor antimicrobial efficacy.96 Additional amide, 
thioester, and ketone derivatives of bottromycin A2 at this position recapitulated these trends: the thioester 
analogs showed the lowest plasma stability, but most potent MIC values. Conversely, the ketone analogs 
showed equivalent in vitro activity (compared to the original NP), with better plasma stability compared to 
the thioesters. 
 
Figure 4.6: Bottromycin biosynthesis and structure. (A) General bottromycin BGC (B) Structure of 
bottromycin and table of congeners. Modifications attributed to YcaOs in red. (C) Sequence alignment of 




 Upon genome sequencing of producing organisms, bottromycin’s complex structure was found to 
originate from a ribosomal precursor peptide, cementing its identity as a RiPP. Whole genome sequencing 
of Streptomyces bottropensis38,97 and Streptomyces sp. WMMB27298 uncovered the BGC by matching 
peptides with the deduced sequences for bottromycin A2/B2/C2 (GPVVVFDC) and bottromycin D 
(GPAVVFDC). Heterologous expression confirmed that these BGCs were indeed responsible for 
bottromycin biosynthesis. For Streptomyces sp. WMMB272, mutagenesis via a shuttle vector was 
employed to mutate the bottromycin D core peptide Ala3 to Val3, resulting in the production of bottromycin 
A2 from the native producer. An additional bottromycin BGC was identified in Streptomyces scabies, which 
showed significant sequence similarity to the ones from S. bottropensis and S. sp. WMMB272.99 Unlike the 
vast majority of RiPPs, the bottromycin precursor peptide displays an N-terminal core sequence and, instead 
of an N-terminal leader peptide, the precursor has a C-terminal extension called a “follower” peptide, which 
presumably contains residues required for binding and subsequent modification by the biosynthetic 
enzymes.38  
 
Figure 4.7: (cont.) 
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Figure 4.7: Biosynthesis of bottromycin. Proposed pathway determined through gene deletion in a 
heterologous host (S. coelicolor) and analysis of detected intermediates.   
 
The current proposed biosynthetic pathway for bottromycin was deduced using heterologous 
expression systems and untargeted metabolomics approaches (Figure 4.7). Individual deletions of the three 
radical SAM methyltransferases halted production of bottromycin A2 and produced either B2, D2 or E2, 
allowing the roles of each radical SAM to be assigned.100 From mass spectral network analysis of 
metabolites produced by strains individually lacking each standalone YcaO, among other tailoring genes, 
a more complete picture of bottromycin biosynthesis was revealed. Thiazoline formation was indeed 
dependent on the YcaO encoded next to the precursor peptide (Figure 4.6), thus this protein is established 
as a standalone azoline-forming YcaO. Also confirmed was that the all of the -methylation events occur 
prior to macroamidation, which is consistent with their functions being follower peptide-dependent.27 
Conversely, thiazoline oxidation and O-methylation occur late in the maturation pathway.101 The genes 
required for macroamidine formation include the second YcaO and a putative macrocyclase partner with 
similarity to amidohydrolases; therefore, these proteins were proposed to act together in macroamidine 
formation.15 The nature of their interaction has not yet been characterized so it is uncertain if the hydrolase 
should be considered a YcaO partner protein, analogous to the E1-like protein in RiPP cyclodehydratses. 
The involvement of a YcaO in transforming an N-terminal Gly and internal Val into a macroamidine is 
clearly distinct from the cyclodehydration of Cys, Ser, or Thr, but at a conceptual level, there is a clear 
similarity; in both cases a nucleophile attacks the peptide bond, formally eliminating water in an ATP-
dependent process (Figure 4.8).  
 
Figure 4.8: (cont.) 
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Figure 4.8: YcaOs catalyze diverse reactions via a similar backbone-activation. We hypothesize that 
YcaOs ubiquitously use ATP to O-phosphorylate peptide backbones, generating a common 
hemiorthoamide intermediate upon nucleophilic attack. Phosphate elimination yields different functional 
groups dependent on the identity of the nucleophile. See Chapter 5 for studies on thioamide formation. 
 
4.4 Characterizing bottromycin heterocyclases 
Despite remarkable efforts to characterize bottromycin’s numerous PTMs, the heterocyclizations 
to form the hallmark N-terminal macroamidine and C-terminal thiazoline remained enigmatic (Figure 4.9). 
Furthermore, when compared with annotated function of the BGCs, functions for several of the proteins 
could not be readily assigned. Specifically, two proteins belonging to the YcaO superfamily (BmbD and 
BmbE) lacked definitive purpose, but have previously been hypothesized to be involved in 
heterocyclizations.38,99 Previous work from our group and others on members of the YcaO superfamily have 
demonstrated function as an azoline heterocyclase which convers Cys, Ser, and Thr side chains to 
azolines.18,57  
 
Figure 4.9: Dissecting bottromycin biosynthesis. (A) Biosynthetic gene cluster for bottromycin from 
Streptomyces bottropensis. (B) precursor peptide and heterocycle-forming post-translational modifications 




All reconstitution efforts have focused on proteins with both YcaO and Ocin-ThiF-like domains, 
either as fusions or discrete enzymes and have been demonstrated to be responsible for catalysis of 
cyclization and substrate binding, respectively.27 In contrast, the bottromycin BGC contains no discernable 
Ocin-ThiF domains and bear little sequence similarity to canonical heterocyclase YcaOs (Figure 4.9a). 
Despite this enigmatic nature, preliminary genomic neighborhood analysis indicate that the majority of 
proteins containing the YcaO domain lack an Ocin-ThiF in the nearby cluster, suggesting a potential 
difference in biosynthetic utility. 
 
 
Figure 4.10: MALDI-TOF-MS of recombinant bottromycin heterocyclases. (A) precursor peptide 
BmbC calcd m/z 4675 (B) thiazoline product of BmbD. (C) BmbD reaction omitting ATP. (D) amidine 
product of BmbE. (E) BmbE reaction omitting ATP. 
 
To assign function to BmbD and BmbE, we recombinantly expressed and purified both proteins as 
N-terminal MBP fusions from Escherichia coli. The precursor peptide BmbC was expressed similarly as 
an MBP fusion, with an engineered tobacco etch virus (TEV) protease site to remove the affinity tag, 
producing the N-terminal core sequence after cleavage and HPLC purification. Both proteins were found 
to cyclodehydrate the precursor peptide in an ATP-dependent manner, as assessed by matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) mass shifts (-18 Da), analogous 
to previous reconstitution efforts from this superfamily (Figure 4.10). Ala mutants to conserved Glu-rich 
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regions shown previously to bind ATP were necessary for turnover, suggesting despite the divergent 
primary sequence, the ATP-binding described is conserved (Figure 4.11). Selective chemical reactivity 
with either the N-terminal amine of Gly1 or the sulfhydryl Cys8 side chain was exploited to determine that 
only the BmbD product could be N,N-dimethylated and the BmbE product could be alkylated but not vice 
versa, indicating the respective sites of modification (Figure 4.12). To confirm catalytic function of BmbD 
and BmbE, products were analyzed by high-resolution electrospray ionization tandem MS analysis (HR-
ESI-MS/MS), which localized thiazoline and amidine cyclizations in the expected positions (Appendix 
B2). NMR analysis was performed on tryptic fragments of an N15K mutant to generate analytical quantities 
of the thiazoline and amidine products via trypsin cleavage of the follower peptide after cyclodehydration. 
 
Figure 4.11: (cont.) 
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Figure 4.11: Conservation of ATP biding motifs in bottromycin cyclodehydratases. The conserved 
glutamate-rich motif present in previously characterized RiPP YcaO cyclodehydratases were mutated to 
alanine and checked for activity perturbation. As with TOMM cyclodehydratases, each point mutant 






Figure 4.12: Chemical labeling evidence for thiazoline and amidine formation. Products of BotD and 
BotE cyclodehydratases are distinct, isobaric dehydrations of the bottromycin precursor peptide. (A-B) 
Reactions with BotD or BotE synthetases were alkylated at the cysteine thiol with bromoethylamine or 
methylated at the N-terminus by reductive amination. Products of the reactions were visualized by MALDI-
TOF MS as shifts of 10 Da for dimethylation of the thiazoline substrate and 25 Da for the ethylamine 
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Figure 4.12: (cont.) alkylated amidine substrate. (C) Precursor peptide mutant C8A was only processed by 
the amidine-forming bottromycin synthetase. 
 
All 15 amino acid residues of bottromycin N15K were assigned from TOCSY, NOESY and COSY 
spectra. 1H chemical shifts and the absence of long range NOEs corresponded to a random coil peptide as 
expected. In the thiozaline form, all residues were assigned and significant differences compared to 
bottromycin were observed in the region around the modified Cys residue. The chemical shifts changed 
significantly for the HN of Asp7, Met9, Thr10 and Ala11. Further changes were observed for the Ha shifts 
of Asp7 and Met9 and Hb of Met9. Moreover, the shifts of the Ha and Hb protons in the Cys ring are in 
good agreement with shifts described in literature for one double bond containing thiazoline rings in 
peptides. Spectra of the amidine form suffered from line increased line broadening in the amide signal 
region which made the assignment of resonances more difficult. Of the amino acids that form part of the 
ring, only proline could be assigned unambiguously. Although spin systems of three valines were identified, 
the lack of sequential NOEs prevented their assignment. All three valine Hb and Hd and proline Ha, Hb 
and Hg shifts are clearly affected strongly by the reaction. Additional smaller changes were detected for 












Wild type - GPVVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + + 
Core  - GPVVVFDC   
Follower  - MTADFLNDDPNNAELSALEMEELESWGAWDGEATS   
Follower F13A GPVVVFDCMTADALNDDPNNAELSALEMEELESWGAWDGEATS - - 
Follower L14A GPVVVFDCMTADFANDDPNNAELSALEMEELESWGAWDGEATS - + 
Follower N15A GPVVVFDCMTADFLADDPNNAELSALEMEELESWGAWDGEATS + + 
Follower D16A GPVVVFDCMTADFLNADPNNAELSALEMEELESWGAWDGEATS + + 
Follower D17A GPVVVFDCMTADFLNDAPNNAELSALEMEELESWGAWDGEATS + - 
Follower E22A GPVVVFDCMTADFLNDDPNNAALSALEMEELESWGAWDGEATS + + 
Follower L23A GPVVVFDCMTADFLNDDPNNAEASALEMEELESWGAWDGEATS - + 
Follower S24A GPVVVFDCMTADFLNDDPNNAELAALEMEELESWGAWDGEATS - + 
Follower L26A GPVVVFDCMTADFLNDDPNNAELSAAEMEELESWGAWDGEATS + + 
Follower E27A GPVVVFDCMTADFLNDDPNNAELSALAMEELESWGAWDGEATS - - 
Follower M28A GPVVVFDCMTADFLNDDPNNAELSALEAEELESWGAWDGEATS + + 
Follower E29A GPVVVFDCMTADFLNDDPNNAELSALEMAELESWGAWDGEATS + + 
Follower E30A GPVVVFDCMTADFLNDDPNNAELSALEMEALESWGAWDGEATS + + 
Follower L31A GPVVVFDCMTADFLNDDPNNAELSALEMEEAESWGAWDGEATS - - 
Follower E32A GPVVVFDCMTADFLNDDPNNAELSALEMEELASWGAWDGEATS + + 
Follower D16* GPVVVFDCMTADFLN - - 
Follower A21* GPVVVFDCMTADFLNDDPNN - - 
Follower L26* GPVVVFDCMTADFLNDDPNNAELSA - - 
Follower L31* GPVVVFDCMTADFLNDDPNNAELSALEMEE - - 
Follower E32* GPVVVFDCMTADFLNDDPNNAELSALEMEEL - - 
Follower S33* GPVVVFDCMTADFLNDDPNNAELSALEMEELE - - 
Follower W34* GPVVVFDCMTADFLNDDPNNAELSALEMEELES - - 
Follower G35* GPVVVFDCMTADFLNDDPNNAELSALEMEELESW + + 
Follower A36* GPVVVFDCMTADFLNDDPNNAELSALEMEELESWG + + 
Follower N15K GPVVVFDCMTADFLKDDPNNAELSALEMEELESWGAWDGEATS + + 
Core ^2P GPPVVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
Core ^2A GAPVVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
Core ^2G GGPVVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
Core P2G GGVVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + + 
Core ΔP2 GVVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + - 
Core ΔV3 GPVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
Core V3A GPAVVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - + 
Core V4A GPVAVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - + 
Core V4G GPVGVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
Core V4I GPVIVFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + + 
Core V5A GPVVAFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - + 
Table 4.1: (cont.)  
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Core V5G GPVVGFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - + 
Core V5L GPVVLFDCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + + 
Core D7A GPVVVFACMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + + 
Core D7N GPVVVFNCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + + 
Core D7T GPVVVFTCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS + + 
Core C8A GPVVVFDAMTADFLNDDPNNAELSALEMEELESWGAWDGEATS N/A + 
Core C8P GPVVVFDPMTADFLNDDPNNAELSALEMEELESWGAWDGEATS N/A - 
Core C8S GPVVVFDSMTADFLNDDPNNAELSALEMEELESWGAWDGEATS N/A  
Core ^9C GPVVVFDCCMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
Core ^9S GPVVVFDCSMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
Core ^9T GPVVVFDCTMTADFLNDDPNNAELSALEMEELESWGAWDGEATS - - 
     
 
 
Table 4.1: Precursor peptide sequences and processing by bottromycin YcaOs. Processing was 
analyzed by endpoint MALDI-TOF MS for the presence of a dehydrated mass. “+” indicates the presence 
of a dehydrated mass while “-“ indicates only the parent peptide mass was detected. 
 
Bioinformatic searches for bottromycin clusters show several tightly related BGCs from several 
Streptomyces species with high conservation in the biosynthetic machinery as well as the precursor peptide 
sequences. Based on this conservation in the core sequences, we expected the heterocyclases to show 
extremely high selectivity for the native substrate peptides. Previous work using heterologous expression 
systems showed limited promiscuity for mutant precursor sequences. With our in vitro assays, 21 mutants 
were assessed for heterocyclization by an endpoint MALDI-TOF-MS assay (Table 4.1). Contrary to 
expectations, mutations in several key points were tolerated in multiple cases, including the residue where 
macrocyclization with the backbone occurs (Val4) and near the thiazoline heterocyclization site (Asp7), 
including mutants which were not processed in previous studies (Figure 4.13).40 Unlike other described 
azoline-forming heterocyclases,18,45,102 BmbD was unable to process additional cyclizable residues and only 
cyclized at the Cys8 site. Similarly, the amidine-forming BmbE was found by HR-ESI-MS/MS 
fragmentation to consistently form the amidine macrocycle at the Val4 carbonyl (Appendix B2). This 
suggests that while some promiscuity with respect to core sequence is tolerated by the bottromycin 





Figure 4.13: Substrate tolerance of bottromycin heterocyclases. (A) Core peptide promiscuity 
displaying cyclodehydrated mutant precursors. (B) Follower peptide alanine mutants that inhibited 
heterocyclase processing. 
 
In previously studied RiPP cyclodehydratase systems, the ThiF-Ocin/E1-activating-like protein is 
responsible for substrate binding while the YcaO protein performs catalysis. However, the bottromycin 
heterocyclases are catalytically competent independent of a ThiF-Ocin protein or any additional partner, 
indicating that these enzymes are performing both binding and cyclization functions. Given the unique 
nature of these cyclodehydratases, we sought to investigate the enigmatic follower peptide proposed to be 
involved in substrate recognition. To probe the role of the follower peptide in bottromycin heterocyclase 
reactions, stop mutations were introduced at intervals in the C-terminal portion of the precursor peptide to 
find the minimal substrate for processing by BmbD and BmbE (Figure 4.14a). In homologous bottromycin 
clusters from other Actinomycetes, core and follower peptide sequences are highly conserved and only 
show significant sequence divergence after Gly35. Consistent with these trends, truncation mutants N-
terminal to Gly35 (closer to the core peptide) abolished cyclodehydration by both BmbD and BmbE, while 
the G35* mutant was still processed, indicating the sequence conservation in the follower peptide mirrors 





Figure 4.14: Minimal follower peptide for bottromycin cyclodehydratase processing. (A) Truncation 
mutants to the bottromycin precursor peptide were made by introducing stop codons at evenly spaced 
intervals N-terminal to the point where precursor follower peptide sequences diverge. (B) Adjacent mutants 
were made after the last-processed mutant, indicating an identical minimal follower motif for both 
bottromycin cyclodehydratases. 
 
4.5 Characterization of bottromycin’s unique follower peptide 
Point mutations along the follower peptide were introduced to determine the role of the follower 
peptide sequence in binding and processing of the bottromycin precursor. Fifteen Ala mutations were made 
and assessed by endpoint MALDI-TOF-MS assay (Figure 4.15). Intriguingly, thiazoline and amidine-
forming cyclodehydratases displayed divergent processing capabilities for several residues, suggesting 
fundamental differences in the substrate recognition. Intriguingly, the RiPP recognition element (RRE)27, 
which binds precursor peptide substrates, appears to exist as a fusion with the radical SAM 








Figure 4.15: Distinct follower peptide residues guide thiazoline and amidine formation. Single alanine 
mutants were made in the bottromycin follower peptide in heavily conserved regions. Masses consistent 
with cyclodehydrations were visualized by MALDI-TOF MS. 
 
4.6 Bioinformatic prospecting of standalone YcaOs 
Although YcaOs involved in RiPP azolin(e) biosynthesis are the most well-studied among this 
family of enzymes, previous bioinformatic prospecting has suggested that the number of “standalone” 
YcaOs far outnumber those with characterized binding partners (e.g. Ocin-ThiF-like or E1-activating-
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like).73 This suggests that for these YcaOs, there are either currently-uncharacterized binding partners (i.e. 
not bona fide standalones), or as is the case with bottromycin, no required partner protein. Moreover, taking 
together the sequence diversity in this family with the novel reactivity seen with the bottromycin YcaOs 
demonstrated here, it is intriguing to consider the biosynthetic capabilities of a generalized amide backbone 
phosphorylation/activation mechanism. In an effort to tease apart the large number of putative standalone 
YcaOs, we used our previously-described BGC annotation tool, RODEO (Rapid ORF Description and 
Evaluation Online), to analyze co-occurring genes with a combination of curated and custom hidden 
Markov models (HMM) (Figure 4.16a). Our analysis provided  estimations on the types of RiPP BGCs 
containing YcaOs and indicate that the majority (>60%) do not contain a readily-identifiable partner 
protein, referred to in previous work as the thiazole-oxazole modified microcin (TOMM) “C-protein” 





Figure 4.16: RODEO prospecting of YcaO superfamily classes. (A) Flow chart describing the 
classification methods used for grouping YcaOs based on contexts. Classifications were made to generate 
a conservative estimate of standalone YcaOs (i.e. any Ocin-ThiF-like protein would disqualify any YcaO 




In a sequence similarity network displaying relatedness of standalone YcaOs as nodes, the 
bottromycin cyclodehydratases both form small distinct clusters, consistent with both the small number of 
homologous BGCs in sequenced organisms as well as the lack of homology between the two enzymes 
(Figure 4.17-4.19), which is expected given the highly divergent catalytic activity. Intriguingly, a much 
greater percentage of the standalone YcaOs are more similar to the amidine-forming enzyme than the 
thiazoline-forming enzyme, which may indicate that the amidine PTM may be present in other currently-
unidentified RiPPs (Figure 4.19). On the basis of our survey, we hypothesize that YcaO-mediated amide 
activation leading to novel heterocycles/carbonyl substitutions may be a rich area to look for new RiPP 




Figure 4.17: Sequence similarity network of phylogeny of non-TOMM YcaOs. The Enzyme Function 
Initiative Enzyme Similiarity Tool (EFI-EST) was used to generate sequence similarity networks for YcaOs 
belonging to BGCs that did not contain an E1-activating-like protein (TOMM “C” protein) or an Ocin-
ThiF-like protein (TOMM “F” protein), i.e. “non-TOMM”, using default values for the sequences obtained 





Figure 4.18: Sequence similarity network of non-TOMM YcaOs related to BmbD. SSN from the 
phylogenetic analysis were analyzed using HMMER 3.1b1 hmmscan utility against a profile hidden 
Markov model (pHMM) comprised of bioinformatically-identifiable BmbD sequences. Scores were binned 





Figure 4.19: Sequence similarity network of non-TOMM YcaOs related to BmbE. SSN from the 
phylogenetic analysis were analyzed using HMMER 3.1b1 hmmscan utility against a profile hidden 
Markov model (pHMM) comprised of bioinformatically-identifiable BmbE sequences. Scores were binned 




Title Name Count 
YcaO  YcaO-like family 13811 
ABC_tran  ABC transporter 10786 
AAA_21  AAA domain  putative AbiEii toxin  Type IV TA system 6337 
MFS_1  Major Facilitator Superfamily 6093 
SMC_N  RecF/RecN/SMC N terminal domain 5990 
ABC_membrane  ABC transporter transmembrane region 5768 
Radical_SAM  Radical SAM superfamily 4665 
Sugar_tr  Sugar (and other) transporter 4407 
Aminotran_5  Aminotransferase class-V 4286 
Fer4_12  4Fe-4S single cluster domain 3872 
AAA_17  AAA domain 3814 
S1  S1 RNA binding domain 3753 
Lactamase_B  Metallo-beta-lactamase superfamily 3730 
Fer4_14  4Fe-4S single cluster domain 3692 
MFS_4  Uncharacterised MFS-type transporter YbfB 3648 
Form_Nir_trans  Formate/nitrite transporter 3505 
Gly_radical  Glycine radical 3491 
EPSP_synthase  EPSP synthase (3-phosphoshikimate 1-carboxyvinyltransferase) 3478 
NTP_transf_3  MobA-like NTP transferase domain 3442 
Pyr_redox_2  Pyridine nucleotide-disulphide oxidoreductase 3432 
DUF4131  Domain of unknown function (DUF4131) 3370 
HTH_1  Bacterial regulatory helix-turn-helix protein  lysR family 3273 
Bac_DNA_binding  Bacterial DNA-binding protein 3269 
Cytidylate_kin  Cytidylate kinase 3254 
PCB_OB  Penicillin-binding protein OB-like domain 3240 
DUF4496  Domain of unknown function (DUF4496) 3237 
Nitroreductase  Nitroreductase family 3231 
APH  Phosphotransferase enzyme family 3213 
S1_2  S1 domain 3210 
LysR_substrate  LysR substrate binding domain 3182 
Cytidylate_kin2  Cytidylate kinase-like family 3120 
LpxK  Tetraacyldisaccharide-1-P 4'-kinase 3104 
CTP_transf_3  Cytidylyltransferase 3102 
Trm112p  Trm112p-like protein 3074 
Competence  Competence protein 3034 
AAA  ATPase family associated with various cellular activities (AAA) 3016 
DUF421  Protein of unknown function (DUF421) 2925 
DUF2064  Uncharacterized protein conserved in bacteria (DUF2064) 2898 
MobB  Molybdopterin guanine dinucleotide synthesis protein B 2872 
tRNA-synt_2b  tRNA synthetase class II core domain (G  H  P  S and T) 2856 
Keratin_assoc  Keratinocyte-associated protein 2 2852 
HTH_42  Winged helix DNA-binding domain 2823 
HTH_24  Winged helix-turn-helix DNA-binding 2820 
HU-DNA_bdg  DNA-binding domain 2800 
DUF218  DUF218 domain 2783 
Methyltransf_11  Methyltransferase domain 2757 
Methyltransf_31  Methyltransferase domain 2736 
DUF2318  Predicted membrane protein (DUF2318) 2639 
Acetyltransf_1  Acetyltransferase (GNAT) family 2601 
DmsC  DMSO reductase anchor subunit (DmsC) 2581 
Seryl_tRNA_N  Seryl-tRNA synthetase N-terminal domain 2563 
Fer4  4Fe-4S binding domain 2557 
Abhydrolase_5  Alpha/beta hydrolase family 2525 
AAA_assoc_2  AAA C-terminal domain 2521 
MgsA_C  MgsA AAA+ ATPase C terminal 2520 
LolA  Outer membrane lipoprotein carrier protein LolA 2486 
Molydop_binding  Molydopterin dinucleotide binding domain 2417 
DUF2092  Predicted periplasmic protein (DUF2092) 2411 
Molybdopterin  Molybdopterin oxidoreductase 2395 
FtsK_SpoIIIE  FtsK/SpoIIIE family 2383 
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Response_reg  Response regulator receiver domain 2347 
AAA_26  AAA domain 2344 
Ftsk_gamma  Ftsk gamma domain 2321 
Fer4_11  4Fe-4S dicluster domain 2315 
Molybdop_Fe4S4  Molybdopterin oxidoreductase Fe4S4 domain 2288 
Pyr_redox  Pyridine nucleotide-disulphide oxidoreductase 2217 
Fer4_2  4Fe-4S binding domain 2194 
Filament  Intermediate filament protein 2143 
Peptidase_M48  Peptidase family M48 2131 
A2L_zn_ribbon  A2L zinc ribbon domain 2121 
HATPase_c  Histidine kinase-  DNA gyrase B-  and HSP90-like ATPase 2120 
FtsK_4TM  4TM region of DNA translocase FtsK/SpoIIIE 2114 
HTH_AsnC-type  AsnC-type helix-turn-helix domain 2023 
adh_short  short chain dehydrogenase 1951 
AsnC_trans_reg  AsnC family 1942 
Acetyltransf_7  Acetyltransferase (GNAT) domain 1929 
XK-related  XK-related protein 1916 
HTH_3  Helix-turn-helix 1911 
MarR_2  MarR family 1903 
AA_permease_2  Amino acid permease 1886 
BPD_transp_1  Binding-protein-dependent transport system inner membrane component 1876 
adh_short_C2  Enoyl-(Acyl carrier protein) reductase 1866 
ABC2_membrane_3  ABC-2 family transporter protein 1856 
AAA_16  AAA ATPase domain 1847 
AA_permease  Amino acid permease 1839 
Pyr_redox_3  Pyridine nucleotide-disulphide oxidoreductase 1829 
Methyltransf_23  Methyltransferase domain 1826 
DUF4345  Domain of unknown function (DUF4345) 1817 
Acetyltransf_10  Acetyltransferase (GNAT) domain 1797 
OsmC  OsmC-like protein 1761 
HTH_19  Helix-turn-helix domain 1754 
HTH_31  Helix-turn-helix domain 1719 
KR  KR domain 1713 
Isochorismatase  Isochorismatase family 1644 
ABC2_membrane  ABC-2 type transporter 1594 
Sigma70_r4_2  Sigma-70  region 4 1568 
TetR_N  Bacterial regulatory proteins  tetR family 1460 
HTH_18  Helix-turn-helix domain 1443 
HTH_AraC  Bacterial regulatory helix-turn-helix proteins  AraC family 1395 
TfuA  TfuA-like protein 1350 
 
Table 4.2: Co-occurrence of genes with non-TOMM YcaOs. RODEO was used to inspect BGC contexts 
for genes co-occurring with YcaOs with no locally-encoded E1-activating-like/Ocin-ThiF-like proteins. 
The most common 100 Pfam hits are shown, organized by occurrence. Genes predicted to be involved in 
transport are red, regulation are yellow, ATPase-like are green, putative RiPP biosynthetic genes are in blue 





For canonical azoline-forming YcaOs, the ThiF-like/E1-activating-like proteins necessary for 
efficient processing are commonly found in YcaO BGCs and the combination of these two proteins is 
referred to as the “cyclodehydratase”, either as a complex (e.g. linear azole-containing peptides) or as a 
single fused protein (e.g. thiopeptides, cyanobactins). Our reconstitution efforts demonstrate that YcaO 
proteins alone are necessary and sufficient for the two cyclodehydrations. This is contrary to previous 
reports, which suggest that other proteins in bottromycin BGCs are acting in a cooperative fashion with 
BmbD and BmbE, namely BmbH, putatively annotated as a metalloprotease.29,101 Interestingly, while there 
are a significant number of bioinformatically-identifiable BmbE/macrocyclase homologs, these BGCs do 
not also contain ortholog metalloprotease genes (Table 4.2), unlike Ocin-ThiF/E1-activating-like proteins. 
 
4.7 Conclusions 
Bottromycin’s YcaOs are tightly conserved across several BGCs, but show significantly lower 
similarity outside of this family with other standalone YcaOs (particularly BmbD) (Figure 4.18-4.20). 
Online database queries show a limited number of bottromycin BGCs with extremely high conservation, 
but few “missing link” clusters that exhibit variance. This genetic isolation of bottromycin BGCs may 
partially explain the peculiarities of this RiPP family: lack of dependence on an identifiable partner protein, 
reliance on an inverted follower peptide and convergent evolution to a thiazoline-forming YcaO that bears 
little resemblance to the much more genetically common TOMM azoline cyclases. We speculate these 
idiosyncrasies may be the outcome of sustained evolutionary pressure to maintain bottromycin biosynthesis 
among producers – a hypothesis supported by the little variation seen in precursor peptides and extremely 




Figure 4.20: Bottromycin BGCs from sequenced organisms. (A) Homologous clusters from predicted 
bottromycin producing strains were identified correlating BLAST searches for BotD and BotE to gene 
clusters with identifiable orthologs to the required biosynthetic enzymes. (B) Putative precursor peptides 
for bottromycin scaffolds aligned by Clustal Omega (“*” indicates identical residues, “:” indicates more 
similar residues, “.” Indicates less similar residues) 
 
As the majority of sequences within the YcaO superfamily are in poorly-characterized biosynthetic 
contexts, there is a large potential for new biosynthetic chemistry and by extension, new natural product 
structures. Among the most commonly co-occurring genes in BGCs without C-proteins were those with 
homology to a TfuA-like protein, previously annotated as a trifolitoxin biosynthetic protein (Table 4.2).103 
The recently-isolated RiPP thioviridamide contains both YcaO and TfuA genes, but no canonical azoline 
motif.104-106 Furthermore, the YcaOs that co-occur with TfuA-like proteins appear to show divergent 
sequences from those characterized previously or here, as evident by our SSN and cladogram analysis, 
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where it groups away from both the bottromycin YcaO clades and the E1-like dependent YcaO from 
microcin B17 biosynthesis. As with bottromycin, where new chemical functionality in a RiPP indicated an 
expansion of catalytic function for the YcaO superfamily, we expect a diversity of both new reactions and 
scaffolds to be mined from this protein family. 
In summary, our work has demonstrated the roles of the bottromycin heterocyclase enzymes in the 
major PTMs of this natural product and assigned a new catalytic function to the YcaO superfamily. Our 
binding and mutational analysis support the unique nature of these enzymes with respect to previous RiPP 
pathways. Lastly, our bioinformatics prospecting of the superfamily suggests more intriguing biosynthetic 
catalysis remains to be uncovered. 
 
4.8 Experimental 
General materials and methods. Reagents used for molecular biology experiments were purchased from 
New England Biolabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, MA) or Gold Biotechnology 
Inc. (St. Louis, MO). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Escherichia 
coli DH5α and BL21(DE3) strains were used for plasmid maintenance and protein overexpression, 
respectively. Plasmid inserts were sequenced at ACGT Inc. (Wheeling, IL). MALDI-TOF-MS analysis was 
performed using a Bruker UltrafleXtreme MALDI-TOF-TOF mass spectrometer (Bruker Daltonics) in 
reflector positive mode at the University of Illinois School of Chemical Sciences Mass Spectrometry 
Laboratory. ESI-MS/MS analyses were performed using a SYNAPT ESI quadrupole TOF Mass 
Spectrometry System (Waters) equipped with an ACQUITY Ultra Performance Liquid Chromatography 
(UPLC) system (Waters).  
Molecular biology techniques. Oligonucleotides were purchased from Integrated DNA Technologies Inc. 
(Coralville, IA). Genes optimized for recombinant expression in Escherichia coli were synthesized by 
GenScript (Piscataway, NJ) as previously described. Site-directed mutagenesis on BotA was performed 
using the QuikChange method (Agilent) as per the manufacturer’s instructions using Platinum Taq (Thermo 
Fisher) or PfuTurbo (Agilent) DNA polymerase. The primers for each mutant are listed in Table 1. The 
mutations were verified by sequencing using the maltose-binding protein (MBP)-forward primer or the T7 
reverse primer. 
MBP-tagged enzyme overexpression and purification. E. coli BL21 (DE3) cells were transformed with 
a pET28 plasmid encoding the MBP-tagged enzyme of interest. Cells were grown for 24 h on LB agar 
plates containing 50 µg/mL kanamycin at 37 °C. Single colonies were picked to inoculate 10 mL of LB 
containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol and grown at 37 °C for 16-18 h. This 
culture was used to inoculate 1 L of LB containing 50 µg/mL kanamycin and 34 µg/mL and grown to an 
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optical density OD600 of 0.6 then placed on ice for 15 min. Protein expression was induced with the addition 
of 100 µM isopropyl β-D-1-thiogalactopyranoside (IPTG), 500 µM ZnSO4 and 2 mM MgSO4. Expression 
proceeded for 16 h at 16 °C. Cells were harvested by centrifugation at 3,000 × g for 20 min, washed with 
phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4) and 
centrifuged at 4,000 × g for 20 min. The cell pellet was flash-frozen and stored at -80 °C for a maximum 
of three weeks before use. 
Cell pellets were resuspended in enzyme lysis buffer (50 mM Tris-HCl pH 7.3, 150 mM NaCl, 2.5% 
glycerol (v/v)) containing 4 mg/mL lysozyme, 2 µM leupeptin, 2 µM benzamidine HCl, 2 µM E64 and 30 
mM phenylmethane sulfonyl fluoride (PMSF). Cells were homogenized by sonication (3 x 40 s with 10 
min nutation periods at 4 °C). Insoluble cell material was removed by centrifugation at 20,000 × g for 60 
min at 4 °C. The supernatant was then applied to a pre-equilibrated amylose resin (NEB; 10 mL of resin 
per L of cells). The column was washed with 30 mL of lysis buffer (with 0.5 mM tris-(2-carboxyethyl)-
phosphine (TCEP)) followed by 30 mL of wash buffer (lysis buffer with 400 mM NaCl, 0.5 mM TCEP). 
The MBP-tagged proteins were eluted using 30 mL elution buffer (lysis buffer with 300 mM NaCl, 10 mM 
maltose, 0.5 mM TCEP). Elution was concentrated using a 30 kDa MWCO Amicon Ultra centrifugal filter 
(EMD Millipore). A buffer exchange with 10 × volume of protein storage buffer (50 mM HEPES pH 7.3, 
300 mM NaCl, 2.5% glycerol (v/v), 0.5 mM TCEP) was performed prior to final concentration and storage. 
Protein concentrations were assayed using both 280 nm absorbance (theoretical extinction coefficients were 
calculated using the ExPASy ProtParam tool; http://web.expasy.org/protparam/) and a Bradford 
colorimetric assay using bovine serum albumin (BSA) as a standard (Thermo Fisher Scientific). Purity and 
possible truncation were assessed by Coomassie-stained SDS-PAGE gel.  
MBP-tagged precursor peptide overexpression and purification. E. coli BL21 (DE3) cells were 
transformed with a pET28 plasmid encoding the MBP-tagged peptide of interest. Cells were grown for 24 
h on LB agar plates containing 50 µg/mL kanamycin at 37 °C. Single colonies were picked to inoculate 10 
mL of LB containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol and grown at 37 °C for 16-18 
h. This culture was used to inoculate 1 L of LB or TB containing 50 µg/mL kanamycin and 34 µg/mL and 
grown to an optical density OD600 of 1.2 then placed on ice for 15 min. Protein expression was induced 
with the addition of 100 µM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 2 mM MgSO4. Expression 
proceeded for 1 h at 30 °C for LB or 16 h at 16 °C for TB. Cells were harvested by centrifugation at 3,000 
× g for 20 min, washed with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 
and 1.8 mM KH2PO4) and centrifuged at 4,000 × g for 20 min. The cell pellet was flash-frozen and stored 
at -80 °C for a maximum of three weeks before use. 
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Cell pellets were resuspended in enzyme lysis buffer (50 mM Tris-HCl pH 7.3, 150 mM NaCl, 2.5% 
glycerol (v/v)) containing 4 mg/mL lysozyme, 2 µM leupeptin, 2 µM benzamidine HCl, 2 µM E64 and 30 
mM phenylmethane sulfonyl fluoride (PMSF). Cells were homogenized by sonication (3 x 40 s with 10 
min nutation periods at 4 °C). Insoluble cell material was removed by centrifugation at 20,000 × g for 90 
min at 4 °C. The supernatant was then applied to a pre-equilibrated amylose resin (NEB; 10 mL of resin 
per L of LB, 30 mL of resin per L of TB). The column was washed with 30 mL of lysis buffer for LB 
expressions or 60 mL of lysis buffer for TB expressions (with 0.5 mM tris-(2-carboxyethyl)-phosphine 
(TCEP)) followed by 30 mL of wash buffer for LB expressions or 60 mL of wash buffer for TB expressions 
(lysis buffer with 400 mM NaCl, 0.5 mM TCEP). The MBP-tagged proteins were eluted using 30 mL 
elution buffer for LB expressions or 60 mL of elution buffer for TB expressions (lysis buffer with 300 mM 
NaCl, 10 mM maltose, 0.5 mM TCEP). Elution was concentrated using a 30 kDa MWCO Amicon Ultra 
centrifugal filter (EMD Millipore). A buffer exchange with 10 × volume of protein storage buffer (50 mM 
HEPES pH 7.3, 300 mM NaCl, 2.5% glycerol (v/v), 0.5 mM TCEP) was performed prior to final 
concentration and storage. Protein concentrations were assayed using both 280 nm absorbance (theoretical 
extinction coefficients were calculated using the ExPASy ProtParam tool; 
http://web.expasy.org/protparam/) and a Bradford colorimetric assay using bovine serum albumin (BSA) 
as a standard (Thermo Fisher Scientific). Purity and possible truncation were assessed by Coomassie-
stained SDS-PAGE gel.  
Precursor peptide cleavage and HPLC purification. MBP-tagged precursor peptides at a concentration 
of 300 µM were cleaved with tobacco etch virus (TEV) protease at a concentration of 55 µM for 16 h at 25 
°C. MBP and TEV were precipitated by incubating the reaction at 85 °C for 10 minutes, then spun at 4,000 
× g for 30 min. The soluble fraction was purified by either high-performance liquid chromatography 
(HPLC) or medium-pressure liquid chromatography (MPLC). 
For LB expressions, soluble fractions were purified by HPLC using a Betasil C18 column (100 Å pore size, 
250 × 4.6 mm, 5 µM particle size) (Thermo Scientific) with a mobile phase of 10 mM NH4HCO3/MeCN 
gradient from 15% to 30% aq. MeCN over 30 minutes, then held at 95% aq. MeCN for 10 minutes at 1 mL 
min-1. Elution of the precursor peptide was monitored at 220 and 280 nm. Fractions were analyzed via 
MALDI-TOF and dried under reduced pressure. Peptides were finally dissolved in a minimal volume of 10 
mM NH4HCO3, flash-frozen and lyophilized overnight to dryness.  
For TB expressions, soluble fractions were dried under reduced pressure onto 5 g of Celite 545 adsorbent. 
Precursor peptide adsorbed onto Celite was purified by MPLC using a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Rf C18 cartridge (43 g media, 100 Å pore size, 20–40 µm particle size, 400–632 
mesh) using a mobile phase of 10 mM aq. NH4HCO3/MeCN at 30 mL min-1 over a gradient from 10–40% 
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MeCN (20 column volumes), then 40–95% MeCN (5 column volumes). Elution of the precursor peptide 
was monitored at 220 and 280 nm. Fractions were analyzed via MALDI-TOF and dried under reduced 
pressure. Peptides were finally dissolved in a minimal volume of 10 mM NH4HCO3, flash-frozen and 
lyophilized overnight to dryness. 
In vitro cyclodehydration of bottromycin precursor peptides. The following reaction conditions were 
used for cyclodehydration in synthetase buffer (50 mM Tris-HCl pH 8.5, 125 mM NaCl, 20 mM MgCl2, 1 
mM TCEP, 5 mM ATP): BotA precursor peptide (50 µM), MBP-BmbD (10 µM) or MBP-BmbE (10 µM) 
in a final volume of 50 µL. The reaction mixture was incubated at 25 °C for 5 h, centrifuged to remove 
insoluble material (17,000 × g, 10 min, 25 °C), and desalted using C18 ZipTips (EMD Millipore), eluted 
into 2 µL of 75% aq. MeCN saturated with sinapinic acid and spotted on a stainless steel MALDI target. 
Samples were analyzed by a Bruker UltrafleXtreme MALDI-TOF MS using manufacturer methods for 
reflective positive mode. 
Chemical labeling of cyclodehydration products. Cyclodehydration reactions described previously were 
subjected to either N-terminal dimethylation or cysteine thiol alkylation. Reactions were performed in 
previously described synthetase buffer for cysteine alkylation or a 3-(N-morpholino)propanesulfonic acid 
(MOPS) variant for dimethylation (identical to synthetase buffer with 50 mM MOPS pH 7.5 replacing Tris-
HCl). For dimethylation, reactions were precipitated by adding equal volume of MeCN, removing insoluble 
proteins by spinning at 17,000 × g for 15 min, then drying the soluble fraction under reduced pressure. 
Samples were re-dissolved in 80 µL of water and 30 mM BH3-C5H5N and 20 mM aq. CH2O were added. 
Reactions were briefly sonicated and incubated at 25 °C for 16 h. For cysteine alkylation, 10 mM 
BrCH2CH2NH2 was added and incubated at 25 °C for 16 h. Samples were desalted using C18 ZipTips, 
eluted into 2 µL of 75% aq. MeCN saturated with sinapinic acid and spotted on a stainless steel MALDI 
target. Samples were analyzed by MALDI-TOF MS. 
Tandem mass spectrometry characterization of cyclodehydrated products. In vitro cyclodehydrations 
were conducted as described previously on a 100 µL scale reaction.  Reactions were centrifuged to remove 
insoluble material (17,000 × g, 10 min, 25 °C) and 2 µg of GluC endoproteinase (Worthington Biochemical) 
or 0.25 µg of AspN and 5 mM ZnSO4 was added and incubated for 60 min at 25 °C. Reactions were again 
centrifuged to remove insoluble material (17,000 × g, 10 min, 25 °C), and desalted using C18 ZipTips, 
eluted into 20 µL of 75% aq. MeCN and were analyzed by ESI MS/MS. 
Purification of amidine intermediate. The following reaction conditions were used for cyclodehydration 
in synthetase buffer (50 mM Tris-HCl pH 8.5, 125 mM NaCl, 20 mM MgCl2, 1 mM TCEP, 5 mM ATP): 
BmbC precursor peptide (50 µM), MBP-BmbE (5 µM) in a final volume of 10 mL. The reaction mixture 
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was incubated at 25 °C for 5 h, and 1 volumetric equivalent of acetonitrile was added to precipitate enzyme 
at 25 °C for 30 min, then centrifuged to remove insoluble material (17,000 × g, 15 min, 25 °C). The soluble 
fraction containing processed precursor peptide was dried under reduced pressure. 
Dried samples were dissolved in 10% MeOH/10 mM NH4HCO3 and purified by preparative HPLC with a 
Perkin Elmer Flexar HPLC equipped with a Betasil C18 (Thermo Scientific) reverse phase column (250 × 
10 mm, 5 µm particle size, 100 Å pore size). A mobile phase of 10 mM aq. NH4HCO3/MeOH was utilized 
at a flow rate of 4 mL min-1 with a method of: 10% MeOH (isocratic, 5 min), 10%–30% MeOH (gradient, 
35 min), 30%–95% MeOH (gradient, 5 min), 95% MeOH (isocratic, 3 min). Elution was monitored at 220 
nm and fractions containing cyclodehydrated bottromycin precursor peptide were dried under reduced 
pressure to yield a white solid.  
Dried bottromycin peptide was dissolved in 0.5 mL of 10 mM NH4HCO3 and cleaved with 100 µg of 
sequencing-grade trypsin (Promega) for 3 h at 37 °C, then transferred to 16 h at 25 °C. Reactions were then 
stored at -20 °C until further purification. 
Final purification was performed by HPLC with a Perkin Elmer Flexar HPLC equipped with a Betasil C18 
(Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å pore size). A mobile 
phase of 10 mM aq. NH4HCO3/MeOH was utilized at a flow rate of 1 mL min-1. Bottromycin N15K-
amidine was injected as 1 mL solution with a method of: 40% MeOH (isocratic, 5 min), 40–75% MeCN 
(gradient, 40 min). Elution was monitored at 220 nm and spotted on 2 µL of 75% aq. MeCN saturated with 
sinapinic acid and spotted on a stainless steel MALDI target for confirmation by MALDI-TOF MS. 
Purification of thiazoline intermediate. The following reaction conditions were used for 
cyclodehydration in synthetase buffer (50 mM Tris-HCl pH 7.5, 125 mM NaCl, 20 mM MgCl2, 1 mM 
TCEP, 5 mM ATP): BmbC precursor peptide (50 µM), MBP-BmbD (5 µM) in a final volume of 10 mL. 
The reaction mixture was incubated at 25 °C for 5 h, and 1 volumetric equivalent of acetonitrile was added 
to precipitate enzyme at 25 °C for 30 min, then centrifuged to remove insoluble material (17,000 × g, 15 
min, 25 °C). The soluble fraction containing processed precursor peptide was dried under reduced pressure. 
Dried samples were dissolved in 10% MeOH/10 mM NH4HCO3 and purified by preparative HPLC with a 
Perkin Elmer Flexar HPLC equipped with a Betasil C18 (Thermo Scientific) reverse phase column (250 × 
10 mm, 5 µm particle size, 100 Å pore size). A mobile phase of 10 mM aq. NH4HCO3/MeOH was utilized 
at a flow rate of 4 mL min-1 with a method of: 10% MeOH (isocratic, 5 min), 10%–30% MeOH (gradient, 
35 min), 30%–95% MeOH (gradient, 5 min), 95% MeOH (isocratic, 3 min). Elution was monitored at 220 
nm and fractions containing cyclodehydrated bottromycin precursor peptide were dried under reduced 
pressure to yield a white solid.  
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Dried bottromycin peptide was dissolved in 0.5 mL of 10 mM NH4HCO3 and cleaved with 100 µg of 
sequencing-grade trypsin (Promega) for 3 h at 37 °C, then transferred to 16 h at 25 °C. Reactions were then 
stored at -20 °C until further purification. 
Final purification was performed by HPLC with a Perkin Elmer Flexar HPLC equipped with a Betasil C18 
(Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å pore size). A mobile 
phase of 10 mM aq. NH4HCO3/MeOH was utilized at a flow rate of 1 mL min-1. Bottromycin N15K-
thiazoline was injected as 1 mL solution with a method of: 40% MeOH (isocratic, 5 min), 40–75% MeCN 
(gradient, 40 min). Elution was monitored at 220 nm and spotted on 2 µL of 75% aq. MeCN saturated with 
sinapinic acid and spotted on a stainless steel MALDI target for confirmation by MALDI-TOF MS. 
Preparation and purification of fluorescein-labeled bottromycin precursor peptide. The double 
mutant, C-terminal His-tagged construct (C8S-S43C-His) was generated via site-directed mutagenesis and 
prepared and purified using above methods. Purified, lyophilized peptide was labeled with 6-
(iodoacetamido)fluorescein (IAF, Sigma) by reducing 500 µM of precursor peptide in 10 mM NH4HCO3 
buffer with 500 µM TCEP for 30 minutes at 25 °C. 5 molar equivalents of IAF was dissolved in 1 volumetric 
equivalent of N,N-dimethylformamide and added to the reduced peptide for 45 minutes at 25 °C away from 
light. Reaction was quenched with the addition of 20 mM dithiothreitol (DTT) and further incubation for 
60 minutes at 25 °C away from light. The reaction conversion was monitored by desalted using C18 
ZipTips, eluted into 2 µL of 75% aq. MeCN saturated with sinapinic acid and spotted on a stainless steel 
MALDI target and analyzed by MALDI-TOF MS. 
Labeled peptide was purified by HPLC with a Perkin Elmer Flexar HPLC equipped with a Betasil C18 
(Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å pore size). A mobile 
phase of 10 mM aq. NH4HCO3/MeOH was utilized at a flow rate of 1 mL min-1. Bottromycin N15K-
amidine was injected as 1 mL solution with a method of: 40% MeOH (isocratic, 5 min), 40–95% MeCN 
(gradient, 20 min). Elution was monitored at 220 nm, 280 nm and 495 nm. 
Nuclear magnetic resonance characterization of thiazoline and amidine intermediates. The three 
compounds were dissolved in D6MSO. All solution NMR data was recorded at 305 K on a 700 MHz Bruker 
Avance spectrometer equipped with a cryogenically cooled probehead. Standard TOCSY, NOESY and 
COSY spectra with solvent suppression were acquired for each compound with 1H spectral widths of 8400 
Hz. FIDs for TOCSY and COSY spectra had 2406 and 256 points, and 2048 and 448 points for NOESY 
spectra. TOCSY spectra were recorded with mixing times between 70 and 100 ms and NOESY spectra with 
150-200 ms. Spectra were referenced to DSS. All spectra were processed in TopSpin 3.2 and analysed with 
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CHAPTER 5: EXPANDING NATURAL PRODUCT POST-TRANSLATIONAL 
MODIFICATIONS: (II) THIOAMIDE-FORMING YCAOS 
This work is previously published8and in preparation for publication9 
 
5.1 Introduction 
 During bioassay-guided isolation for compounds with antitumor activity, a novel NP was isolated 
from Streptomyces olivoviridis. This compound, thioviridamide, was reported to induce apoptosis 
selectively against two oncogene-expressing cell lines as well possessing antibiotic activity.1 Structural 
elucidation revealed thioviridamide contained several unusual functional groups, including a 2-hydroxy-2-
methyl-4-oxopentanoyl moiety, five peptide backbone thioamides, β-hydroxylation and N1, N3-
dimethylation of His, and an S-(2-aminovinyl) Cys macrocylization.2 The latter modification has been 
previously observed in other ribosomally synthesized and post-translationally modified peptides (RiPPs)3 
including gallidermin, mutacin 1140, mersacidin, and cypermycin, suggesting that thioviridamide would 
also be of ribosomal origin.  
Thioviridamide was confirmed to be a RiPP after sequencing the S. olivovidiris genome and 
identification of the precursor peptide, TvaA, which contained the core sequence VMAAAASIALHC 
(Figure 5.1). Heterologous expression in S. lividans confirmed the gene cluster tvaA-O to be responsible 
for thioviridamide biosynthesis. Of these genes, tvaH belongs to the YcaO superfamily, although 
thioviridamide contains no azolines. Moreover, no genes in the tva cluster are similar to known partner 
proteins (E1-like or Ocin-ThiF-like) normally associated with azol(in)e biosynthesis, further underscoring 
a distinc role for this YcaO. The authors suggest that thioamide formation may be catalyzed by tvaH, 
representing the first example of a thioamide-forming YcaO. Interestingly, TvaI which is annotated as a 
“TfuA-like” protein is often found immediately adjacent to a YcaO protein in many other genomic contexts 
which has also given rise to this type of YcaO being referred to as TfuA-associated YcaOs.4  
The potential for a thioamide-forming reaction is fascinating, because if it does indeed follow the 
proposed YcaO-like chemistry (see Chapter 4), then the atom which ultimately replaces the peptide 
                                                     
8 This chapter is adapted in part from Brandon J. Burkhart, Christopher J. Schwalen, Greg Mann, James H. Naismith, 
Douglas A. Mitchell “YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function” 
Chem. Rev. 2017, (8), 5389–5456. This work was supported in part by the U.S. National Institutes of Health 
(GM097142 to D.A.M.) and fellowships from the Chemistry-Biology Interface Training Grant Program (2T32 
GM070421 to B.J.B. and C.J.S.). Additional financial support came from the David and Lucile Packard Fellowship 
for Science and Engineering (to D.A.M.) and the University of Illinois at Urbana–Champaign Department of 
Chemistry (Robert C. and Carolyn J. Springborn Endowment to B.J.B.) and a National Science Foundation Graduate 
Research Fellowship (DGE-1144245 to B.J.B.). J.H.N. acknowledges the European Research Council (339367) and 
UK Biotechnology and Biological Sciences Research Council (K015508/1) and is a Royal Society Wolfson Merit 
Award Holder and 1000 talent scholar at Sichuan University. 




backbone oxygen is not substrate-derived but rather exogenously delivered in a form chemically equivalent 
to H2S. If the YcaO domain is confirmed to carry out this transformation, it would significantly enhance 
the synthetic scope of this enzyme superfamily, since one could imagine other types of nucleophiles being 
used in similar ways.  
 
Figure 5.1: Thioviridamide biosynthesis and structure. (A) The BGC for thioviridamide from 
Streptomyces olivoviridis. (B) Sequence of precursor peptide TvaA and structure of thioviridamide and 
analog JBIR-140. Stereochemistry of some JBIR-140 residues was determined by Marfey’s method and 
assumed to be consistent in thioviridamide. 
 
 As thioamides are an exceedingly rare modification in most NPs and in RiPP scaffolds in particular, 
additional examples of thioamide installation in RiPPs would bolster the genetic link between the 
hypothesized subclass of YcaOs (termed TfuA-associated YcaOs) and the thioamide PTM. However, 
examples in the thiopeptide literature indicated that there were at least two scaffolds from this RiPP class 
that were assigned with thioamides. 
 
5.2 Background on thiopeptides 
Despite the large number of known thiopeptides and their congeners, these compounds share many 
overall similarities in their structures, biosynthesis, and biological effects. As mentioned above, the six-
membered nitrogenous heterocycle is a class-defining feature of the thiopeptides, but it appears in different 
oxidation states and substitution patterns which has led to the classification of five different thiopeptide 
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series termed a through e (Figure ).5 The a series possess a fully reduced piperidine, as exemplified by some 
thiopeptins, whereas the b series has a 1,2-dehydropiperidine ring with thiostrepton being the archetype 
member. The c series currently has only one member, Sch 40832, which displays a bicyclic piperidine fused 
to an imidazoline. The d series is most populous and harbors a tri-substituted pyridine ring as in micrococcin 
P1. Lastly, the e series exhibit hydroxylated pyridines as illustrated by nosiheptide. In addition to the 
macrocycle that is formed by the central pyridine/piperidine heterocycle, members of the a-c series contain 
a second macrocycle made from a connection at this central heterocycle to a side chain of the macrocycle 
through a quinaldic acid moiety. The e series also harbor a second macrocycle, but it is smaller and attached 
to two side chains of the primary macrocycle through an indolic acid moiety. 
 Early insights into the biosynthesis of thiopeptides came through feeding studies using isotopically 
labeled amino acids (thoroughly reviewed elsewhere5), among other metabolic precursors, to trace the 
chemical origins for various parts of the structure.6-17 These studies revealed that all structural components 
of thiopeptides were derived from amino acids, as implied by their structures and degradation products. 
The azol(in)e heterocycles came from the cyclodehydration of Cys, Ser, and Thr while the dehydroamino 
acids derived from dehydration of Ser and Thr. The nitrogenous six-membered heterocycle originated from 
Ser residues and was first proposed to form through a cycloaddition reaction in 1977 (Figure 5.2c).18 The 
quinaldic acid moiety in the secondary macrocycle of the a-c series thiopeptides originated from tryptophan 
and required a ring expansion transformation, and similarly the indolic acid linked secondary ring of the e-
series also derived from tryptophan through a unique rearrangement reaction.  
The next major advance in understanding thiopeptide biosynthesis required discovery of their 
BGCs. Because of their peptidic nature, they could be made initially by the ribosome (i.e. RiPPs) or by 
NRPSs.19 Attempts to identify DNA sequences within producing organisms that might encode a precursor 
peptide matching the deduced precursor sequence of known compounds were initially fruitless, and 
chloramphenicol, an antibiotic that inhibits protein translation, did not seem to block production of 
nosiheptide, which suggested that the ribosome is not needed in thiopeptide biosynthesis.20,21 Other 
evidence showed that the quinaldic acid and indolic acid moieties found in some thiopeptides had their 
carboxylic acid groups activated with ATP, consistent with NRPS coupling mechanisms.22 Moreover, a 
NRPS putatively involved in micrococcin biosynthesis was identified,23 and other heterocycle containing 
and macrocyclic compounds (e.g. bacitracin) were known to be made by modular NRPSs.24,25 However, as 
more RiPPs were studied and discovered in the 2000s, the potential of a ribosomal origin for thiopeptides 
gained more traction.19 Dehydratases from the lanthipeptide subclass of RiPPs were known to transform 
Ser and Thr residues into dehydroamino acids,26 and heterocycles derived from the peptide backbone in the 
azol(in)e-containing RiPPs were also recognized as being much more prevalent.27-29 Consequently in 2009, 
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a RiPP biosynthetic origin for thiopeptides was proven nearly simultaneously by several independent 
research groups.30-34 
 At present, BGCs for 14 thiopeptides have been verified using genetic manipulations and/or 
heterologous expression. Currently, these include thiocillin,30,32,35,36 thiostrepton,32,34,37 siomycin,32 
nosiheptide,31,38,39 GE2270,33,40,41 thiomuracin,33,42 nocathiacin,43,44 cyclothiazomycin,45,46 TP-1161,47  
GE37468,48 berninamycin,49 lactocillin,50 nocardithiocin,51 and lactazole.52 Many natural congeners of these 
compounds are known to be produced by the same BGC. Based on these studies, all necessary biosynthetic 
genes were found to cluster near a precursor peptide (designated the “A” gene/protein) of typically 50-60 
amino acids (Figure 5.2a). Additionally, a primary set of six essential proteins emerged for building the 
core thiopeptide scaffold and included a split LanB dehydratase (B and C), [4+2] cycloaddition enzyme 
(D), dehydrogenase (E), cyclodehydratase partner protein (F), and cyclodehydratase (G). Despite the 
institution of a “standard” nomenclature,53 the labeling of these genes tends varies between BGCs, and this 
nomenclature is quite different compared to other subclasses. Usually, thiopeptide genes are clustered, but 
one counter example, cyclothiazomycin C, has a fragmented BGC with the [4+2] enzyme being distally 
encoded.54 In the remainder of this section, the biosynthesis of the core thiopeptide scaffold, the formation 
of the two tryptophan derived secondary rings, and C-terminal amidation are described. These steps have 
been expertly reviewed55-57 so here we provide an overview of the most recent findings. 
The roles of the aforementioned core biosynthetic enzymes were first assigned through 
bioinformatic analysis and characterization of partially processed intermediates in genetically manipulated 
strains.41,49,58-60 Although not conclusive, these studies suggested the biosynthetic order of events began 
with azol(in)e formation, then Ser/Thr dehydration, followed by macrocyclization through a putative [4+2] 
cycloaddition. The cyclodehydratase (G) was readily identified based on its obvious homology to azoline-
forming YcaO proteins,4,61 and similarly, the role of the dehydrogenase (E) in azoline oxidation to their 
corresponding azole heterocycles was easily recognized via homology with other flavin-dependent 
dehydrogenases known to dehydrogenate azoline heterocycles in RiPP pathways.62 However, the role of 
the cyclodehydratase partner protein (F) was not realized because its genetic deletion abolished thiopeptide 
production without providing any intermediates.31,45,52 The F-protein has low similarity to the 
cyclodehydratase protein (G) but is most clearly homologous to ThiF, an adenylating protein involved in 
thiamine biosynthesis and part of the E1-like superfamily.63,64 In public genome databases, this protein is 
most often annotated as “Ocin-ThiF-like.” Importantly, this ThiF-like partner protein contains the RRE, 
which binds the precursor peptide, and potentiates YcaO catalyzed cyclodehydration.42,65,66 Accordingly, 
the thiopeptide cyclodehydratase is most accurately described by the combined activities of the partner 
protein and YcaO because both are necessary for azoline biosynthesis.42 Notwithstanding these 
observations, there are rare examples of thiopeptide producers that do not locally encode a ThiF-like protein 
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homolog (e.g. Streptomyces bernensis, the producer of berninamycin49). The next step, dehydration of 
Ser/Thr residues is performed by a dehydratase composed of two proteins (B and C) that are homologous 
to the N- and C-terminal domains of class I lanthipeptide dehydratases respectively (referred to as a split 
LanB). These proteins catalyze dehydration through glutamylation of the hydroxyl group (B protein) using 
glutamyl-tRNAGlu with subsequent elimination (C protein).42,67,68 A formal [4+2] cycloaddition of two 
dehydroalanines forms the six-membered nitrogenous heterocycle (Figure ).42,69 The identity of the [4+2] 
cycloaddition enzyme was inferred by its absence in goadsporin,60,70 which structurally resembles a 
presumed intermediate during thiopeptide biosynthesis. Deleting this gene in thiopeptide BGCs resulted in 
the isolation of linear intermediates lacking this 6-membered heterocycle.52,58,71 Unexpectedly, the [4+2] 
enzyme has high similarity to the elimination domain of LanB dehydratases and possibly evolved through 
a duplication event. Whether or not the cycloaddition is concerted (Diels-Alder) or stepwise has yet to be 
evaluated, but these studies support a cycloaddition product as common biosynthetic intermediate from 
which subsequent reductions lead to the (dehydro)piperidine in the b and a series. Also from this 
intermediate, dehydration and -elimination of the leader peptide gives rise to the pyridine of the d series; 
for the e-series a cytochrome P450-type hydroxylase installs the hydroxypyridine.38 Ultimately, the 






Figure 5.2: Overview of thiopeptide biosynthesis and macrocycle architecture. (A) Thiopeptide BGC 
highlighting the enzymes that form the minimal thiopeptide scaffold. (B) Structure of micrococcin P1  with 
hallmark modifications color-coded: YcaO-catalyzed cyclodehydration (blue), lanthipeptide-like 
dehydrations (purple) and [4+2] cycloaddition (orange). The four-ring motif important for TipA recognition 
is also highlighted (red). (C) Biosynthesis of the 6-membered nitrogenous heterocycle and corresponding 
series designations.  
 
 After formation of the distinctive (primary) macrocyclic structure of thiopeptides, another common 
modification common is a secondary macrocycle connected through a quinaldic or indolic acid moiety 
(Figure 5.3-5.4).57 The quinaldic acid derivative found in thiostrepton (Tsr) and other a-c series 
thiopeptides begins with C-2 methylation of tryptophan with overall retention of stereochemistry of the 
methyl group via a radical S-adenosylmethionine (rSAM) methyltransferase (TsrM, also known as 
TsrT),9,72-74 and then an aminotransferase catalyzes deamination (TsrV, also called TsrA, note: naming 
conventions varies between research groups).34 Next a putative oxidase (TsrQ) forms an intermediate that 
presumably undergoes ring opening and recyclization that may be enhanced by the action of polyketide-
like cyclase (TsrS, also called TsrD).75 After formation of the quinaldic acid moiety, the ketone is reduced 
stereospecifically to an alcohol (TsrN, also called TsrU),75 and a probable next step is attachment to a side 
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chain of the primary macrocycle, which has been suggested to be catalyzed by an adenylate forming enzyme 
(TsrJ).15,22 A putative cytochrome P450 oxygenase (TsrI) forms an epoxide likely after initial attachment to 
a side chain of the main scaffold.76 Lastly, the leader peptide is removed by an α/β-hydrolase fold protein 
(TsrB, also called TsrI),34,77,78 and the newly formed N-terminus attacks the epoxide stereospecifically to 
complete the macrocycle with the aid of the hydrolase.78. Formation of the quinaldic acid macrocycle seems 
required for in vivo production as no intermediates are isolated when these genes are inactivated.75 In 
contrast, the indolic acid moiety found in e series thiopeptides (e.g. nosiheptide, Nos) begins with a radical-
mediated rearrangement to form 3-methylindolic acid (Figure 5.4b).31,56 This step is performed by a rSAM 
enzyme (NosL) that has been extensively investigated in vitro and begins by abstracting hydrogen from the 
amino group.79-84 After fragmentation-recombination, the order of biosynthetic steps is not clear, but the 2-
methylindole appears to be linked through its carboxylate to the main macrocycle by an ATP-dependent 
ligase (NosI?), based on a previously observed adenylated intermediate.22,31,43 The side ring can be further 
processed while attached to the peptide with methylation by a rSAM methyltransferase (NosN) and 
subsequent hydroxylation by an unidentified protein.31 Lastly, the side ring is then likely closed by an 
acyltransferase (NosK?) to complete its maturation. This final condensation which completes the side ring 
appears to take place prior to macrocyclization.31,43,71 Thus, thiopeptide secondary rings have many 
commonalities in their biosynthesis and assembly,22,56,57 and attachment of the indole/quinaldic acid is 
somewhat malleable, exemplified by the observation that  exogenously supplied fluorinated 
indole/quinaldic acids can be incorporated into the mature product without loss of activity.75,82 The only 
exception to this related biosynthetic pathway for side ring formation is cyclothiazamycin which forms its 
secondary ring through a thioether linkage between the main macrocycle to its tail via an unknown 




Figure 5.3: Thiopeptide secondary macrocycles. (A) Quinaldic acid derived ring in siomycin (red). (B) 
Indolic acid derived ring in nosiheptide (blue). (C) Thioether crosslink formed ring in cyclothiazomycin 







Figure 5.4: Secondary macrocycle formation. Formation of quinaldic (A) and indolic (B) acid moieties. 
 
 The last prevalent modification during thiopeptide biosynthesis is amidation of the C-terminal 
residue in the tail and is accomplished through two distinct strategies (Figure 5.5).56,57 The first pathway, 
as exemplified during nosiheptide biosynthesis, utilizes an “amidase” (NosA) to catalyze acrylic acid 
dealkylation of a C-terminal dehydroalanine residue (Figure 5.5a). Notably, the precursor peptide contains 
an extra Ser that is absent in the mature product.31,39,85,86 This mechanism is unlike other peptide amidations, 
which usually occur through oxidative cleavage of a C-terminal Gly residue.87,88 A second route to C-
terminal amide formation is seen in thiostrepton-like pathways and necessarily follows a different 
mechanism as there is no extra Ser residue in the core peptide (Figure 5.5b). Accordingly, amidation was 
proposed through transamidation performed by an asparagine synthetase-like protein (TsrT, also called 
TsrC) and requires a de-esterification process.32,34 The C-terminus is normally in the form of a methylester 
installed by a methyltransferase (TsrP, also called TsrF), but a carboxylesterase (TsrU, also called TsrB) 
reforms the C-terminal carboxylate which undergoes subsequent amidation.37 The free carboxylic acid has 
some reduced potency relative to the amide but the methylester is the most potent derivative, indicating that 
the C-terminus has an important influence on bioactivity.37 C-terminal amidation also enhances potency of 
other biologically active peptides, particularly hormone/signaling peptides,89 but its effect on activity varies 
among thiopeptides as it does not markedly affect nosiheptide or thiomuracin potency.39,42 Overall C-
terminal amidation appears to be a commonly occurring step in thiopeptide biosynthesis as very few 
thiopeptides have a free C-terminus. Other unique modifications (hydroxylation, methylation, 




Figure 5.5. Two mechanisms of thiopeptide C-terminal amidation.  (A) nosiheptide and (B) 






Table 5.1: Sequence comparison of the core regions for known thiopeptides. Thiopeptides with the 
same precursor peptide vary in ancillary tailoring to give different compounds. Groups of related 
thiopeptides are separated based on azol(in)e position (gray shading), ring size, and secondary ring. Group 
representatives are in bold font. Azol(in)e, blue; dehydroamino acids, orange; piperidine/pyridine, green; 
secondary ring, magenta. aName of the most common congener or parent compound. bCore sequences are 
from BGCs or inferred from the structure of the mature product. cThe number of atoms in the primary 




 Although thiopeptides contain common features and biosynthetic steps as described above, each 
compound is made unique by variable ancillary tailoring steps. Thiopeptide BGCs often possess 
methyltranferases, cytochrome P450 oxidases, or other enzymes that have been linked to specific 
modifications, and although the precise timing for many of these modification is not known, they are not 
required for the formation of the thiopeptide core structure.37,38,41,42 Nonetheless, most thiopeptide BGCs 
produce multiple congeners through these enzymes, so even though there are over 100 known thiopeptides, 
the number of encoding BGCs is much less. Analysis of the known thiopeptide parent compounds indicate 
that ~40 precursor peptides are necessary to account for all compounds, as inferred from their structures. 
The peptides also tend to share a common pattern in the position of their azol(in)es, especially among 
thiopeptides with the same ring size (Table 5.1). Accordingly, there is much that can be learned about how 
thiopeptide scaffolds are formed by comparing their different structures, even if the BGC remains unknown. 
Here, these distinctive thiopeptide subfamilies are reviewed with a focus on their unique biosynthetic steps 
and chemical properties. 
Since its isolation in 1955, thiostrepton91-94  (also known as bryamycin95-98) has been one of the 
most studied thiopeptides (Figure 5.6). Several highly related, 26-membered macrocycle compounds have 
been reported, including siomycin,99,100 Sch 18640,101 thiopeptin,102,103 and Sch 40832.104 With the discovery 
of the thiostrepton and siomycin BGCs in 2009,32,34 the biosynthesis of their primary scaffold, secondary 
macrocycle, and C-terminal amide is known to be performed by the enzymes discussed previously. 
However, thiostrepton/siomycin are unusual in that they encode an extra dehydratase glutamylaton protein 
(glutamylation domain) and possess a doubly hydroxylated Ile, which is likely installed by a cytochrome 
P450 hydroxylase (TsrR). Thiostrepton also possesses inverted stereochemistry at the thiazoline in position 
9, which could originate from D-Cys, but this inversion seems likely to occur spontaneously after 
posttranslational modification.105 Additionally, it is not clear which protein is responsible for reducing the 
presumed dihydropyridine intermediate post-cycloaddition to the final dehydropiperidine. 
Reprogramming of the thiostrepton precursor peptide has shown that the presence of only one 
dehydrated residue in the secondary macrocycle of the mature product is not due to a limitation of the 
enzymes, as substitution with Ser or Thr at Ala2 or Ala4 also results in modification like in the other 
members.71,77,106 Other studies have also sought to increase the water solubility of thiostrepton without 
reducing target potency by introducing polar residues at positions 2 and 4. These positions were chosen 
because they point toward bulk solvent in the co-crystal structure of thiostrepton bound to the 50S ribosome 
and are less likely to affect binding potency. Unfortunately, charged residues at these positions were 
rejected by the biosynthetic pathway. The biosynthetic machinery were more tolerate to variations at 
position 4 than position 2, but of the accepted residues, generally hydrophobic residues were the only 
substitutions that retained activity.77,106 Interestingly, the introduction of dehydrobutyrines in this region by 
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genetic manipulation resulted in decreased activity, and none of the native sequences utilize Thr, perhaps 
suggesting that nature has already selected against less potent derivatives. Despite these lower potencies 
against live bacteria, in vitro translation inhibition was approximately identical for most of the substitutions, 
indicating the lowering in whole cell activity comes from other sources such as uptake, export, or 
stability.77,106  
Other changes to the tryptophan-derived macrocycle have also been investigated. Exogenously 
supplied fluorinated or methylated quinaldic acid can be incorporated into thiostrepton by the native 
biosynthetic pathway and results in a slightly more potent derivative.77,107 The quinaldic acid ring can also 
be contracted if Val or Ile are substituted at position 2 because the  leader protease appears to cleave the 
peptide just before Val/Ile so the traditional position 1 will be removed when position 2 is Val/Ile.77 
Additionally, a fourth ring has been formed by introducing a Cys into the side ring that can then 
adventitiously react with a dehydroalanine in the tail region.106 However, both of these modifications likely 
disrupt the structure of the quinaldic acid ring, preventing it from interacting with the 23S ribosomal subunit 
properly, and result in dramatic loss of antibacterial activity. By similar logic, mutation of Thr7 also 
decreases potency as this conserved residue also interacts with RNA when bound.76,108 Unexpectedly, a C-
terminal carboxylate is also detrimental to thiostrepton potency,37 but it is not clear why from a structural 
view and could be due to uptake or other steps outside of target binding. Overall, these data indicate that 
bioengineering of thiostrepton’s side ring tended to abrogate antibacterial activity, but it should also be 
noted that most of the tested mutants did not significantly change thiostrepton ability to inhibit the 





Figure 5.6: Thiostrepton biosynthesis and structure. (A) Thiostrepton BGC. (B) Precursor peptide and 
structure for thiostrepton A. 
 
5.3 Precedent for thioamide-containing RiPPs 
 Two previously discovered thiopeptides were reported to contain thioamide functional groups, 
although no comment was made on the purpose of these modifications and no information was known about 
the biosynthesis (Figure 5.7). Sch 18640, termed a “thiostrepton-type” antibiotic, was isolated from 
Micromonospora arborensis by the Schering Corporation in 1981.110 Notably, the compound was 
characterized by 252CF plasma desorption mass spectrometry alongside a thiostrepton standard to give the 
exact masses used to determine the chemical formula, which showed a deviation of a net loss of one oxygen 
and gain of H2S. In conjunction with the 13C NMR spectroscopy, it was determined that Sch 18640 
contained a fully reduced piperidine ring and a single amide to thioamide replacement. Thiopeptin was 
isolated as a number of related compounds from Streptomyces tateyamensis by a group at Merck and others 
in the 1970-80s.102,103,111 Spectroscopic characterization revealed functional groups characteristic of 
thiopeptides, including a combination of piperidine/dehydropiperidine congeners, placing it within the 
“a/b” series of classifications. Careful analysis of the carbonyl 13C signal adjacent to the thiazole in the 
main macrocycle, along with comparison to synthetic thiazole-4-carboxamide fragments to confirm the 
observed δc=s shifts. Ultimately, a single carbonyl signal was observed with δ ppm > 180, which was 
attributed to a single thioamide, proposed to occupy the same position as in Sch 18640. 
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 Future thiopeptides isolated that belong to this series do not show evidence for this modification, 
and no further work was done characterizing this transformation. However, in light of the extensive 
thioamidation present on thioviridamide, coupled with the enigmatic YcaO present in its BGC, we 
hypothesized the presence of this enzyme, potentially in combination with the TfuA-annotated gene, may 
be responsible for this post-translational modification. Indeed, surveys of putative BGCs containing YcaOs 
that lacked typical biosynthetic partners such as the E1-ubiquting activating-like protein or the Ocin-ThiF-
like protein (previously annotated “C” and “F” proteins, see Chapter 4) showed that approximately 10% 
co-occurred with TfuA-like proteins, suggesting that this may in fact be a new uncharacterized biosynthetic 
partner for a novel RiPP PTM.  
 Moreover, independent work from this lab10 found that similar enzymes are responsible for a 
thioamidation reaction on methyl-coenzyme M reductase α subunit. In this study within methanogenic 
Archaea, highly-conserved TfuA-YcaO occur on the genome of methanogenic microbes and is shown to 
play a role in fitness. Biochemically, thioamidation of a peptide fragment identical to the portion of the 
native α subunit is modified to form a thioamide in vitro. Bolstered by these results and genetic implication 
in RiPP biosynthesis, we sought to characterize this potentially new chemistry within the YcaO superfamily 
and utilize this information for discovery of new NPs.  
 
 
Figure 5.7: Comparison of thioamide-containing thiopeptides. Thiostrepton (Streptomyces azureus), 
Sch 18640 (Micromonospora arborensis) and thiopeptin (Streptomyces tateyamensis) with thioamide 
modifications highlighted in red and other structural variations highlighted in blue. 
 
5.4 Connecting genes to RiPP thioamide biosynthesis 
 Due to lack of sequencing data on the two known thioamide-containing thiopeptide producing 
strains, Micromonospora arborensis NRRL 8041 was obtained from the Agricultural Research Service 
                                                     
10 Dipti D. Nayak, Nilkamal Mahanta, Douglas A. Mitchell, and William W. Metcalf, “Post-translational 




Northern Regional Research Laboratory (ARS-NRRL) and Streptomyces tateyamensis ATCC 21389 was 
obtained from the American Type Culture Collection (ATCC) and subjected to whole-genome sequencing. 
Querying contigs with Basic Local Alignment Search Tool with genes from the thiostrepton BGC yielded 
hits that resembled thiopeptide BGCs, including ancillary tailoring enzymes required for formation of the 





Figure 5.8: Sequenced clusters of thioamide-containing thiopeptide producers. (A) Sequenced gene 
clusters of Sch 18640 and thiopeptin alongside gene clusters for thiostrepton and siomycin, the closest 
analogs that lack thioamides. BGCs for thioamide-containing thiopeptides generally have the same  
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Figure 5.8: (cont.) architecture with an additional YcaO and TfuA-like gene present. (B) Putative precursor 
peptides and structures of relevant thiopeptides, thioamides highlighted in red. 
 
 Identified BGCs contained prerequisite machinery for thiopeptide biosynthesis, including typical 
split LanB dehydratases responsible for dehydroalanine/dehydrobutyrine, YcaO azoline heterocyclase 
systems (with commensurate dehydrogenase for oxidation to azole) and a macrocyclase to perform the 
cycloaddition (Figure 5.8a). Within the BGC, precursor peptides could be identified that contained the core 
sequence that corresponds to unmodified Sch 18640/thiopeptin, with leader peptides that contain sequence 
motifs similar to both thiostrepton and siomycin. Notably, two additional open reading frames (ORFs) 
present in the thioamide clusters showed homology to the YcaO and TfuA hidden Markov models and to 
each other. Additional ORFs show homology to the ancillary tailoring enzymes consistent with the class of 
thiopeptides reported. 
 
5.5 Discovery of new thioamide-containing thiopeptides via genome-mining 
 Using the TfuA-YcaO pair present in Micromonospora arborensis and Streptomyces tateyamensis 
as queries, the National Center for Biotechnology Information (NCBI) GenBank was searched for 
analogous sequences proximal to thiopeptide-like clusters. Clusters were annotated based on similarity to 
known thiopeptide clusters, gene homology and potential precursor peptide sequences – representative 























Table 5.2: Predicted thioamide-containing thiopeptides. RODEO genome mining to look for co-
occcurrence of TfuA-YcaO pairs within thiopeptide BGCs identified several candidate clusters. A.        
162 
 
Table 5.2: (cont.) saalfeldensis’ BGC showed high similarity to thiostrepton-type thiopetpides and 
contained a similar precursor peptide.  
 
 Select strains were grown on a panel of 12 liquid and solid media to screen for thiopeptide 
production. Cultures grown on liquid media had both mycelia and broth extracted, while whole-colony 
analysis was performed on the cultures grown on solid media and analyzed via matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. Parent ions in a consistent mass 
range with predicted precursor peptides/typical thiopeptide molecular weights were subjected to chemical 
derivatization specific for dehydroamino acids to support the presence of dehydroalanine or 
dehydrobutyrine. 
 As detection methods for NPs have become more sensitive, there is greater opportunity for 
compound identification in complex extracts, particularly with the refinement of mass spectrometry (MS) 
techniques. However, in these samples it can be challenging to correctly identify NPs of interest in the 
presence of a large number of metabolites. Reactivity-based screening offers an attractive option to augment 
MS methods with targeted chemical derivatization of known functional groups. For small amounts of 
analytes that contain a predicted functionality, a selective, covalent modification with defined substrate 
scope can “tag” relevant reactive substrates via mass shift.112 Differential mass spectrometry can then be 
used to identify masses of interest that possess fixed numbers functional groups, informing on structure 
while consuming insignificant amounts of sample and benefiting from the high sensitivity of modern MS 
practices.113  
All characterized thiopeptides contain dehydroamino acids in the form of dehydroalanine or 
dehydrobutyrine – products from lanthipeptide dehydration of serine or threonine residues, respectively. 
These PTMs are susceptible to Michael-type conjugate addition via soft nucleophiles, such as thiolates. 
Common, commercially available thiolates such as dithiothreitol (DTT) can be utilized in this manner to 
covalently modify dehydroalanines reliably under basic conditions (dehydrobutyrine labeling is less robust 
and is largely analyte dependent). Previous work in our lab has used this technique successfully for 
microscale thiopeptide detection from crude extracts with a variety of thiolate-bearing probes.114 
A screening hit from Amycolatopsis saalfeldensis NRRL B-24474 was found to be consistent with 
multiple cyclodehydrations, lanthipeptide dehydrations and an amide to thioamide PTM. Primary sequence 
of the corresponding precursor peptide “ASSSSCTTCICTCSCSS” suggests 5 possible thiazoline 
heterocyclizations (with potential for dehydrogenations to azoles), up to 6 likely lanthipeptide dehydrations, 
and conjugation to a quinaldic acid secondary macrocycle if consistent with previous structures from this 
thiopeptide series. Conjugate addition labeling confirmed 5 lanthipeptide dehydrations with a potential 





Figure 5.9: Thiol labeling of dehydroamino acids of saalfelmuracin. Candidate thiopeptide containing 
thioamide (termed “saalfelmuracin”) was subjected to DTT labeling of dehydroamino acids with 10 mM 
N,N-diisopropylethylamine and 20 mM DTT at 16 hr at 25 °C. Extract signal showed Na+/K+ adducts (black 
trace). Crude labeling reaction showed presence of multiple DTT adducts with significant baseline noise 
and Na+/K+ adducts (red trace). C18 ZipTip concentration into 75% aq. MeCN improved signal of parent 
ions and reduced salt adduct signal (blue trace).  
 
 Small quantities of novel NPs from screening have served as means for MS characterization for 
other RiPP natural products (see Chapter 2) at early stages of isolation, obviating scale up efforts in the 
event of a re-discovered compound. In addition to the genomic evidence, which suggests a unique core 
peptide sequence, high-resolution mass spectrometry (HR-MS) is integral for chemical formula 
confirmation and obtaining fragmentation data to support suspected structures. Small-scale extracts of 
mycelia from Amycolatopsis saalfeldensis were concentrated with C18 ZipTips and eluted into 75% 
aqueous acetonitrile and analyzed by HR-MS. The major species present was consistent with the proposed 
structure of dehydrated, cyclized thiopeptide scaffold (Figure 5.10a). The major fragment seen was 
consistent with loss of a dehydroalanine fragment (Figure 5.10b), but the parent ion was otherwise 




Figure 5.10: HR-MS of proposed saalfelmuracin structure. (A) Major ion species present is consistent 
with the proposed structure of saalfelmuracin. (B) The major fragment seen is consistent with fragmentation 
at the C-terminal dehydroamino acid tail. Thioamide and DTT labeled dehydroamino acids are labeled in 
red. 
 
 With some aspects of the structure verified and no entries in online natural product databases or 
literature precedent, the compound was dubbed “saalfelmuracin” and large-scale cultures were initiated for 
further characterization by spectroscopic techniques and bioactivity testing. Screening data indicated that 
the production of saalfelmuracin relative to contaminating metabolites was optimal on ISP2 media. 
Comparison between mycelial extracts and aqueous solid media extracts indicated less saalfelmuracin was 
present in the media relative to the mycelia and methanol was a significantly more effective extraction 
solvent than chloroform. 
 Methanolic extracts of mycelia and C18 solid phase extraction column were combined and purified 
by iterative reverse-phase C18 chromatography. Two masses which eluted close to one another were 
predicted to be thiopeptide congeners with the major species (>90%) as the full length predicted structure 
(saalfelmuracin A) and the minor species as C-terminal hydrolysis product of a loss of dehydroalanine 
(saalfelmuracin B) on the basis of mass and retention time. 
  
5.6 Conclusions 
 Exploration of new chemical space in natural products is a promising strategy to address the need 
for new medicinal compounds. However, genetic prospecting and empirical results from screening efforts 
indicate that rediscovery of known compounds remain an issue due to (i) BGCs of compounds which are 
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highly distributed among organisms and (ii) abundance of compounds which have been previously 
explored. To address this, genome-mining, or in silico screening to prioritize BGCs predicted to produce 
novel compounds, stands to enhance screening hit rates, but requires reliable data connecting genes to 
biosynthetic function. Specifically, the ability to predict natural product structure ab initio without prior 
characterization will directly correlate to the success of this technique. Hence, efforts to expand the 
knowledge of NP tailoring reactions with an emphasis on novel chemical transformations/functional groups 
is critical for effective genome-mining. 
 Through genomic-context analysis, we found the TfuA-like proteins to be an unidentified gene 
frequently co-localized with YcaOs. While YcaOs have been consistently characterized in RiPP BGCs as 
azoline-forming cyclodehydratases, recent work by our group has shown that this large superfamily is 
capable of other transformations (see Chapter 4) in NP biosynthesis. The TfuA-associated YcaOs 
presented a promising new subfamily to investigate, as they were previously implicated in the biosynthesis 
of thioviridamide, which contained no typical PTM associated with this enzyme family. 
 Bioinformatic characterization of the TfuA-YcaO proteins showed a surprisingly high presence in 
potential RiPP BGCs, and through process of elimination, were expected to be involved in the biosynthesis 
of the multiple thioamides. The YcaOs themselves showed low similarity to both types of characterized 
cyclodehydratases – azoline-forming (i.e. TOMM cyclodehydratases) and amidine-forming (i.e. 
bottromycin macrocyclases). Although thioamide installation is a rare functional group present in NPs, two 
examples were found in the literature in the thiopeptide class of RiPPs. While spectroscopic evidence 
confirmed the presence of one thioamide in Sch 18640 and thiopeptin, the producing organisms were not 
sequenced. 
 Whole-genome sequencing revealed nucleotide contigs with complete thiopeptide BGCs from both 
Micromonospora arborensis and Streptomyces tateyamensis (producers of Sch 18640 and thiopeptin, 
respectively). Both BGCs contained prerequisite thiopeptide biosynthetic enzymes, and showed high 
sequence similarity to previously characterized thiopeptides of similar structures, such as thiostrepton and 
siomycin, and gratifyingly contained two additional ORFs with similarity to TfuA-like proteins and the 
YcaO superfamily. Furthermore, the extra YcaOs showed lowered similarity to the canonical azoline-
forming cyclodehydratases, both in other thiopeptide BGCs and when compared to the locally-encoded 
Ocin-ThiF-YcaO ORFs. Taken together, this provided compelling evidence for the role of the TfuA-YcaO 
pair in thioamide biosynthesis. 
 Using RODEO (Rapid ORF Description and Evaluation Online) our in house platform for BGC 
annotation, we located several other putative thiopeptide BGCs with machinery for thioamide PTMs. A 
screen of these clusters produced a new candidate compound, “saalfelmuracin” which importantly, was 
shown by HR-ESI-MS to have a chemical formula consistent with a thioamidation (replacement of oxygen 
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with sulfur atom). Current efforts are underway to further characterize saalfelmuracin spectroscopically and 
to provide further evidence to link the TfuA-YcaO pair to biosynthesis of the thioamide through 
reconstitution and genetic experiments. 
 Overall, connection of the thioamide PTM in RiPPs to an under-characterized group of enzymes 
within the YcaO superfamily and the TfuA-like proteins serves as a proof of concept for new protein family 
characterization for NP discovery. By prioritizing under-explored proteins with little characterization 
related to NP biosynthesis, new roles of biosynthetic enzymes can be discovered. These proteins can then 
serve as genetic handles for bioinformatic identification of new relevant BGCs, which can then be 
prioritized based on predicted novelty. Hence, this method is complementary to identifying unusual 




Bioinformatic screening for thiopeptide clusters. Thiopeptide candidate clusters were obtained by 
protein BLAST searches into NCBI GenBank using TfuA-YcaO sequences from Micromonospora 
arborensis and Streptomyces tateyamensis. This was cross-referenced to BLAST results for biosynthetic 
enzymes as queries (LanB, YcaO, macrocyclase) from known thiopeptides thiostrepton, thiomuracin, and 
nosiheptide. Clusters containing prerequisite machinery in addition to a TfuA-YcaO pair were considered 
candidate clusters (i.e. at least two copies of YcaO-domain containing proteins should be present, with both 
an Ocin-ThiF-like protein and a TfuA-like protein).  
Preparation of high molecular weight genomic DNA. Micromonospora arborensis NRRL 8041 and 
Streptomyces tateyamensis ATCC 21389 were grown in liquid ATCC172 medium until a dense culture had 
developed (~5 d). A 5 mL portion of the culture was pelleted (4,000 × g, 10 min), and the supernatant was 
removed by aspiration. The cells were resuspended in 2 mL of TE25S buffer (25 mM Tris, 25 mM EDTA 
disodium salt, 30% sucrose, pH 8) and large clumps of cells were broken up by physical disruption with a 
glass rod. Lysozyme was added to a final concentration of 10 mg/mL and the suspension was incubated at 
37 °C with agitation. After 1 h, 6 mL of modified lysis buffer (569 mM 4-aminosalicylic acid sodium salt, 
69 mM sodium dodecyl sulfate, 100 mM Tris, pH 8) and 20 μL of proteinase K (New England Biolabs, 30 
U/mg at 20 mg/mL) were added. The suspension was then incubated at 75 °C for 30 min, with the 
suspension being mixed once by gentle inversion several times after 15 min. An equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1, v/v) was then added and mixed by gentle inversion several 
times. The mixture was centrifuged at 10,000 × g at 4 °C for 10 min, and the aqueous phase was transferred 
to a new container using a wide bore pipet. To the aqueous phase, an equal volume of chloroform:isoamyl 
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alcohol (24:1, v/v) was added and mixed by gentle inversion several times. The mixture was again 
centrifuged at 10,000 × g at 4 °C for 10 min, and the aqueous phase was transferred to a new container 
using a wide bore pipet. Extraction with chloroform:isoamyl alcohol was performed five times until the 
aqueous phase appeared clear of protein contaminant. The aqueous phase was then transferred to a 50 mL 
conical tube, to which 0.1 volume equivalents of 5 M NaCl was added. The tube was then filled to the top 
with isopropyl alcohol and the mixture was gently inverted several times to mix. After decanting, the 
mixture was decanted and washed with 70% aq. EtOH twice, then dissolved in nuclease-free ddH2O and 
quantified by A260 with a Nanodrop spectrophotometer (Thermo Scientific). 
 
Whole genome sequencing of thioamide-containing thiopeptide producers. Paired-end sequencing with 
read length 100 nt was conducted by the Roy J. Carver Biotechnology Center (University of Illinois, 
Urbana, IL, USA) using an Illumina HiSeq2500. The genome of S. alba YIM 90003 was assembled and 
mapped with CLC Assembly Cell software (CLC bio). The National Center for Biotechnology Information 
(NCBI) Basic Local Alignment Search Tool (BLAST) tblastn command was used to query contigs for 
the TfuA and YcaO sequences. 
 
Screening of Actinomycetes for thiopeptide production. Prioritized strains were grown on each ATCC 
Media 172, ISP Media 4, R2A, modified AltMS, GUBC, mannitol soya, ISP Media 2, AGS, tryptic soy 
broth, nutrient broth, V8 and Staib’s medium were prepared as liquid media or solid media with the addition 
of 1.5% agar on 10 cm sterilized petri dishes. Cultures were incubated at 30 °C for 14 d prior to whole-cell 
mass spectrometry. A portion of cell mass (pinhead-sized) including aerial hyphae was picked from the 
plate and placed in 2 µL of sat. 50% aq. MeCN solution of α-cyano-4-hydroxycinnamic acid (CHCA) with 
0.1% trifluoroacetic acid (v/v) on a ground steel MALDI target. Additional aliquots of matrix (2 µL) were 
spotted and allowed to dry on the cell mass three times to extract metabolites onto the plate. Samples were 
analyzed using a Bruker UltrafleXtreme MALDI-TOF MS using manufacturer methods for reflector 
positive mode. 
 
Recipes of atypical Actinomycetes media. For the following media, the following components were added 
to 1 L of ddH2O: 
R2A: 0.5 g yeast extract, 0.5 g peptone, 0.5 g casamino acids, 0.5 g D-glucose, 0.5 g soluble starch 
(Amresco), 0.3 g sodium pyruvate (Sigma), 0.3 g K2HPO4, 0.05 g Mg2SO4∙7H2O, 18 g agar. 
AltMS: 20 g mannitol (Sigma), 10 g malt extract (Sigma), 10 g soya flour, 15 g agar. 
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GUBC: 5 mL glycerol, 10 g sucrose, 5 g beef extract (Amresco), 5 g casamino acids, 5 mL solution A (1 
M Na2HPO4, 1 M KH2PO4), 5 mL solution B (to 1 L: 59.3 g MgSO4∙7H2O, 6.67 g CaCl2∙2H2O, 0.0185 g 
(NH4)6Mo7O24∙4H2O, 0.198 g FeSO4∙7H2O, 100 mL of Hutner’s metals, pH to 6.8). 
Mannitol soya: 20 g mannitol, 20 g soya flour, 20 g agar. 
V8: 200 mL V8 vegetable juice mix, 3 g CaCO3, 18 g agar. 
Staib’s medium: 70 g crushed nigerseed, 1 g D-glucose, 1 g yeast extract, 1 g KH2PO4, 18 g agar. 
Hutner’s metals (additive for GUBC): to 1 L: 2.5 g EDTA∙2Na, 10.95 g ZnSO4∙7H2O, 5 g FeSO4∙7H2O, 
1.54 g MnSO4∙H2O, 0.392 g CuSO4∙5H2O, 0.250 g CO(NO3)2∙6H2O, 0.177 g Na2B4O7∙10H2O, pH  with 5 
drops H2SO4. 
 
Isolation of saalfelmuracin A and B. Amycolatopsis saalfeldensis NRRL B-24474 was grown on ISP2 
with 1.5% agar on 15 cm sterilized petri dishes (n = 20) and incubated at 30 °C for 28 d. Cells were harvested 
by scraping cell mass from the plates with razors and collectively extracted with 600 mL MeOH with 
shaking at room temperature overnight. The methanolic extract was vacuum-filtered and dried under 
reduced pressure onto 5 g of Celite 545 adsorbent.  
Spent agar was frozen at ˗20 °C overnight and then allowed to thaw. The agar was squeezed and 
filtered through cheesecloth to harvest the aqueous portion, which was vacuum-filtered with Whatman filter 
paper and loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) pre-equilibrated with H2O. 
The loaded column was washed with 200 mL of H2O, and bound material was eluted with successive 50 
mL portions of 5%, 10%, 25%, 50% and 75% aq. MeCN, followed by 100 mL of MeCN. Fractions were 
analyzed via MALDI-TOF MS. Fractions containing anantin B1 and B2 were pooled with the methanolic 
extract and dried under reduced pressure onto 5 g of Celite 545 adsorbent. 
Anantin adsorbed onto Celite was purified by medium pressure liquid chromatography (MPLC) 
using a Teledyne Isco Combiflash EZprep equipped with a RediSep Rf C18 cartridge (130 g media, 60 Å 
pore size, 40–63 µm particle size, 230–400 mesh) using a mobile phase of 10 mM aq. NH4HCO3/MeOH at 
85 mL min-1 over a gradient from 20–60% MeOH (10 column volumes), then 60–95% MeOH (5 column 
volumes). Fractions were analyzed via MALDI-TOF and dried under reduced pressure.  
Saalfelmuracin A and B were dissolved in 7 mL of water each and filtered with a 0.22 µm syringe 
filter (BD Technologies) prior to injection. HPLC was performed using a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 5 µM particle size) with a 
mobile phase of 10 mM aq. NH4HCO3/ MeOH (gradient from 10 to 95% MeOH) at 19 mL min-1. Fractions 
containing saalfelmuracin A and B were dried under reduced pressure, resuspended in H2O, flash-frozen, 
and lyophilized overnight to dryness.  
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Final HPLC was performed with a Perkin Elmer Flexar HPLC equipped with a Betasil C18 
(Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size). Saalfelmuracin was dissolved 
separately in 1.5 mL of water, subjected to centrifugation at 17,000 × g to remove precipitate, and injected 
with a mobile phase of 10 mM aq. NH4HCO3/MeOH with a gradient from 10–95% over 30 min at a flow 
rate of 1 mL min-1. Elution was monitored at 220 nm and appropriate fractions were dried under reduced 
pressure, dissolved in water (2 mL), flash-frozen, and lyophilized overnight to dryness. Saalfelmuracin A 
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Takano, Sang Yup Lee, Tilmann Weber, Marnix H. Medema “antiSMASH 4.0 - Improvements in 
Chemistry Prediction and Gene Cluster Boundary Identification” Nucleic Acids Res. 2017, (45), W36-W41. 
doi: 10.1093/nar/gkx319. Copyright 2017 Oxford Academic Press. 
 
I developed the extension of the RODEO scoring algorithms/metrics for the lanthipeptide, sactipeptide and 


















































APPENDIX B: SPECTROSCOPIC CHARACTERIZATION OF COMPOUNDS AND NEW 
NATURAL PRODUCTS 
 
I developed the purification strategy and purified lasso peptides (Appendix B.1) and bottromycin 
cyclodehydratase products for MS and NMR characterization (Appendix B.2-B.3). Additionally, I 
performed the peptidase digestion and dethreading assays for lasso peptides (Appendix B.1). 
 
B.1 Characterization and degradation characterization of lasso peptides 
Mass spectrometry and HPLC characterization of purified lasso peptides. (A) High resolution mass 
spectrum of either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error from the 
expected chemical formula. The [M+H]+ or [M+2H]2+ (indicated) of the carboxypeptidase Y-digested lasso 
is shown for cases when cleavage was observed (anantin B1 and moomysin). (B) CID spectrum of the 
[M+H]+ or [M+2H]2+ ion. Labeled peaks correspond to identified b- and y- ions. (C) schematized 
unthreaded lasso peptide bubble diagram with identified fragment ions. Extent of carboxypeptidase Y 
digestion is indicated with an arrow for anantin B1 and moomysin. (D) Table of masses of the observed b- 
and y-ions shown in panels B and C. (E) Analytical HPLC trace of purified lasso peptides monitored at 220 

























































Asx 39.86333 22.4% L 
Glx - - - 
Ser 12.45667 7.0% L 
His - - - 
Gly 23.52667 13.2% L 
Thr - - - 
Cit 6.943333 3.9% - 
Ala 12.17333 6.8% L 
Arg - - - 
Tyr - - - 
Val 11.84667 6.7% L 
Met - - - 
Phe - - - 
Ile - - - 
Leu 59.06 33.2% L 
Lys 12.16667 6.8% L 

























Moomysin LP2006 Lagmysin 
Ala - - - - L 
Arg - - - L - 
Asn L L - L - 
Asp - - L - - 
Cys - - - - - 
Gln - - - - L 
Glu - - - L - 
Gly L L L L L 
His L L L - L 
Ile L L - - - 
Leu - - - - L 
Lys - - - - - 
Met - - - - - 
Phe L L - L - 
Pro - - - L L 
Ser L L L L L 
Thr - - - - - 
Trp L  L L - 
Tyr L L L - - 




Supplementary Figure B.1 (parts i – w). NMR characterization of LP2006, lagmysin, and citrulassin 
Supplementary Figure B.1i: 1H NMR (CD3OH, 900 MHz) of LP2006 
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Supplementary Figure B.1j: 1H-13C HSQC (CD3OH, 900 MHz) of LP2006, 
13C 0-80 ppm 
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Supplementary Figure B.1k: 1H-13C HSQC (CD3OH, 900 MHz) of LP2006, 




Supplementary Figure B.1l: 1H-1H TOCSY (CD3OH, 900 MHz) of LP2006 
215 
 
Supplementary Figure B.1m: 1H-1H NOESY (CD3OH, 900 MHz) of LP2006. Annotated in red are 








Supplementary Figure B.1o: 1H-13C HSQC (CD3OH, 900 MHz) of lagmysin, 
13C 0-70 ppm 
218 
 
Supplementary Figure B.1p: 1H-13C HSQC (CD3OH, 900 MHz) of lagmysin, 
13C 112-147 ppm 
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Supplementary Figure B.1r: 1H-1H NOESY (CD3OH, 750 MHz) of lagmysin. Annotated in red are 
strong NOE correlations confirming the Leu1-Asp8 isopeptide linkage. NOEs between ring and tail 

















Supplementary Figure B.1v: 1H-1H NOESY NMR (CD3OH, 750 MHz) of citrulassin A. Annotated in 
red are strong NOE correlations confirming the Leu1-Asp9 linkage. NOEs between ring and tail residues 





Supplementary Figure B.1w: 1H-1H TOCSY NMR (CD3OD, 750 MHz) of anantin B1, citrulassin A, 
lagmysin, and LP2006 amide regions. Recalcitrance to backbone amide solvent exchange is consistent 






Supplementary Tables B.1(a - c) : NMR chemical shift assignments for LP2006, citrulassin, and 
lagmysin. 
Supplementary Table B.1a: NMR chemical shift assignments for LP2006 
 δ (ppm) 
Residue NH Hα Cα Hβ Cβ Others, H (group) Others, C (group) 
Gly1 9.38 4.51, 3.65 42.6 3.65 – – – 
Arg2 9.24 4.86 49.6 1.87, 1.83 26.3 1.81, 1.70 (γ, CH2), 3.26, 3.17 (δ, CH2) 23.9 (γ), 39.4 (δ) 
Pro3 – 4.37 61.2 2.10, 1.97 28.2 2.01, 1.96 (γ, CH2), 3.64, 3.50 (δ, CH2) 25.4 (γ), 47.3 (δ) 
Asn4 8.22 4.13 53.6 2.72, 2.67 35.2 7.65, 6.86 (δ, NH2) – 
Trp5 8.26 5.14 54.5 3.32, 3.08 28.4 7.88, 7.29, 7.06, 6.98, 7.31 (arom, CH) 118.7, 110.9, 121.1, 118.5, 123.0 (arom) 
Gly6 8.15 3.90, 3.26 45.0 3.26 – – – 
Phe7 7.46 4.90 54.5 3.64, 2.60 36.4 7.39, 7.31, 7.31 (arom, CH) 128.3, 128.8, 126.4 (arom) 
Glu8 8.93 4.34 56.3 2.18, 2.08 25.9 2.47, 1.97 (γ, CH2) 37.1 (γ) 
Asn9 8.20 4.13 51.1 3.29, 3.23 36.8 7.87, 6.95 (δ, NH2) – 
Asp10 7.96 4.48 49.7 3.10, 2.33 37.0 – – 
Trp11 7.98 4.70 56.3 3.88, 3.84 22.3 7.81, 7.38, 7.13, 7.02, 7.11 (arom, CH) 118.9, 110.8, 120.8, 118.2, 123.0 (arom) 
Ser12 7.43 5.42 56.0 4.96, 3.64 60.8 – – 
Cys13 8.14 4.28 54.5 3.02, 2.90 40.4 – – 
Val14 8.50 3.94 60.5 2.25 29.9 1.07, 1.01 (γ, CH3) 19.7, 17.9 (γ) 
Arg15 n.d. 3.95 58.7 2.13, 2.03 28.7 1.69, 1.65 (γ, CH2), 3.24 (δ, CH2) 25.8 (γ), 40.4 (δ) 
Val16 n.d. 4.17 60.3 2.41 29.3 1.05, 1.03 (γ, CH3) 18.9, 16.7 (γ) 




Supplementary Table B.1b: NMR chemical shift assignments for lagmysin 
 δ (ppm) 
Residue NH Hα Cα Hβ Cβ Others, H (group) Others, C (group) 
Leu1 8.16 4.44 53.6 1.63 42.9 1.63 (γ, CH), 0.94, 0.924 (δ, CH3) 24.7 (γ), 21.7, 22.5 (δ) 
Ala2 7.45 4.73 49.4 1.67 15.8 – – 
Gly3 8.41 4.62, 3.64 42.7 – – – – 
Gln4 7.60 4.45 52.7 2.03, 1.90 29.6 2.21 (γ, CH2), 7.54, 6.83 (ε, NH2) 31.1 (γ) 
Gly5 8.67 4.29, 3.58 41.6 – – – – 
Ser6 8.69 4.85 obsc. 3.93, 3.79 60.7 – – 
Pro7 – 4.21 61.4 2.16, 1.83 29.1 2.15, 1.98 (γ, CH2), 3.99, 3.70 (δ, CH2) 25.4 (γ), 47.3 (δ) 
Asp8 8.88 4.87 obsc. 3.40, 2.69 37.6 – – 
Leu9 8.02 3.99 54.9 1.63 42.9 1.74 (γ, CH), 0.97, 0.92 (δ, CH3) 24.7 (γ), 21.9, 20.5 (δ) 
Leu10 7.49 4.62 50.9 1.94, 1.47 40.2 1.61 (γ, CH), 0.96, 0.92 (δ, CH3) 24.7 (γ), 21.7, 20.0 (δ) 
Gly11 7.97 4.34, 3.57 42.5 – – – – 
Gly12 7.26 4.63, 3.57 40.9 – – – – 
His13 8.45 4.95 obsc. 2.51, 2.25 n.d. 7.51 (δ, CH), 6.71 (δ, NH), 8.55 (ε, CH) 134.7 (δ), 128.8 (ε) 
Ser14 9.40 5.11 obsc. 4.16, 3.82 64.6 – – 
Leu15 8.58 4.52 53.0 1.68 40.5 1.81 (γ, CH), 0.99, 0.96 (δ, CH3) 24.2 (γ), 22.2, 20.8 (δ) 





Supplementary Table B.1c: NMR chemical shift assignments for citrulassin A. 
 δ (ppm) 
Residue NH Hα Cα Hβ Cβ Others, H (group) Others, C (group) 
Leu1 7.87 4.29 55.88 1.91, 1.89 44.35 1.64 (γ, CH), 1.00, 0.93 (δ, CH3) 25.5 (γ), 22.5, 22.9 (δ) 
Leu2 7.77 4.59 51.7 1.86, 1.63 40.3 1.57 (γ, CH), 1.03, 0.92 (δ, CH3) 25.8 (γ), 23.7, 21.0 (δ) 
Gly3 7.66 3.68, 3.64 44.5 – – – – 
Leu4 7.89 4.47 50.9 1.75, 1.63 40.25 1.69 (γ, CH), 0.97, 0.94 (δ, CH3) 24.8 (γ), 22.5, 19.6 (δ) 
Ala5 8.01 4.59 50.6 1.36 16.2 – – 
Gly6 8.80 4.44, 3.44 42.5 – – – – 
Asn7 8.22 5.09 49.6 2.88, 2.63 36.9 7.54, 6.78 (δ, NH) – 
Asp8 9.46 4.65 52.2 3.47, 2.51 35.4 – – 
Cit9 8.56 3.98 57.8 1.85, 1.76 32.4 1.66, 1.64 (γ, CH2), 3.19, 3.12 (δ, CH2), 6.26 (ε, NH) 26.9 (γ), 38.9 (δ) 
Leu10 8.39 4.72 51.3 1.52, 1.44 44.1 1.55 (γ, CH), 0.92, 0.87 (δ, CH3) 24.8 (γ), 19.6, 22.7 (δ) 
Val11 8.4 3.72 60.0 2.69 27.6 1.26, 0.85 (γ, CH3) 22.2, 19.4 (γ) 
Leu12 7.35 5.09 50.9 1.57, 1.40 44.2 1.48 (γ, CH), 0.74, 0.86 (δ, CH3) 24.9 (γ), 20.5, 20.5 (δ) 
Ser13 7.83 4.45 50.9 4.06, 3.84 62.3 – – 
Lys14 9.06 4.71 51.3 1.88 ,1.79 33.5 1.59, 1.55 (γ, CH2), 1.68 (δ, CH2), 2.94 (ε, CH2) 22.8 (γ), 27.8 (δ), 40.1 (ε) 




B.2 Mass spectrometry characterization of bottromycin cyclodehydratase products. Thiazoline and 
amidine formation were confirmed by MSn fragmentation. (A) schematic representation of the modified 
products and (B) fragmentation data with assigned peaks corresponding to the ions of interest. Mutated 
residues are shown in red. 
 










































































B.3 NMR characterization of cyclodehydration products  


































Supplementary Figure B.3h: 1H-1H NOESY (C2D6OS) of BmbC-N15K-trunc amidine  
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Supplementary Table B.3: 1H NMR shift assignments of cyclodehydratase products. Shift assignments 
in ppm of BmbD and BmbE products compared to unmodified peptide. na unambigious assignment not 
possible from spectra; * resonances with the same shift . Protons with different shifts are highlighted in 
gray. 
 
 
 
 
 
